From bb6bf8fc9dfb89947b824f69f9ad0e62631807af Mon Sep 17 00:00:00 2001 From: Gowtham Rao Date: Mon, 9 Oct 2023 14:31:49 -0400 Subject: [PATCH] Release version 3.26.1 * Ensures cohorts that are withdrawn or deprecated, do not appear in log * Update function getPhenotypeLog * package maintenance --- DESCRIPTION | 2 +- NEWS.md | 6 + R/Phenotypes.R | 14 + docs/404.html | 2 +- ...ohortDefinitionSubmissionRequirements.html | 2 +- ...ortDefinitionsInOhdsiPhenotypeLibrary.html | 6 +- ...SetDefinitionsInOhdsiPhenotypeLibrary.html | 6 +- ...icalDescriptionForConditionPhenotypes.html | 2 +- .../GuidanceOnCohortDefinitionSetRObject.html | 2 +- docs/articles/GuidanceOnLiteratureReview.html | 2 +- .../GuidanceOnPerformingPeerReview.html | 2 +- .../GuidanceOnWritingAnEvaluationReport.html | 2 +- ...itingCohortDefinitionLogicDescription.html | 2 +- .../HowToUsePhenotypeLibraryRPackage.html | 6 +- ...dWordsWithSpecialMeaningToPhenotypers.html | 2 +- docs/articles/SubmittedCohortDefinitions.html | 2 +- .../ValidityChecksForCohortDefinitions.html | 2 +- docs/articles/index.html | 2 +- docs/authors.html | 2 +- docs/index.html | 2 +- docs/news/index.html | 7 +- docs/pkgdown.yml | 2 +- docs/reference/PhenotypeLibrary-package.html | 2 +- docs/reference/getPhenotypeLog.html | 2 +- docs/reference/getPlCohortDefinitionSet.html | 2 +- docs/reference/getPlConceptDefinitionSet.html | 2 +- docs/reference/index.html | 2 +- docs/reference/listPhenotypes.html | 6 +- extras/PhenotypeLibrary.pdf | Bin 86520 -> 86364 bytes inst/Cohorts.csv | 302 +++++++++--------- inst/OrcidLog.csv | 2 +- inst/cohorts/794.json | 9 +- inst/doc/HowToUsePhenotypeLibraryRPackage.pdf | Bin 197082 -> 196773 bytes inst/sql/sql_server/794.sql | 74 +---- 34 files changed, 221 insertions(+), 259 deletions(-) diff --git a/DESCRIPTION b/DESCRIPTION index 6a385058..c9c4c371 100644 --- a/DESCRIPTION +++ b/DESCRIPTION @@ -1,7 +1,7 @@ Package: PhenotypeLibrary Type: Package Title: The OHDSI Phenotype Library -Version: 3.26.0 +Version: 3.27.0 Date: 2023-10-09 Author: Gowtham Rao [aut, cre] Maintainer: Gowtham Rao diff --git a/NEWS.md b/NEWS.md index f09a7bf7..d474a0fb 100644 --- a/NEWS.md +++ b/NEWS.md @@ -1,3 +1,9 @@ +PhenotypeLibrary 3.27.0 +====================== +Accepted Cohorts: No cohorts were accepted in this release. + +New Cohorts: No new cohorts were added in this release. + PhenotypeLibrary 3.26.0 ====================== Accepted Cohorts: No cohorts were accepted in this release. diff --git a/R/Phenotypes.R b/R/Phenotypes.R index 255431db..84c80a55 100644 --- a/R/Phenotypes.R +++ b/R/Phenotypes.R @@ -130,6 +130,20 @@ getPhenotypeLog <- function(cohortIds = NULL, string = tolower(.data$status), pattern = "accepted" ) + ) |> + dplyr::filter( + stringr::str_detect( + string = .data$cohortName, + pattern = stringr::fixed("[W]"), + negate = TRUE + ) + ) |> + dplyr::filter( + stringr::str_detect( + string = .data$cohortName, + pattern = stringr::fixed("[D]"), + negate = TRUE + ) ) } diff --git a/docs/404.html b/docs/404.html index 50919f47..a412890c 100644 --- a/docs/404.html +++ b/docs/404.html @@ -32,7 +32,7 @@ PhenotypeLibrary - 3.26.0 + 3.27.0 diff --git a/docs/articles/CohortDefinitionSubmissionRequirements.html b/docs/articles/CohortDefinitionSubmissionRequirements.html index f1dcc81e..b6d50990 100644 --- a/docs/articles/CohortDefinitionSubmissionRequirements.html +++ b/docs/articles/CohortDefinitionSubmissionRequirements.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.26.0 + 3.27.0 diff --git a/docs/articles/CohortDefinitionsInOhdsiPhenotypeLibrary.html b/docs/articles/CohortDefinitionsInOhdsiPhenotypeLibrary.html index 9d7bee18..e0c07e83 100644 --- a/docs/articles/CohortDefinitionsInOhdsiPhenotypeLibrary.html +++ b/docs/articles/CohortDefinitionsInOhdsiPhenotypeLibrary.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.26.0 + 3.27.0 @@ -150,8 +150,8 @@

2023-10-09

window.URL.revokeObjectURL(url); }); }); -
- +
+ @@ -132,8 +132,8 @@

2023-10-09

-
- +
+ diff --git a/docs/articles/GuidanceOnCohortDefinitionSetRObject.html b/docs/articles/GuidanceOnCohortDefinitionSetRObject.html index 838a5601..5989b4e7 100644 --- a/docs/articles/GuidanceOnCohortDefinitionSetRObject.html +++ b/docs/articles/GuidanceOnCohortDefinitionSetRObject.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.26.0 + 3.27.0 diff --git a/docs/articles/GuidanceOnLiteratureReview.html b/docs/articles/GuidanceOnLiteratureReview.html index f3bcf545..78292c85 100644 --- a/docs/articles/GuidanceOnLiteratureReview.html +++ b/docs/articles/GuidanceOnLiteratureReview.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.26.0 + 3.27.0 diff --git a/docs/articles/GuidanceOnPerformingPeerReview.html b/docs/articles/GuidanceOnPerformingPeerReview.html index 26ccf38e..3870f9fe 100644 --- a/docs/articles/GuidanceOnPerformingPeerReview.html +++ b/docs/articles/GuidanceOnPerformingPeerReview.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.26.0 + 3.27.0 diff --git a/docs/articles/GuidanceOnWritingAnEvaluationReport.html b/docs/articles/GuidanceOnWritingAnEvaluationReport.html index 9cdad61c..6d41a322 100644 --- a/docs/articles/GuidanceOnWritingAnEvaluationReport.html +++ b/docs/articles/GuidanceOnWritingAnEvaluationReport.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.26.0 + 3.27.0 diff --git a/docs/articles/GuidanceOnWritingCohortDefinitionLogicDescription.html b/docs/articles/GuidanceOnWritingCohortDefinitionLogicDescription.html index 48a860d9..aa10eb67 100644 --- a/docs/articles/GuidanceOnWritingCohortDefinitionLogicDescription.html +++ b/docs/articles/GuidanceOnWritingCohortDefinitionLogicDescription.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.26.0 + 3.27.0 diff --git a/docs/articles/HowToUsePhenotypeLibraryRPackage.html b/docs/articles/HowToUsePhenotypeLibraryRPackage.html index 4f10fe94..de7e3e41 100644 --- a/docs/articles/HowToUsePhenotypeLibraryRPackage.html +++ b/docs/articles/HowToUsePhenotypeLibraryRPackage.html @@ -33,7 +33,7 @@ PhenotypeLibrary - 3.26.0 + 3.27.0 @@ -151,7 +151,7 @@

Retrieval
 PhenotypeLibrary::getPhenotypeLog()
-
#> # A tibble: 550 x 81
+
#> # A tibble: 540 x 81
 #>    cohortId cohortName        cohortNameAtlas cohortNameFormatted cohortNameLong
 #>       <dbl> <chr>             <chr>           <chr>               <chr>         
 #>  1        3 Cough or Sputum   [P] Cough or S~ Cough or Sputum     Cough or Sput~
@@ -164,7 +164,7 @@ 
Retrieval#>  8       10 Nausea or Vomiti~ [P] Nausea or ~ Nausea or Vomiting  Nausea or Vom~
 #>  9       11 Malaise and or f~ [P] Malaise an~ Malaise and or fat~ Malaise and o~
 #> 10       12 Rhinitis or comm~ [P] Rhinitis o~ Rhinitis or common~ Rhinitis or c~
-#> # i 540 more rows
+#> # i 530 more rows
 #> # i 76 more variables: librarian <chr>, status <chr>, addedVersion <chr>,
 #> #   logicDescription <chr>, hashTag <chr>, isCirceJson <dbl>,
 #> #   contributors <chr>, contributorOrcIds <chr>,
diff --git a/docs/articles/ReservedWordsWithSpecialMeaningToPhenotypers.html b/docs/articles/ReservedWordsWithSpecialMeaningToPhenotypers.html
index 1fb29920..62488f7a 100644
--- a/docs/articles/ReservedWordsWithSpecialMeaningToPhenotypers.html
+++ b/docs/articles/ReservedWordsWithSpecialMeaningToPhenotypers.html
@@ -33,7 +33,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     
 
diff --git a/docs/articles/SubmittedCohortDefinitions.html b/docs/articles/SubmittedCohortDefinitions.html
index 3c7dbb7e..dab42e71 100644
--- a/docs/articles/SubmittedCohortDefinitions.html
+++ b/docs/articles/SubmittedCohortDefinitions.html
@@ -33,7 +33,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     
 
diff --git a/docs/articles/ValidityChecksForCohortDefinitions.html b/docs/articles/ValidityChecksForCohortDefinitions.html
index 3f18e701..6d40167e 100644
--- a/docs/articles/ValidityChecksForCohortDefinitions.html
+++ b/docs/articles/ValidityChecksForCohortDefinitions.html
@@ -33,7 +33,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     
 
diff --git a/docs/articles/index.html b/docs/articles/index.html
index b21acd91..7d7c6cb4 100644
--- a/docs/articles/index.html
+++ b/docs/articles/index.html
@@ -17,7 +17,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     
 
diff --git a/docs/authors.html b/docs/authors.html
index 96898171..f64cac8f 100644
--- a/docs/authors.html
+++ b/docs/authors.html
@@ -17,7 +17,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     
 
diff --git a/docs/index.html b/docs/index.html
index ca773a2c..3d111917 100644
--- a/docs/index.html
+++ b/docs/index.html
@@ -33,7 +33,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     
 
diff --git a/docs/news/index.html b/docs/news/index.html
index 433f632c..2ad0f14e 100644
--- a/docs/news/index.html
+++ b/docs/news/index.html
@@ -17,7 +17,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     
 
@@ -96,6 +96,11 @@ 
Changelog 

       Source: NEWS.md
     
 
+    

+
PhenotypeLibrary 3.27.0

+
Accepted Cohorts: No cohorts were accepted in this release.

+
New Cohorts: No new cohorts were added in this release.

+

     

 
PhenotypeLibrary 3.26.0

 
Accepted Cohorts: No cohorts were accepted in this release.

diff --git a/docs/pkgdown.yml b/docs/pkgdown.yml
index f81df80b..cc5c2791 100644
--- a/docs/pkgdown.yml
+++ b/docs/pkgdown.yml
@@ -15,5 +15,5 @@ articles:
   ReservedWordsWithSpecialMeaningToPhenotypers: ReservedWordsWithSpecialMeaningToPhenotypers.html
   SubmittedCohortDefinitions: SubmittedCohortDefinitions.html
   ValidityChecksForCohortDefinitions: ValidityChecksForCohortDefinitions.html
-last_built: 2023-10-09T14:52Z
+last_built: 2023-10-09T17:51Z
 
diff --git a/docs/reference/PhenotypeLibrary-package.html b/docs/reference/PhenotypeLibrary-package.html
index b72a22de..d2c1ebea 100644
--- a/docs/reference/PhenotypeLibrary-package.html
+++ b/docs/reference/PhenotypeLibrary-package.html
@@ -17,7 +17,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     

 
diff --git a/docs/reference/getPhenotypeLog.html b/docs/reference/getPhenotypeLog.html
index bf428395..1073bb85 100644
--- a/docs/reference/getPhenotypeLog.html
+++ b/docs/reference/getPhenotypeLog.html
@@ -17,7 +17,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     
 
diff --git a/docs/reference/getPlCohortDefinitionSet.html b/docs/reference/getPlCohortDefinitionSet.html
index 53fd73b0..787e9c14 100644
--- a/docs/reference/getPlCohortDefinitionSet.html
+++ b/docs/reference/getPlCohortDefinitionSet.html
@@ -17,7 +17,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     
 
diff --git a/docs/reference/getPlConceptDefinitionSet.html b/docs/reference/getPlConceptDefinitionSet.html
index 201ab1f7..20be8d29 100644
--- a/docs/reference/getPlConceptDefinitionSet.html
+++ b/docs/reference/getPlConceptDefinitionSet.html
@@ -17,7 +17,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     
 
diff --git a/docs/reference/index.html b/docs/reference/index.html
index 90314458..a5e4f8ee 100644
--- a/docs/reference/index.html
+++ b/docs/reference/index.html
@@ -17,7 +17,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     
 
diff --git a/docs/reference/listPhenotypes.html b/docs/reference/listPhenotypes.html
index 902995bb..54b06753 100644
--- a/docs/reference/listPhenotypes.html
+++ b/docs/reference/listPhenotypes.html
@@ -17,7 +17,7 @@
       
       
         PhenotypeLibrary
-        3.26.0
+        3.27.0
       
     
 
@@ -117,7 +117,7 @@ 
Value

     
Examples

     
listPhenotypes()
 #> Warning: listPhenotypes is deprecated. use getPhenotypeLog
-#> # A tibble: 550 x 81
+#> # A tibble: 540 x 81
 #>    cohortId cohortName        cohortNameAtlas cohortNameFormatted cohortNameLong
 #>       <dbl> <chr>             <chr>           <chr>               <chr>         
 #>  1        3 Cough or Sputum   [P] Cough or S~ Cough or Sputum     Cough or Sput~
@@ -130,7 +130,7 @@ 
Examples

 #>  8       10 Nausea or Vomiti~ [P] Nausea or ~ Nausea or Vomiting  Nausea or Vom~
 #>  9       11 Malaise and or f~ [P] Malaise an~ Malaise and or fat~ Malaise and o~
 #> 10       12 Rhinitis or comm~ [P] Rhinitis o~ Rhinitis or common~ Rhinitis or c~
-#> # i 540 more rows
+#> # i 530 more rows
 #> # i 76 more variables: librarian <chr>, status <chr>, addedVersion <chr>,
 #> #   logicDescription <chr>, hashTag <chr>, isCirceJson <dbl>,
 #> #   contributors <chr>, contributorOrcIds <chr>,
diff --git a/extras/PhenotypeLibrary.pdf b/extras/PhenotypeLibrary.pdf
index 752c51935f6adea22708dab7978bedde5b6d4edb..fe1e208611375e4ff08f6baf026deb6e3bcdb95c 100644
GIT binary patch
delta 17428
zcmV(sK<&TyqXpce1+el11&&NgF&&fl17Cl%)0HGB#c2@I2=SB~RiAUM?qy@tq^IVS
zV#+!N1F#LM6s3ZSPEklij7Umg5hEJMM%8Q_MmUJ#{>Y_Q*$gF>8%szH^
zTHRE2xqq)%EgtvpG>fb*4`o}5W0%;Qby><*{{v?v(hfUQ_2aRW^(W=8eFD6Tlio0N
zC*<#B_PpbtHRZhrim;%)nMHrq>Mp#OS@Tesic=eJZM@H>;|Py#FAs;j(d)putaDXV
z&jZTA1NE{;b31zqRBj!T<_=j(DRpBLbxyx<(AyM!J@I;q-rEuWRdDCo*~B&g|9o#v1+7#aEuw&O3}
zJ_nsTjd%}1t5ub^COv-(m9Ll3NM-S6n47mQ4&)#fLP`-8mWWd7C#b3%ha&2FX~0R
z=fT1ivZDB&Z+M@8Uln6O?RHuS*G2uzq4xv!n
zu76b*@`sh)Yazk{#ZMz#^pYjw^hC_y?SX85k)W6uQFo%doSpm))1(Yvvj_-!qXRfH
zIgYNa|b(iC6!cc+qP|^f{LvQDt5)F
zeD%CS
zcUvofHPFEdAfckFC#Ng}pp{Y90?1f_tX$0;0IDA54nPZlBGAGLR<@}F|5#Vg)>Iigm`}++5x&drl%|Pyd
zd*JQ_0D>$WJS_i7;IG`;>0b#syE^@~aQv(L3#RJi=I&
z|B3Ae{Hq2yS^u@Pbh7aHr=)-B{=)p#x|;z(ZUA>HZ})$HVwqb3EP-y$4rV@oWB&zn
zb_M<`4G%XU$mTyYU<9~Y*_gRnI#{{6{e}69{ZDuPvrfSOQoWh8vxCpSyq*4K^*?g}
zy1Q99STiHAvHy)};r=(a4G@ID^3SZufvlYXY^?v5TY5PEhtAW=^&4{0a#jpStGD0JGuW2384MIW10ECkL3RbivL>({%@i8|Bc-L%F+LFiT_{k^M8ew
z_Hb}eHgo(t0RP@GfWJ$|3I!#-kg+1sW61e`YvI1HD*9!j9^{@O{)O92zHPsmYHw*S(hN^!D!ClkG`EPFj
zqZ%bA%l~=!2S!}n$s6Fu#Kz4FU}EQG`+NWXCd9|i>Hoh8`7a>0|2!+1xw`_r0S15T
zW@Y<-SM~qn_n#-D{{kZgvT(BeXLK~&%|Moar|o|V{!v?axVru&`Ckj*Z`J>C{@2`F
zS$SJoAgr%ASqOyKWn^c%H{j-vO-mXK4X{Cug*ulvYnBuR);aZm&4~EPS8e)UAIjYF
zga1#b&+?h`$Dus^uZaO12b%sgtE)mHe+s&P!6Ni+>TVu}U*A}a%aJqBbz=OkmlSuQ
z^toBJf9*}HsT-HQ!w~=I=5U3(exeJc@GJ_%qI`5l39v|SipTCjYXQS(C_X!J~rBa3q5#9$dDHgPbFZ68<2WNmg4SX>U!U7@dx_VlgF)QIj3Ex4n0}R%a`zf
zZN-C>@*(agCR^qu2Z_z682ACJ=!$u~g4b1e7-AfINs=%l>7>N0ro3@u&x+jn8u!LU
zlQ4gVefAn(91!uSC3;0BgQA3M=MTCzt*GqCQnr3rqNS`hD=%86nx1yF&@2yUBY_B&
zlrT!PXhY!ls+2v^(pckecYhK%p+2yGTFs2%#@usNrZFKPBvUNgkyq5ciy*70sGeOI
z{dvqI?5lbuXPn5sAOS?$b_$
z$bScaFk!J_bvTu;(}iyW2z2X5;~7{tJr_nvIYPvnukC$Re4p8Zm3V{D{tA&&?X^|V
z=^RZ><$M7D#nUr;IiVoG7MtRKpqFI%BgA8%)h`tsS8u-5(78F&d27}aCTBA(!M4QQ
ze!`-TSSJk%98+^fxL2)Jp0Lt8-_u*ue&Pw!x7EVhRtRSq#QRX`ixy)K$0>Tj`s%MzXET5?S2
zC=MXFr8=HTNZ!7hC=7&Uf$~NGR7d^gW0DF}LG6p=;T0!{!_5Tb4aDKxixKm=i{G>n
z9<*bC7rsy{F+*eh+*=wflmZFYLKA|2S2oH!RSY%!P1x~E@+kanzcPO4^hSl*DA8K;T~G%Ub>=X7exM!BW?bq9WN&F1uaM{X#1Tk?aWL80Vq<}#@Hc=2f<
zS6kl_qlWc8E~qbptP&DWRVN$b#~(ApxG&^p=pjdO
z0Gz;HkLs>o#NRo8j`XTdgU}c8>+fmA3Hf#nZQOk}lQMGO6lBfg@8%{dr}lL0p_3VPpu)5j!hvK~|ez#Uh()ibZ%7RQ~6EHH%F{hS(?|Lst
zpNSxkiFe5AtLPT}v2&auxsvs?*y!RqN5cglmLDY4{noHD{Fkk3{F2i;(#c@Bblze`
z2vPWNaFnA7Tjp!n`lCKq9+xdOIOzXxqiSs8%7Wi)M6w5J@H
zfb~S1ts|*#Xcs25lit!2BHJu2&hQxem{YSR20v_tpyAqfJC+bdlT
z=b>WA63m=@gqktYsu1F(uuu+PFV!OO=QKHuZYAA+h!;2*P`?_7jMzQ;(Kq20EM&|i
zoG+#B8^Q`9Tb&V1B9h;u|CB%UOM0Fv73%OrCfBJ=45ji>I_)$SVKJNw
z;!)pW_+=oQ#u%bl-QKqpS(q??qLHC7UZIEfyu(c-U20Hw>WjQqYuhSWC0tMKlQD6&
zVH2}|zx~XxI7mE>nIkCdi5z3&cc%1OW+2sQ3Y%TwRa8wpm;*X-iamPXoZnHIPV4;f
zP|JJ@dHYKk*7MBEg+g{!J%g;$5R}xC>fr-Ze}*J*g{oEis8XtYNvYu>5$c}>*(QOm
zw{>@w8gR8F3U{0Co*9RCn36=hzzw%4YH=)ony|l^pUsTPz8NVaWzpe7u}m@h?2iz>
zK2+4+T_Qx{Ff8dj!9Zz2$PHlmRF^Pq4VX+htqb}wfe#7j4ExmEOL{HkEd7n!OhXMn
zGZ0(AAu9w!dbqyucur(Qno~xJx7xzI(MNfMk|3%ed5Bs}+
zt6qEF+_86U=05eCEZ7!>S%VD?*6%BnHqu6Y#ZyB_nt1JkFPu~*B6^moCeCU%IPFdD
z^^80rZLQ5^j9(o@1_y%CxiY%8|5lul}Ekif#i>qXcQA5_ZKw3LL(xwl}Yod
zgjGu`KU~-~H6yEgY&CFZo<36WE*8v`ZP|O2zxk?E}
zFy)0Zh{)93?muX@>nvLma2v@PHMI_Z;KyAx=j?Js0QXQoP=7dsf-_q^bo!|pC{~nNORCfj&8Wr_mj!s${1JW3();yVR&SnY#Pg<
zHd?MRK2VG#gW?$A5~Q%e4KT?C^q;!4BW^HE2?|kcX68t1Q`N1Ht`3znNy6VH@FR4-
zKytj_f(&;DsR*%+&>F)_Ole1dOER&;3#D~RsIpQ78&R6J05+M`uR@r1ty()jaXF5D
z?l0qvXuXhghm|}YU!=ZzVv(=juMxe)LlOAjSbh=nsC*L&AmuQc$NV0|RTEtETdNt)
zSi1x+U@j#4c!kC}Bmz;Hlw6D8Di|-}jlX}z2BsO(0X{w1H5h-7u!|Ufj%;w{()5GO
zHml4wyN`|=M|&(1qmSD?tHdLV7nlO7SWcsI*|8|fv&Keu`@sW`_UR`MlcjOdGGxek9
zmCzsQhNKdB1py5ujZ%o=HjhANzitLL#~+T&p7=?h>k8eOZ|4?qr5}S
z={KE@r4f?NFP?#3vo8A*>{BSROzO=*pQq_9{HZ;lTaQ%!Ia$xAeuCCG=>D>5;i-N1
z%5}iyLPdOyJogUnPnky3D#7QdyKd|S30^SY{%yDH7F#tX-VN|lRZ%ehEL4Ym+ke7t
zyRch4Crh@<`6t8ikHtb0n+FXc6U
zvs&*iNh~*-HhCNUJzL7{kT$XCfQ*1q{s#uP&m*9vGEvPzhv(UkI>=X}+>_)1Or${F
zHy2I^md>5_V)-4AxVw!X8mCt=ELmk0bu3u3{zRJO;`ahJ`N(^7<}>h`wb{wlnjf*;
zx8mDc>b%B(#U~kNg!)3K1H)63u(aMciO^7PRJE(bq!&WmNRmauc53b0KQA&lQaQ<=
z7MKFr2e&;j>Y^v^yspLOS)AAD%KT6;##PV0o3{ryyI>Y-a|rA(
zjK+UO6Gg$&s{k?b$sYMUWHCTUQ#Y7($i`3s#S;~Sbu2uoV(iC{LPf_K&$UW#_PMv7&;;G@fa?QDN)caC&m3r2PbPSOQ60)Yx}iZ+p7kb&2&Qx!e&?Q$(!bX-
zzzp94n=kRhPQS2QvaNSY#5@gQbD-T3DjV0$VLhe`XMj1?mYXdB&p*1otaLbIlM=lr
zS5>eliEUD#Pk!l1_0{0FALkz;D_p^c`QgKZMxFy@xwVHA=Vp3~IlWPd@~pH$FaAhAFG}cEKL{9{8tiYA02@220lg?|X-@*-%JScWeIF=Kq=8GKW{1;6Uj0aIrnGlq@T
zB21J8U>o@=`CjL7!dpbfY
zehgv)o)LDUkQX*4)a_Nn^|(#}lSyC-j?N^g-{sVz(P_|+-G8mvJ!Z)hA~g;M%X$sY
zWU`n_ymEyxDxuNM&XvO_oUf)qj=v5g9?*3jr3;W
z8NdB(tsmz|2u`{c+^`%6HZ|a+E)+7jm7Wao5n$gRR
zOpY;b!8OWjQy=p97eXEDJ>NT0@J43KRpWl7bM@mCm2T|+5uhJLRI^a0!?y(dqWKdQTcS9ztV|?ROTuzUjNIGpi{A`oVHE*i@?nY@Jl*WjSsVw{wJX%~a!I3nP(
z*+)Z)<;cE8AY&IjGwW%82f|eveA2NE`}S8d3_9&TbxP_E4sHu~jxE^sw+w33G)mi#
znOcARO!Y2f*fdaVY5ZUU={l2_5zBJr2)a#f
zuNGnFX+5rPv3K{SUr;H?0^Ni_LGhAkM4>HriTD@v)YtQkb@IM{I<|R=bbL>T71esC
zY+Q}T?VmvyqEqa?MoaQ-DRKZP|MqL2j#J&sJt}~E-?$eUQ?^%!0b0AIl=)MWkl!eA
zl0${LMF{HqaMx2tJF|Wri)fgJL;{(~rA4Lk8Io-Hx>mb422H!h&L(2FzX+sfbbVN&
zo4|dTU84E{e_il@X$WtY01x03oOUShYreVwawyfe-o|sF%iZ}jl16mCjLgwf>(UBP
zw~9S?$Dul*`48`5zQ+X|Ka}<(5?yt)SOAl0(sQ?S(YDd$QnRuk{|`BYC&D&q#A=sK
zN(X|*FG@18>9&tGH|eT`cA~{~2^@G#{pR+X+OF1TEI$r^qYng{u-iSsZscCPiQ7$A
zU`2}(vB;XKDnd)p)V-j22uH&d$9CZ
zx{x9e9xVK+aT;hQ+7l3joP*QMsV#fMcg95Jk&{YB=O6K6a4anBwj~ABQ_EHW}40c
zA<@lm54wZXkpt{10HjMHco)vpWHEb5`Ll;y?0D`j0w?`u|4*eWm14qd*-uEQ=CN6Y
zN*HvAANZUn%~!}43ESU=p1NJblWwxg%u0dWl$Hd4PLzHo$7@s#ys%O(=-iQm9yktm
z)?cJz0yd;~p^&BKk6-7p(FWUoOQN$>s*=ZjIQKWf?{!|zA`7jI9Oue7Exc>LZb>8O`o4
zAvkJ(BxqV~gijRx5!}m;F{oWI$few%J_v%!Www^0NV1q~I}%HDx5oD!Z0O}#z7a{r
z@~YCKFc}t97fD{orossW+W88NZ2rUyP8N40OoSInd&+bW0Cll#3neeJCbg=abV6aR
zL01j_sI*2~*MICUznk9PZ=`zowO~rHOuFoUV@)c|Ql+_u&THlNodCuq=H!pIcxIjw
zX`&H{>duOdQ%oMBYiFB>;+(R|SmVKtg@$=wWR93t$lwbcyW84ICrem*z73=U9q&%P
z*{ad5Zv@ioZ>MggSMNgnud`^3y%T<25}f-pG4IH@yv*al!+C4wyo|
zg?R8BAG_Pum4a8lY+}aFSW@d>1qq0wG$Ni=mtHyT!d2Ny@`E{75C$>gU-;6GCL@yA
zVugpka!&ZO)P!#{1f4pXzJ0kU;f&LJRHJhxqoh_$SJ&=6@`t`ws^rEupYcOri;Or4
z#KwF^i95yt^m3P~ltU%4OVt;D$tS^NcH^a2`|S+kp=aZhE`A+N2h3^gU@FH(#&W9+**4?{P&t1I+zxSV@`%WSXe(TGQC
zZ?n7^u(b3SF-KOeVW6&{kiDHB8z8dB%IAX)Lx*FYX(WZi-h|Z8;@dAAO8w4pGjqJ&
zA{LO3Alv!FM5fgN-Le!j;;JD9IA-yq&Is(4FjO(n_*~T-eM;FsCum&r-f^GsaOou$
zb>wAaaFL;G5QecNNa4DF_>&7uC5Nip-0t8{%Pq|uQ(qKq*}eCMx`{I5N+za5lzSj7
zqWX>!nDT+isGs2BZ-GPvB+BKACo0`PhVOn(J8t>mJ;pW
zO@8q`oo#h0xO0A+jO*L+1iv284Hh)>EV)pu_bjnqns?0)m$^>
zR4?Szsul*Qisa__KUOpC2zEfLMbT|V2@`@~il|GlGt=s_<)3f}%?P(%!0UB1
z8$#BzOkSB1oNY7Qjla*-81%5rKVhOD#ae*A5Ch-Fs4L=~FX6`Y`d|(myib}cEDpT4
z-j2=RcNkVCAyy@S)jl4v3LMKgsK&SEh64j$LO*~US*cYQYK~!EtcvAcYgu3>xM9LN
z^qlDHD!~P#COdM|cGwOwP^M^#>F**9jDys;h^^W~+iHK9Xxu-HemdPDd4PQdyY8Y%
zfh5LTZZ2t|j*9(B=PtxO^vF%Go%Q&%%
z+Oavo^jdOrnk>@f6KV;@lY433sis6kQ9L8AL>l~X0He??3LW4K)AiAnQ4P3rCE}Yu
zUGI94XYtYUwNwfsDIOws9CAowHD0}|wGzI}ZtsBWzbmWTgE};5_|nvEVAA$FiF~p2
zBWqtKh`kGcMAwD1I|vHIoTJcjg5?FdX=Z@asH7gLsQCg
z*O`N>5^VTC{@E~Ote!q^#vuj5Vd-s+aU#LfFkJ={@f4@J2+#Q?h9F$_DMb9dyCI*Cs
z$p*E0=E?SHJ?vH9)DTCy<;c#zs;+WGq8r8-y(Cq*U4Wt$E6E0{-cg446?yv|El-E^
zD*CTAu76IJL9xGu4pQNxJc$%TQ!9dCJh*372rtn@t}7&pI$o$@`*68v)?4U&cigpe
zutmFn5xw)pAkLz)*p~D)^7qs77oKFi!8thDR
zBm?pJ<2HSDVV=;Fj0V}1@3>
z?6DU52V#P
zq{(g#@f@Jld1@M*nl^UMV#JdBNkV^2gT*1Oi1g{Q3;Mb0Qx}HAQx;Xp!L?%ImhL`(
z!@e6CTztwK9P|CT3SnP@Z2qDyWxn-WRrVSgq_yy4$p@1P#db-ko&D7QLtfr&kO54I#HBjZ?`i8}*$9oVxA*lHF
z{Y&Pf2D|3&@c6lA<(QG1kVFKk5_rGNfz)EdDiWw9_%o9Z1ye`4145i(&93VgBYpaH
z!N)uS=U0IfT3(;^XUmK1J2Hn6Hgyc<(XD+
zpGbKm;44kjqxn?v@h&@`c)LGFuuU_|)6=!*?ysfnd(0{VO-WV8S?~UvU*BF7+)l4z
z`rb!We&X5=i1{?`$qhCMY!&=}h$E#g(jmLqH@CvdZ8xKULZ}I-s{T?_Pa2S^szM_w
zBbsg4Q(VaRh?tbsq~l(|N!k{J%n$7pnWZu9fy#qRNzO+~H=tNM8BP{l&q)VSY$FYgx@J062pW<1{sWtakpQzR8<||9v>q&w_5DCH+=l
ze$80pGds)=n6lqREg*A$Ra?vWAouwz`UBOgtakHT>UYSwAdN|#xOyz{A{NPuTtw(&
zN1`kzO(%fMsORB2vJJdb)SLSAeJIyJFCP0)CI!{kOh0Pi1BWS?fCLJI3aHIgwCYtG
z6Yg&5n~iE-n8PU!ir1J$HOh@eR&hd_BpT|Df|4T{a~}3|u?mKc%EHuJ+S&Eot&z^BNMolb_IMv1Rp@Y@`IQ8^gVC&v>GUG5
zWocf8Mz!=<#Rh(V>xXz>fp0+eGKnfP|KaA?=pORn-&|CT=krL(oXHU4Zpa_FLr-9y
z4pUn()twkfZSKk2^@DfM>=e^Z2dm}Ozd}V8?M1L|8{H3E^}}+~-pdi6mPwhz2v(k|
zCf&ln+=eknh3d4Rcm@$&UbmzWOj$y(e`3dPOH&t$3*}9Jw+U;&)`^{D6(#O{z8>p&
zBF-AAsnbeN>TEB#l%6fhg7q6!3$2!=PRyBhniE(+>3jG`eT7%G{qvPa5$HUw_W>Li
z4X$58Uub)1yL)%rH@l^8)`K!E
zb)685)gbkS#$jT0=ftE+NLT$qQ|LMHptSB(vGB)#j{0w^BLkiQ0*pf3@vl$#<~G84
z%;H%G=fsYWxkGZZiB#*%_?nOQKPVnys&D0vmfujxFHpqV+|131Xcl6(QT@#y@e#E?
zOQwXBd|9JS^+^Of+}#D8a@%<9FZHak5B1kww_6cE7r5YX)gVd1=9oucewfXQJO|JT
z=J^SKS2u6H7dSpxQI`-kO0SL0xiFwBw8+Q|B|f;U{Je|=e?fJ44{j!RGA5NWEg3M|
z=2R13ySuM2Tv%Z9_GdIw1}n(NHu!jPX)T$nL1Uyd0Pwc9A-d=O)~J8F_uDr6PF%Ek
zHZBxOu7Ft5$Tb}f-z>&+ekfBGPmmW2CF<*cPahfwpNY;Bcucj3kG)9
zrW4_3;1U$fkKJ`sgFumh3Xqxp**h#=N%Q&4!z4$KD_MBf525+?u+GCn?mZJJu0K|P
zNmoRtHU7&s7NxJ|Q;u?fr<0#}zD`X+oE+tyDvDFkwZdOblt%GeK1FUuPEL7a2%1en
z8{V8gR_?2`u78&kq7{O@9t(3#c9diqw8KTyrvz@%ggc3HX^PVF!NSZEtS`r|78iEl
z;{C2nsZu;Uo4njVur2@^jjoXwM2KLJ2UYY+MJ@d$C;nU70e}}&-63XD39Or(71^AA-(UE|(
zBlF~)@;Gv_;e-r_MrpfQVml*T;-)_aDcDvTltM0O=tE!pDRdjRFzeEPFCz&`;vMC@
zUA{mD)OUSDJ`CNIh~vL!l!%?$T$`RSg%!HZ7GABJu$
zMJ&9&Qy4@7W1h}@13J&1nHq?Pu&GVT4HfrmKzmqKw!S6hCs?Hs+k_LtM;)#nF&w)s
zgH@u$++6UR8VkEtQ!RvlL1p?L6o>3j!pXU_Ci+BKA~;a5;!wuT#d36wg@!?h}o9BE0ve%we;CqtuRxG1Z~JO}1QA
z4%O69F;mc@E}9eLX{@3+aHpvh;57~8$KHTqKRjwQ$@{_>;#F-xq)+u7dLgk`nxJ%E
zO5Ykh!W~Dq%dX*GM8vO?H`9Jj%oW?`Rh-UtP0Nep9u#p4C8V%EmFzkHb!=}c66r!Q
z;0U7C&zaS`ATuw2V;!@a8N@7H@jvXPVJW}&x0TYtW9fGuk*5gqzkvv9Vn3k5x*PR*JT94Au;JTON0T1DnOP|
z_5(}1n|Ea|iYTvsKiQ4sSjw=gph>nqf)H~yK@%*NSe~HaoD4;5Mzz|Rv-9dd9%0(A
z_#U*lU!sVAH{j(thDoQ)Fqg0gwUIG%N2bX~3&t2>RRmcYlC=@Po;Fuq=vBYp9}QqZ
zh!!+|hO?$I;2+z0dERl~gx!?|>hdgi_y&k1GuUhWtmE*DnoO=GlWo{VzNH6C8aMDd&)1E9T|A#AF1{T&h
zP*c9`*<75|iHEjBcH@f-p%`!)#tcpLUIK)6JCYxhU<)U_qt9@-yeAB>2J;Zh5hdG5
zN_X&oP%TUw(s?JNTs08>`HKAkUYxHHca2_y$-ML_Yy;Q(7Y^Qnqew14uVz>YAFn&*@EMC88
zzkP19ZkWWEoX)SRX>4w;cD3^uqB!ealjoDBPLQTNd4VbKWVJ+4$A)iBU2)#}K)B*l
zk`y({j(J7o)(y;Qw)1T-r^X+L$YhHru}8_hVe@5-T}!OL&9G&xf}On}Vx5o|18|{#
zOn@>vpD^u;*===+C55YBSl`r3Da!Ih<)Gfq$C9@VTz0Jd-$G`^6L>OT=sHBHXjEnO
z*H{tUeznd~T{k`6Y+*GIqr~O2wg6ScC}$gW{Ccgkf(gDlsg+P3(40f&F(*fT?2on=
zt=O9z&MJmn`C9ZEr+oJv{XF-O%FUmD)WiVpT=PpwO-J{MWAem1V0um<6BIy4-!sGa
zZ7U8ZpUf@si*dyz%b?5R+?P%x(LAIMeZ~6O#Og$*M?IPmDbUftJ#SnaQ>!?8+UeC9
zr+&Z5@eAz-o`*BhZpk5h*J`rjF89FI(4s>KsmnH~#qk!z5WL#7y#I1G%erfS(im6B
z&@yBSRzzT0{%lcwB?2NR!ui194`P7w<>dYRxcjA)j4Sem#dmP9&#x^8;;KOdQ!b-y
zR}Q)=ez(%g3=xK+tI7+$o*@$%a>OgW>1BWv9?LRT?r~9a-}VuaWwxR+;e_zy>lqDT
zK8-mvohH7td8z)lS5GDuRFqwR=oD+z>Zf^n>72t%61<(|A#x4vm+6(iH+v5K3?KIZ
zTsUy)XVO|D1Xd;Y#dq~m{7)%6ilnU?m=8$&F`cnx=Gww}C}kTPDz$8W&uQH3u_h{Q
ziEBFA`dS6M?#WY=LY}Tx|1x>Ru)}|a--o1nkPe@yD-c8Sp9KBO{b8C!dFiZexo7mgG^9gRP^If5xA?a
ztw^QhxcUwD(ZJAFlaQ-_7j|@&_1UrSkXbChs7ig%uj}~yUYw<7WZ*i=QE%LH_&Qq#
z1J3raqO3d{2s_fHa6L3huW%x~d*%6uBiI>1Pu{Az;zLnfy>AY!K>;0}DV$rFdE3(u
z7};)@sG&%;$E&zT4`nNMtMF?WQ)!PdJM6rO4ZmQS+N@0OWIF-c5gq;6B5%Q8lF)Z=wU0i#Z$0r0BKMSrsA$64TO~=1Zm&#RhdB9h
zww}KHEYOsm{=iFrji0cIF{X7Y?~ujjR3IRs>9;O*Rh0~n`rZ6R#)3`GLzG%e#WY@O
zP|a>auV0g5qrJ*5&%2^SfD$BS4U?5(Bu;dQ*=ob*75cBYM~}Otbo6LkbjkT{oPj;_
z7VW(xTeu=@V=g88+zPSgh~o+XbTETHIYb%F{tE4TPmHW>;|9@EpeDn(WANebwBpzPF?{*FN-A-f`u7IGQpZVKt>}
zGueX>`>lP3ZTBJ0uoM*P^W36Lx<7hDOWQ{5zAt7SuCq?nu}
znuED8e2y1IE_`LNYXKiI8{m}-0cs~~+*!LU1&&4Bk*Z*w_c@R7`<!ONAr*G?|_yN6tN5%Q}L^pyhR#@*KKsUbZ?w@iJb81z1W
zO3)l#ZS+2lOWXvMruy4$S$rzoe182YL9gbQ-nO2hijP|EZ^5FebFr^DcH!oW3ViBZ
zz+GjS+=^Q|8@X~8KbPCXhd-ws>R#ku5{YG2!%Y-*M%n3Fh{9l
zN=qN`&#pD#HEz(XtF_8h3!H4QvI;MM`U&QlU_;k%QNBG|OFhIkiZLF}hToLtxXA4j
z!{U%=Oz!?pmmfQ$%%
z?B*4h3~kO5DZ3Nhhay4?0M6FXkIaD
zYZ9l~2fpvM-xW1Z(}J_dN)EKV%Z621&sZq7pytw`s>5fBmo7hgv^_Ew;xSpzgbS)w
z3LB8&DdFc(DJ`aSTkMroi)cbNbwH)^Dd@R_$*MQVDiETz
z3~Ru5X{}o^kw}(g?E9w|yIU5X)Wn-qyuhl`cL5g>kXU2A0AUGdnF&%^%v0<+?;k;`
zYjHDv%Xy2`bxxn=UVKp(L%d%T!cS0p#KyqUii?`8j8iW<68P$r+e&hOIdZbbrTzW0
z;{&vKQAN9wVw|Av1L+Jwe?8or*W!ug*u?yRAV}UQW6{*C^FuREW)?WLeZs36J0VmQ
z-6W?pO$x8y9XZsy-dw{Uervo}NL~Rbd0v~!t`g;~XH=;Utq`%{#Rmxz9&#YzrBuaM
z0Wm-%7m^78UWFi&owQAVE?#$l``YB%-3~#jm5R^NC%5;bg%DSav-7g?Hm7U_Wq{gv
zUX0|e&H4fN2*RYWs1`^kRjwuyAXhOd!L4SYl^2HV#7B18rBvgUC
zC4=`mhE#-dMw;^IusO#RM|k+`+uHPKZ=Sf%sH~$FE@W!?jEQ;Mr`JFe
z@KlLJ#$4xJQg+sVzgh7cI7P{=mStl$<7$pOvcWR=B~uw;smvVBoKHuMyxrH`ACHAi
zi9Mr`gFFc_@~i&rrQ*h}M41p9YWv@gKAmI=O49XCFZ&C5E5csqRHdzzW*Y4@IBqSI7Nuz?LC}EmH&W$l~J)hO!V%OL*{*u<>?Ce
zA&}-&0x?>f+<95-x<`RvQE(97r|K#^EK)q|&kI}ug+vE--zj+^y~r$-8n!JH9Uy(G
z8T8zRjF8Xtq?eyi3zrCB^pi!zpk6gy#&D!TkHZMszDpx@?2PFxG;Y15PxLc?q?XQ4
zGL59O#H!wZz^7Oce+d?4%eeXuW5iD~lN>Gp$Cc*>HNG|ARmK=AO76H9PV%UsL&^v*
zXEK0plRvO1Fgjn@=^B9c!{6zQ=rOibf?uLW)-Ko|)Abog!(3@2QgER~u;`~96m&;au
zr8=kz2If&=LMuvEzn9g#W0vm%fi6U}q=0?)y~;4IQsDy#(GmF|(y(ibkK9I-(diI&
z%}vaIwgnMP4?CZKe>7DN$(#+?S3CC$Du$GFfhxXx_l0pl3(q?K^(5km5#
z)~s_S7~Tr}B#MM;y)ALJryMfmZcil2zld9~Ttxu(>B_VS>_Kx9bqgw0c!Csv
zLu<^R`*cr8rPf
zJJG{IeU_TV+0C!qH>mKY8%1+
zuh?SW62a<32!dD6LB7J2Y_01G+~LO({9x(Xu;v8~s6`~fCHL4UtioYV9fa_IODuky
z?wWDJ1Kj!<$PJ%H^7riQlWufJ+!5zDSFQ0z513?l(9nwpOF8dQb$Z&8h_&!nl_<+F
z*Arw6k_e=0Rk;119$iM`*mH@2#1o6UNV#9Tuwv9DC8nB92>pfhQtdzsEOL&JA?G%?
zZ4>6Dr}e_6Ya72;s>WTsDgY*b@vCG~hS11&03A%`Y0N3bLU!@+>{GeVZU2#_`@ow;
z^W~g`e3s#nRgv`@xINB3!a!8%+mXV{jVv|wD6RBi|*>8?ee&Ot=xpO57Xn%aFRCo@J-sE5hcNY>8S7yz_Tvv
z>vrwm);hm~2JcjRh1Q`k
ze7la5o{)!tFqXBiS4_r#I2J7&;Sb(86L3FoEQ>ulSg;I`K-34e)<_Rx)e@^%1e0!;
z&#Tj@DVmZl#|5$UN|iHoZtB!0rz;Z8AiX*w)~2epPE3+G6i@a_sX!>N}D(DLDX7|OOhq4#|{cpspDdiR-rJciT$rU=dR
zY2PoOu;9CX_Ko*W;JSd{cim_*r{(JH>)BRE5|@g%*6{3Q)fHq2O%7UpBu9
z?xJrmY+4Z^Y-}qqMQ^oIeQ4&x)8{Vq`n@gJe|DiDRQc+{^)^Yi4f_mDqfF1$NsAs~
z+nLTzPk9Ftf3AkUqwXh;IL-ocMqYnkws*Ml-*brL(dqK?kyStYx
z&^x@A&3ALY<*6IKU*G@R*!-jIR)DVkhILsj9E=l}ICdDG+TBv1H$Um1a7U;=e<0WT
zyxPlJfEZ?m=F@#V
zfece4%jt7K3=>n6?Qc980~xhVjExlxKtLf+feXyAFfcQ~5HmD1GMk>^&1flZWM+=8
z!O+;iVEPVk#ts$(OB1u{EOVXY^(@x3n}fnI7QJc(dNj
z)C|oGGXn!lbaTyshM_ye%+lQ00!^>ErLhURItxQ%3j;KD7KRq4V7>LozBK}>L|15J
zY;KAnW@>7PA!crZ?r7jHd}B*=b;gDU$m)O_;0+8cjE#&i3^X<}#nfzUVLCk`kkK*T
z!qLFh$i>po%+1Z&%-GV>(#_P&1sESrCgyJDrlyW|3N{3l#46a?aTS*&7L`;KrKWLN
Q7+V?`bE&Gj`nz!f03p)6mH+?%

delta 17579
zcmV(rK<>ZXq6PS)1+el11rAM0u^f~417CmC=t>fl;xq_pgm}uWs?WJr_p-5S(o_3M
zF=a+U4{U=fMX8{|C<=*)5lIOwVnpNEs+x`CXao>;CCQc~Gn
zHktZG&5O1|swv<3Gl9S*Vm?HAA=`hvsaE
z5J4EeAYSWE&4AjgmKc{dbfb*4`o}5;~}v(>#~%s{s+tg?p$a0i{3YZ#765D77Z#P{PkX-
z4|S!Rc?X#>rcvG`viCwC!JyF
zPRQTM-1&ij&Xo5aD8hnvW)^={t4(+>v*w|&6{oh|x_F;W#}OXgULFp4t9JnBvd&de
zJrAe>9;lZcn%mj?F!5V4r-xSx0lVJQh6gs_R(Nkk*5U1q--)hwEzj50
zqVN~tjEy7M7PVZuoq9ncXb7e+lfHk3%(Y&%ZzdDl
z6Us`@*Y~JWlijIn;_b@V6w{u+Q+xIpFpz>zxn!}}e5V8>M#(UzCld!SSIfz!2Ry?$
z7;7gwR~0*qrjB$NKo6QjOLIr7#X?@cH=MJ
zJ_nsTjd%w^t5ub^Ha&j}m9Ll3NM-S+pPRQX4&)#fLP}v=b3~L@oAv@I&Lpw(2#9+viwP7anJw@--wYe#iU
zOMsh=CBO=3ZwZi4R?(GHk^#`lC}{#@EJ2noruG08cQbpSIY1F;ZV7U=qytzvx&Z9|
zeE^s{f-Hdll;+BR{D~#z3NQt@I$4?nKiw?7%q^Y%Q85CXEL|LcuCAZo0YF!PwTmgp
z?Xw4NjsPIY+}_>dp9DVTR*wHl$jQa=)576X_X(!r=<4Qb?gDgj1AInRk(B;-o^Cd#
zZvVt~1%9dlj#i(R7LMlb|CIDE-6zba*3A?Mas{|qdb$076U)pJU;%V>vN!eqjQt7b
z^4-j4sW`ky%f
z-CQm0t(Xzm*gs>MyM4yC27(Y+{+Sgykd-5VjrHGh3wNjg(0N$8{HsB<|I7^CXA-6s
zjv#w)fQ6-h6#|QrquXal0PX)B%gq0MB>y*1{NFV
z`q>sSko6}utjw(c76M(RfnJstDnK`L8-SIm{b$dA{w3E0Sy;N*13{Lb-2SVr046q8
z*8if@umPIef&L+Z>)$F%ki~zk;FGR@<Uet`5Xi{4R5E<-2O*3
zUmPv|=iwh1adAg4fG-mpH!pyRotN$N{(UCI$Ij{hzX|y-Ah!QJe=&7)0eS)SKkH^?
z`&adU|KszYC&T{&BLy;dwD@Oq)ZI)$7N67hKL!7&&D~vGK1u%90{E=@KhFP}drM0%
zOLK&kMMraiP}_{`Ot*U6{E-Ps{U7~okRxGEiaqMaO(k(9viTo+(28z&s*QvXB81}!i7?mSuo@&SXUd}6SLg{g{
zYVB`NsHz#2y}}Src5%4CT|UqSQFs&uVNu>Yp#+$JYfQlIMr#Jcs4qS_rA|3|xThKV
zH99ifcMUzTN63(u08b@giW`u2LYC_0ZQ^pFGoGvgl5K
zN_iK*g~^tA&Ou`RAqKw7D!OQvpx}8C5snzoUXm=#NIE7lr6F(B(7h;ky3GCOtWlUh
z!!CQ7FCK_^&>XWUlR;6!wegOwMJp;hG@q>(o@61b#mbA8sj90LBQ(Xs*+3vdB_)g!
zBU&Hyt1@+4v^37B%gvtzPN)~GMk8Z?up#$Ug=s_x2+0)3cHkL(>nzABDynN6PJbGE
z5BscE!5J^IBS-*|zTS)@UisU$dUj+58dfBuCB6r}&QsxHmx|*VKLTBL-JzM3KUOZE
z>aXA5G^4gY{hr8XpUzr5qp<%$BzU6<>d^!AiV9Xaz!~R(Y-!bU4LO
zQ#tLz`+0a|FC-S^*I-lZ_K+-pyoI{=xA>-k{+&E!?BpB2QT1mG9xDVYhLwn4>!GXsJl09V?*V$Iw?JV?j}+GaM+}SgM#S
zS;OUk<`5kI-8jsv!Bq?G-oq=z35)HnNQFZTOa;)&cdLUYiTYRUyhQtdv4$KII+_Cr
zZlQ)}9GbVIDhdN(QK0lE0II$2{61Nksi5Xba_@o@#NlcT@&e*;ZpVsw-z2PB3lG>b
zzzd(LmYAZker(SV6iR`FYoH0ie<>N}9V>Y$TAnak?W
zFp@XmWyYyw0u2iAIUZYouu-n*1a833En6R7Zpi%zS(kj{s8=XC`F$STbU63WpR1*3
zfl2l^}8yihFz15hg+cNYOV84^f}?#Q|2^(yM_2SI2~cXD+e~)
z>e`8aqhb~$#IGn@BF1Tag5?;F>3S{(F8h>>fE807z!bx7gT+WmF*o8ZQ9k-*p;f~a
z%)+lxUVx1EQQaYC+a9Xt!~H4S`M${Jq7AlMCCFg*0xeka$0%nwex8vhRfgbOGr$q-
z`JndVN&J=LK)3RLI2e5nzwVYsoRDwRz}n4wH8~^qMM2gq;b!`0#rU?i9n|x+O|?{^
zB*n<2Xv)s@ciiFjy7dQNH>BE`KS@LZ0N-V;#F-6Rb`){+@V`vhTHJvNZmsk|0xm*-sdmh1g>Y-&fryq>m(!
z`_EU%s*9Lry^&L#A95ut>2Wc|wGIZe-YkW53YD-aPWhQx_zDeI68Qw$MHhY;*yvq5cY98@JR4ea&e6^Sv!~*BGoj
z#&iWq?T=PrVjJl-Eg`b?{M>II18)=IXAm4K9v}X+wm@~df4x@N_6{ULKyh1z^WF?p
zELozdqqk5KCR!yzf)p0Y-t)O?B>uDpr{T4vEAcFU2Lo!LQRtBEy)S(uUcqd}@5Iyj
zv>gLjA!MB6#anBU04K{6f-yw$Tl6jYJ>TTV@lv674`g!fnxrr)?=Qz4CL$~b)4@Dy
z8w~sUvgwSWidAjB^HGI~Ge_zf>Z9Lv(H=LriKI*QYma@9muqZVBrApMsJ%0Op8TvTN6!t)lwe~&v@?54b)nEdf{oS*uig+LgbmSO!@VGj&p*)e^F?mCWD4Mu`Gnb#ujLE(lB_n0t?oF{kG4<$=5V7*3
zsI99+h{S$S(&;Ayr8yxtfaOC?!lWf&EcLiHc=9JcB%mYwLw7s*xs`X
zxB?DYAsEuVmD&4KBJ0C#`xEIal3Hdnp%Q|ZAYk_N_i1o(Z-g}T^vBVCs&+frznyh|
zS~F%2JCTHa!-f-@sO|2}nNjZV~mFVjI@*SQ}q9>Fx~bxd;U=Mf0Q+$EQ*kYEH;
znk|EfO3UqfN3&UBS(AYKlaf(gWB(36>Y_1in&LjB^2f$Ifkte;CFEg(y}tbELJXYFCDrev~vy!rvtFBXm4L
za=c!H3^oU-2(b;(8X`(eXopLGGO;5HrL{|_vQh;bP#V_&)|pk$LYTHKnj2fV90yxF
z3phiXPvqR;CHIGCY0n;5jNq*FO>m>1<)WD(?m_2yIj$ngQ1+FoDXQPmQ?
zZaZ^T<&~GlGDxDbp)HWULWfT&#H`mFGf0fF@u~mDFL2CCJ%P6u_n3${IzA~|89M@#
zOZk4Up=8V4#CiwKNZBlZq8@vf*3tTr)2n27u#A1-K!~2@;!3VqLK3)lzJeu_#OdXI
zs5~aoUw{M|!{IALqsd*Cks?n_jAM_hN)hr)xvN#wC7fU4EhBBTs=@^Bz%h(we6sqP
z&>!iFqyl&W0SzUMQi$O?gFt4tVhT3RAA!u}V3o!V4e`AHm{UZ5M;DT%c0K!6-mdES
zmrmQl5XpLX>DdNs)VVPXw`d>iQ6EtP*t*8QQEs5uI{J+GX7XxqGS
z>32R;7GEaMy@7i#Q*T@%_!xH6i8~{~3*p=Mt(lC3lsy+QDQqVed?Q>>(00oHTz|2}K^J9~NfMq^9Nux)DAb*1uXaj?Kdj^`f!Ib~PqX){;<Ac2pIa8k0YTWaIJ(lWnk
zjaR26mMcxGytUr84dr@ht5{4xM!+!t9fRw~0nkE;sCu{E<7BcH^4T!=D5W10DM;tV
znbV%7W23EDegh=#X6=i{=~)a*R#8bE2iBzbGhK4-R{@)R)U6rw33&DL)Yww>WE}Uk
z_`0SVuTk-TQHCj@p3rgs;P@CUt=Cl&G?Xh<%@Q%`nGiRUWRb9~YTNqOStdssC;7uH
zQxN;Wx(7yW%+DLoOR*Uirxm&~Ulfc{m6Km)Z6Qt0n1x#0LJN9kEcqLCg6vuS`A!z(
zGyQm5FZ>k;d@!-MV*_S?UN_!L+-rw~j8rFq1=4YU1{uxAzmAzR8B8ZEU_wg6S?^A0
z{1-J)6f8Uo5ThRKkWWMB0)#YlLRf!T8z`W7pklC&L?nM7nVc+Cbg1@Nex@Hoxr_-S
zto<9qXgh#bUn%sPH0_uDeU{9$d6p!5HaGdwFvd%SoeX%;PNOOzHsfz#rm+wu9&*_Q
z4>F~HX?x1u-{IgTU(9x$k9E=ZOU=3A6w>z7P=j)cp!22+-Ujl;QW@c_&<
zL0yAg?zIOrLDwtbauH5=r|!_w&ubZA
zif@k1m-J?&zxq%&6bGgAJbM=I+(FaiQb*7
zBG{eGHYU(3KmVZetpC@S^PR{NSMY9TaBsJPXIDvX`R>SQ>1p_3Lh#;GT{5EVncAFx
zce}%>iQar#cUYo4D}BI|KZ?(j61v6L9@C@>H2V!v-XWi&&J3a)povmZ=;*Kq{SXuN
zYxND2dHtc8e9!|sT#$$OD?}|DIZ=%%f_!Ydz#nrdGLhcDJa<|IXDWi)kfak9#MbsR
z)RT`L2wlV~x#jr!7S`ML@>lpHlm_V9<{6&mWk6Ksn
z6DniF>6eiFLjyjFMuZ}-#=p3Q?*wvrk+fe}2G0aBV|@}BeA2uG19j+tX}=*e28~oB
zjg5FBJ4x|L;qTxsHe6U=%}
z4qyTv5jLWcXaD?Evr~!CW2B>7tKkHsjku^uOFwveF?N-zcJi+WSCp0y-;G^x%HP1}!I+!tnGN-sAw
zHo~|D*C4M&y~pEU2z99Ycl}DfjU|mM
z4@-kxe%DbiDGhBcM2$Vaa&LG`zr(Pb`+S&?epyNU6`8EI(UoIyIdz`5d3R!D(vLcq#wVP6o+QM8J8I
zx4IO|fnBpe#wL1Z*24yWgo`xzm_sY}^?nKrI_(a1YT5=4ZZmg|4cPkE3~JPLN}IRe
zHU9XSYMn-~>7cl{uGkfZvT7D^kMA`n{86kGN*-?qN`s{)SAwpkD@>k-EDIGw=+?PC
znuHz4b+|gkUR~$D!KEN`bYlVq#dD$|h1T48;(h4xz|%h~(!@ICAoRqB|s
zan&2vw}LT5$Ju=h=jB^dT^_
z0=MC|Nou?NwIRoUp}biFJb({y+8=p=`Dy~lVN_px8cu=EH>VRw>M{8;G6xSW^NT>8
zO7`3h`>MpIciz2x_cJ(tD6M-Wx~dql049^<$1bO$b;I-dCM7}sNjZcE!d7X-D(6*7
zdx8ePFEVl8Z0@VCzNrw}iWb)h>P?QU;b#Gn5*eDkatAv<{7}5~qw`m{Vd*c*
z4LMR+*VU3(ga|{R|Jvk%!`};IiqK`6y(^e%8bm#URPCuuRO>{oYB@LJSt2c1*)RTT
z55pt;%ANjyL)eL?>D$dp0_
z3_8RlKIc)>1+sbK`Y)k}E|-YptE@89QXn^_1%V@frLXbfGF3eIbv2%=^A)zp}~9QY^xQ_Dx;@ogBI(ACdEA@M?EHWF=i*&=?!*J?t0*S_K1KO7&_3AgEksD=CU(^Xb+Du_QMue4l~(9-f6OkrXV?
zN?i)$K|wWNS7G_9_xC3Dlyh!>(ro8~DlWkonWq~!hMfIoy3Tqj<
za$vH;3T;L2zOVddVtuE9>TZA5gkXVm!P|;|RG6hwV;P;-()AYsjC1VKyOwxn-WSp&
zLlTvZMQg{{JVcj{R(Hi|CFPNZ-3@bfv)-s2G0o6{CpdQ3<;4z`@NfCnkoI)E8+E2j
zhMPW-NY8&AyO5r}3h@J{&=`Au`gTfi?);8@MaCT!Pm=GcVl(|w72KDTjyvvE;A?Py
zdN(c5Eyz-dKYuvck)ASEr1s0ZKxr6%952`$J;)2S#yO;8=o)9?z*J1$c?Wgr{;U3VW#ME_77hZ9gehr9+z2w&UjE)
zb+}TVhuvu{%8&Fb8WqdQx|dAlu`Q2(VD1+?yP7h5euS$Iw>^=deQOKfj=IVNX6
z-|OdxWCG8czuFfkcwNcoH4Fqh%ySv;HITFUT7*)n!g`yPr^Jg`0>fK5;Q_mUOrc*x
z-FXfV-E3-0!KbzzB`gcmYqKEA1xbsEbcWckZUAJb`
zWC$ZDi2Wkslg&{GXKdb(*e=AK!ML#AC^6EEkzZy!3|-(ZF3^V&a&FCkQ#~pNL+)uk
zP4cF|($almj;vgRARR#=J6m5iKvcJ-_ZuCCHpdLpP%4L=F{!Wl*L@sHy^c{+GrXQ6
z7Ld0f+v(lUOv_!m1u164B?Ag@%;J0PA=nFHsA8besfro;xRQTP@TkVE!w%uz{8Jq2
z(9_Vs97EXv3}Z>K!e#M)2N#xd4po<#?e2T?HO(|rZ!~S$t=AtlV%2N<9T=wA6h8Uak?Ou60M$9
ze(`PXbu}uuQ-14=%j?lZ-^s{y5d$H(fmxO*`7+9k*?Y)u5t4C#CAHeaoGfEiT))ey
zp2(?H%=J;rgDXZA$<6R5mojY$Hb6^7F|9?3KLx=QQRiWQPpHY3f50I$AzXU`FIUj4
z30Y4vd1Xp))=hE$d_GfS(Ze&}!$seUH37Y$`aTWO7sMNW5k~ZSVD=om4;soW_Pp0#
z4o$x{7#7DMmLyew-|n#r9LhMTM%ShXg94ty-hdogX_aTH4&k1xishcmSzyMv;lkSV
zoaigcAqB(68*&r2*!D6|CTNP^UPbB|2dHroTeN<07Ic9+4L!^}aZOVd!Rsc5sG?x|oXSdfe#}@zpJt
zn;zsTe6)N`<$@@RyQmHO9MU-TXRj*FM8B!^4RF0zB{e%xyE+YDx|%gi`gRAA50+k3
z&C^d}uL9A36(Oy5f&ww8Xmng5XTNN#d8%%w$s`$?Ql6WR
z99-oPga7f%h9P75@NqQ?DG&imZ)1cL1)h%SJdlK^INnKk$}jN)!g+^6#Mi594EpDb
za?IkOs*_I~t
zfM)j$*$%C{o$`w+;!u|y*=eB45=RueL9F3Z@^{xWP>f;)*+Ath%HWP7Z=Zw3@ekea
zeV6K&TVrKV>@Q&hRQMrzxLhWUf`^%Y}`$YoE!Ecw!p21q1JdNJJ&2SYP@IlDnVNap6$Ct#OWI
z5I%qWs*euL1A4OI0Na;*5aqTZ>KP-ii!`Z!>Sc^v?o;za7BIXVQ6FJbe+y=Y&i!SS
z*xeZVqF=6Vi3v3)W}F&{@w9bFe;rZYp#I_W{RIzZOb&gF+h;=tO5LM>l{W305eyO2oxLoY#ps{ygf#`)1+J?RbOh}to%5-YdOlmZH&I-s)3uey#jAX7z|MpQ;L
z+n~F+knbKbIjd3It$>rXH5Qp4+A%6ieZn1;2bYqZkCe(usy!h#XdGFS>LuViX?~;H
z(rAz)K`D-~*vl6k`s`_rRTM{uP*}T_&I6&fMmuErb!Bm>wdLO5>*(Eo5JK`v_L=W#
z$Y=%a*M}NGO3M7f&68IOwB8^kn2D5qnjk>evfytnpBbU2Uv3Id&h7*@t_^dc^0
z>7Ip#HS}1;`o1fFdw7As7a)6?M5U?!U{hR7H~HXSE-J>;8Ke}>6bNxwQC6cdiSOXbx2VIp&OB3RcAZhI|y;W_EA<%kapq|D(2iw~7!
zt`UCM;mpxt+RZ2)!9?em&8Y>)P>?gc@wRF!s@WKVn$A?KCv&o3eTG#+OJ!+4r%gJ{2+X1M-2I~i;Zq5s;`*Ex$suA6Ja}$d-Qm(xP3Dwe
z8LxjHNfM7LZ7k}HR0X6J(&~|AvcvowZe?Aac?(CaSu~P0%s7mB;Q}*9v=2Z^dQ31@U8+3l3Kmk`!#3dH8A4bV}qgfKD*a
zSGcNwY3;SZ;m(q}gs4G!d1Ts|0bQY4M&?J-o%7<>c@+2)s{Lz76S<=isgy}czv()s
zs`&EF?RSIOSvD_!MnfgAf_!ZKw8g(rOw8ZUP%JUrxHzoW$UMk?rk
zis&>)_if@(daFO=D0enG_=#s~RTad^QC_K{IR#z5`>Tr5D1ObS$j!*fDQ^fxvo2`G
zo7Th1eU{eoFY_%2GuHm$Cr2;Yb}KB7ACbw{Thw9Tj&{P9yOr=Y41?7LceaRQ&s&ZVef{GVIKV@yJUpSMae0DrK02&{M`{SM=fT24{gzlP1A5_r4H_T>j?p%p@H9h(^e`_d-?wuG0ponjY%6H`Pd
zsDNfTF=|y%^kR3y{($W)KnP5XiIRpezvNk*LnS(FY1ZsrpEAku{g~gTv>ykT(HeUv
zkxni~A;j~(FxQx;P9=TPndH6KTE4;-7fp{6xJDDdMBhop3;%$I}ZL$7K=ot-t*poknPQw~z?YHxPD1wp%2RSci
zKgfW5?wMLXGVzC%*O?X3_T%s2nG1hc=9r7gi!u#uh>l=0BfOfo+`j$cMW^HsM>mop
z7GBvX3?_jw`^J0)I?et)-k$(rU6Y&}Chl90cDJNtbxq1outX!a3MYn-I#@MiFmhc6
z`-Kv7b=G%$B>YlUr4R;xmFZWk19pa4eU<5&#q6M35hkjU_q?PgW5nf~tg~00_+Z~M
zpR8o*LEFi7`0_D%%Blyj4vEzE{9YhGkm8k&uE9e-|{XiRQ$57%40E-)MXZ@SFhhWB-9--#ch9&hujo^{mn-(xdtXJ)2Z4O;9=`
zrDp{m>4u}zXi+hPw|)u9N8X^LON3n
zIDlyJbz=1@$jr-sSi!8~MrE%iLDk9@ZWT9#Ny`esS1Owi;6n|@6;ZPJVO;BFw6{CJ
zn1O+o$+W`k0^c~XIXsG9T(0)=hy<2fhr7K=eHZ76LHDD$BuPqxS_MT6!O7Qwo0<5K
zDWz`a=Z?9ak$7~IFy#@ZOpxZe+^{Nl`fg2>LahZ0mHIh<$|=sRKzMN39mhzn#kYhx
zpo;yJZSnHO`9;XGpC}(cN8&DDjB7PULkMj_OeNysumIwn1Re&s`
z>>HL=7w_VBG*MpNPKqnZp_D;qL8EM4Bq8Qhq6SzTu{=TjDH)2`Zh+s`;z(2J0^tj=^3co1}(&1TX_X!Y5VX)KOs_bR@U3Y*R;GLn#@uix_qx_|X#%)>ocFLNVY3j47Jvtpo_|dMH0O(FRUwFY%D(&Z?F^0%{y?`Y}u5{`X^sH1aN90
z3EH6ogRWjd2BPkHBiVKV+?C6Yf>9u;VVbG^ia^TzkXPNwwrH*!w}+WqDjCg#XDly6
zDbdOA>v#k4D1tset3zpZID8Ra;#a-(?a}3br%5*b9*C44oab=^uk%FRzVpzIf$_nu
zndr4@ZOGM$ZKr0=We9{J!Ktq#u!{#tU|;ftXWI|$XJPxSFD5Usqqu*fG+d@tzY3Ye
zCTR6o8Tzk$cNI*v4H%*e#W75mgj}>%z3)g@P@7x1_7u?_OtKoDlv9NAW19`8^{rBW
z5HNR^RJO`wPq)0D?j*T~3C^;h1VjX7ke_aYQd(4&HsSQi*j&}}Qi&wi?(6+uY|UuO
z`FTuSP9vZB92ISj0seXso^=sCA}DsMerd+lxRQm#CeKQw{y?do^;t#y(Om^88u
zb-tF;Vt~>w9k^`ei+}{M9n$-*Sh{+Dys|G@iu0=(+xS3%6fkgk`>VWNLC)m8mW^X+
zUrthp!lJjm{^P20-szCQS0#VlQncD)M6hbRD6leE61PaG;!@d7|2F~x~st{Oyh^VSxo{6=|N+={KJL^Z^ol4B{1z4fxYhPZP}xLvp@wo
z9>NK~i4Wr#Sn`L~tiAfQ@2l?=C0W0PuLLhPE#a!i@nxhUV_ombomR4Rb4xtXpL%^^
zFO1s3iFsV)>l~X(^_}50tyY`<(&%)@s-LlOanm-EV5|A$8yP)L^G2=7P$rs5d@KAe
z`dY8>{^#cpXSvw50f52>6VK#-l1->oIWM~mB$k=ChVt^FqJ&Ni!tZ4Z1V|)!F{w1P
zAF=X9OGm^%nKYc0{kdf>HlzmeJutCL;3lgc$O$wNx7t?AC|rW!H528(iB-8*-FZZ4
zb~9%eR>}aE4#OzS9t&)a+0Y_izAl9A;
zuf*y?>qbo|`0*h8T6B42cfZ33PSM44j;i*6D16_FJ;@aP_vzPlW_vY=N56reew+P{
zgDoM~_;%LE{`LyYkePn36omY!ml=3V5r?h(5m)o_Yu38tEn!wvT7?8IF8kt7H7@Z4$*`tPs&V7%Fzs9{6?lC4XjW_Iz!SvA@dOo(Vps};FB%Wi+Ix~hu
zSy4W^3&_g)QrQ-NlDC0R9sqLO6xhwGKt|12ys>6!S!2sX)IW0FO@
zVQUremm7U%rmxi(Z{2cQh~-otadx>JZpaAVKsfnY*RrHeF>$L(-cVvyP
zjE1-7k0cy_C(4OVimdnP;mzUFA3^m;bwm{2+t*~qLjh{AmTIdmnRX)LMPI(Llt%!&>imX)fuD;!a1Nc+ii!kq0
z=z8!92GQ>?zppN|7`?d}S2M<2e|DkF}4(p)|%H3ZbYL
z6;a;WrN6hqyC6n=M9RH>x$FGfx9UAHpIDr%pJq7Wj@M7Kn~6y!2S=PD1QT2RM=y_f
zz1}2$ulY8Kgme@v33Zz(cCl=PI|tvBU4<&c0CO~(9}bpG#XY~yuY9L<@e=Gkg;<%r
z$%@8r{}=N%ZAP_L)W@x!Yvfl812dMN%p;)ou)U)#0~E!LTJ;A{^|f!pUfiAq#??wJ
zE)!k5f-KsY#dbpzof2@;rlxbobBiUqNQP;D$&B8c4zw3mqmYmY$*PrIUk2h?Tlv1t
z|Ey8hWoR}gqb40!9{H=*lm|5%o~!GLkujX{h4FEN3b)=NuybF(#*-s`hHa`szjS(wAV7gXc;Q3k
zYa$Y=MDUp_+s)7oIE{NPXV;H_@Y4i;;T9rE)jguhzg22zV5|&_RW=RMf7sdEe)R}H
z#CImXSi5urU&uABjQp}kHW1J(pF?tP&D#*>2gfvFFpRBDqjv-5B*bKJa_BU{%eU)l
zO0?3jg{hM6Yt#Z%JH5(yipo=vW6x-?J5<2QThZLpFA>DfGyL5-D1}Td?L&!wYLUvo
zid?fbEA_M93^_zh(^Q28$SZ(hfw+b02=iZ+gVmpOED#;Ar`GXbu~;0_PHT-9iK59F
zkiXwZ;LnI(x9Xqze}RFY+-y|KOJSKKRa~Zl8GBXknC+4bq4eRmc1M-uc&HTiew-|2
z3)Y~14W%I{Oo64bE?e$YUqQitva_vZ!+yZd+XlP$){b3imvJWaIpL;W7+wB>dyfo;
zQiPugKchcU!4s*lY0NHPIsb%aga_uICePBsg|ypnpNhKF60cytyOvLb2Dt_u91r@tWyv}REV6nW1dS>3@i
z2RsgP2FU7+@4Qvcz0T1x+cukPt^zrfm}LEC27>ZQV}15mS8w7?_L*Q+b4#ywqpsTF
z_4Vf94MYy3h?C`fa7X2TTVO$~s0g*L+H@Y|MinYK4*_ob1-8lIH^p~^O^2R8Q{w=d
zm$cXKb!C5GhhnC3eRC6drql|Hv=kNDCV=Qf5XTN?N&J=~EGX#MtP2a!>p5DTBE}i(
zozk9C_{4mj!-0tOP6~wm?=%lc>o+crwB;|yt2bMSJBYN2bH)^ZUm-d%8U_`NFfPw{OlVw?63smHxov+
zF?Oz9>5Ol&QAwqLwFbxTgmB`b*7V2F{;?jTI}=4yEpd$H(YBYlknp~GW8HYZ8Y!${
zAv9*SNhX0Q#>m)CofwZjJiI_e!nY1h_j&x1+ycAkPVf2dNI2PQLuwXX9Kctcc8&vK
zV8UW(lm^dyXlkgH$%KV%5USW}j}ynu?SVQ;pZ_(Zzl4QnTXF{6Q3q0u@;7I;O5>btQ+KZ^V8r)VHlsq{>URE*nC>@RE&cQH||a
zazHBh+RFV*KU+{yf?t5S@LZ%T<1izA66CD5r-FlVyMUEw}A<1_ly)UKr
zy&a64iOxQMP_vvDf8$=*BcP7UJ?~ej?=FVyDWu=_enwcboSXkV<-tfi784T&U3ucq
z`Ictp%0B39=i|KgiJWzK!f)CB>YmC%n14H+aL1C}{+y~W1Q!(?j3RrErM2E`LZHxP
zY|@*lS^Q=u#^Y@n#Ncq4W?(%#Z01n^QeNb5oE1rbQ{dGtIj6NohgR;X>CMkR?o$^2
zLWvnG0c&*Cv|}uzj#EW-Hg80Yd!9gg)jQY2o-2oD7(_W;)*p)s`Xc@&0qGjrWbTrI
zEbZW4NtAr|J!+B}tRoOr5@V6zPYW7?W04)ePzLf5Iu2p5Io_-atu%ApJCg|0D?EUX
zr^xevG+=WW`|PQ+Lv`C*kN*5ws~^O_eqYQqhI&NU{gw)bpEpVP)|!ZFt1=xO-vYBb
zRNKJG5Q%oHNctDUu2vmBDy)BNFHx{8I%DGYs>l+Wuu!B;ZZHicItmq}H`$k35E9e2
zv6$LT@p!#y)35I-=_Dftyfxq#mm)<`|7V#ZLoMn$yH>GP$6c>#d|Le
zCw_ew!9ozh(8E_^0+G5ohc(q3&c+vw>AF2V0PRh&INGp&(Ox8EQK7
z{D}}65v{!r4nuFPm1Mtt>ZGn*2hQYwZu7>=Nzh^1vQ!bvQ{p4NMV{Zj(QJkKJpUi~
z813FNzF&zb>}WNLAAxOv_%VCzsCtf{P=P&XNd{K_V1n~{@uTX}9f|Kc++9UJFj-E0
z7Be0NA|7O^$I0uSNyVAtOUduNn%1;|E|m;>9xaXLgANa!X2jwgh+pxxDuDKXI6ruj
z*osRuUgOK4CD+V5VzsR@KE)S}WhJ0Dy%Sk=ddc!7O4MU1OLs
zd{^xc#(8_iu7N=76UtJX`FQ*lzJ&Z=VhkYUVrK_Z_8`G?@I*QQ;8+JRYwN)wB*0^*
zsLpcUZLX0wx$j|Utzh4Okm{t_2<
zJQAuQng<3e?^T_`NQcLHhx|hHhbP?Z-7pQ8Q(?v#0_u!r?V5OseRUsWQgE#L<1TP%
zoYg=K+hePRpeNiE&A8~1I0d7~{7ba(TFqv{Z_rJz^w`{EK@^jJ%mmJ_!~L(rwd0Hm
zFa2N8A6=w*!F(y4H%HXd#^Xs+9&Z#xkQv0S>Zvw|=wKsJ5A}|Ef_1tN+QAf9`n(q!
zeESn1CY6H@*cEk19<-VVJUrCAS5xsYNwtAeCT$5)kuTy#-L!w`3c_{bGD-wV@vooFa$xI;Z^i4-)cTEIVs&_4#~|
z%%+1FMoi!Nwio>RNkCo=^Eo#yPj$
z7uG*8kDj!`=d*{z5hrg`8>KUSX78`0eh=NyV;$JF)PA#yJ6rsmDL-zm_SU{DowkhW
z(#B37zsHTP_7?jM>dmhw#oSO5-_)w*wEi-$UBSg8aZ{|sQh1FXH}kzPGca7>5^ixl
zzTl*vmH$kJJC7>vPyP_I&+VZ4i!XEc`LUnj*ll-J{NG*WlIOc7aG9wEc`_R{iA}kCj5j&=P72qZ$0+_$)Y9umiDSdapzQg_c
z<;Odpo)C6eyI5f>zsH4nYxt#Xa_;%>HCQLLdtZQSkJ+xa`||B+FV9+8Pkz?Fm+`Uv
z>31n>l{IgiyrAiQ^`>y|pW9s_0=zreKPv|;{`+yMWMqS{%VO>0pLabk&bm?c|JVK&
zhDt}q4C|93`K_0OG7em04%f3S%-(Q3@RdqHyT$h0^e3I^d|b!22qsVGzAv-oMug&=
z=SDpiENQ%EfpxF`|7W~^;QQ~%jH`qvbH3DJ3wLvh@C?{&{nCq(DYIg8^DALrRulc=
z%!=*P%^Ay?q4L{BtQpmLSPe{#j0~nbxHHN@naS>qtC%fKjHe5DF#0lEm|9Lx05O0Y
zGpBC=G0ZGXr+I>CLxb%Bo{WKv+NKtk3I-sckf*=}W>^@Qn_`F=8d(@kKjXz{DQ;q9
zjIP1Z#MErMj5lKki=m-`(exGGjH=9*Mi$#Icr#99Vm1frOz~s%X0
z3j-50L(B|}OwesLvotd_MOSBOVQGLSW^QR>iLMT~GvC+@O`V02fg#x5dSve!8Cjw`
z#=^+d*bqarxq&%`n56+mXc!w{I>y+@3|XBaD4;EjjmM$@Bo>ua6s4wd
RS(q4@T5_qXy863u0RYR%sJH+C

diff --git a/inst/Cohorts.csv b/inst/Cohorts.csv
index a18f8023..f48c8cda 100644
--- a/inst/Cohorts.csv
+++ b/inst/Cohorts.csv
@@ -1,4 +1,4 @@
-"cohortId","cohortName","cohortNameFormatted","cohortNameLong","librarian","status","addedVersion","logicDescription","hashTag","isCirceJson","contributors","contributorOrcIds","contributorOrganizations","peerReviewers","peerReviewerOrcIds","recommendedReferentConceptIds","ohdsiForumPost","createdDate","modifiedDate","lastModifiedBy","replaces","notes","isReferenceCohort","censorWindowStartDate","censorWindowEndDate","collapseSettingsType","collapseEraPad","exitStrategy","exitDateOffSetField","exitDateOffSet","numberOfInclusionRules","initialEventLimit","initialEventRestrictionAdditionalCriteria","initialEventRestrictionAdditionalCriteriaLimit","inclusionRuleQualifyingEventLimit","numberOfCohortEntryEvents","numberOfDomainsInEntryEvents","domainsInEntryEvents","continousObservationWindowPrior","continousObservationWindowPost","numberOfConceptSets","demographicCriteria","demographicCriteriaAge","demographicCriteriaGender","useOfObservationPeriodInclusionRule","restrictedByVisit","hasWashoutInText","domainConditionOccurrence","domainMeasurement","eventCohort","domainObservation","domainVisitOccurrence","domainDeath","domainDrugExposure","criteriaLocationAgePrimaryCriteria","domainDeviceExposure","domainProcedureOccurrence","criteriaLocationFirstPrimaryCriteria","criteriaLocationAgeInclusionRules","criteriaLocationVisitTypePrimaryCriteria","criteriaLocationFirstInclusionRules","criteriaLocationGenderPrimaryCriteria","criteriaLocationConditionSourceConceptPrimaryCriteria","criteriaLocationGenderInclusionRules","criteriaLocationProviderSpecialtyInclusionRules","criteriaLocationVisitSourceConceptPrimaryCriteria","criteriaLocationConditionSourceConceptInclusionRules","criteriaLocationProviderSpecialtyPrimaryCriteria","domainDrugEra","exitDrugCodeSetId","exitPersistenceWindow","exitSurveillanceWindow","domainConditionEra","criteriaLocationProcedureSourceConceptPrimaryCriteria","domainObservationPeriod","criteriaLocationAgeAdditionalCriteria","criteriaLocationGenderAdditionalCriteria","criteriaLocationMeasurementSourceConceptPrimaryCriteria"
+"cohortId","cohortName","cohortNameFormatted","cohortNameLong","librarian","status","addedVersion","logicDescription","hashTag","isCirceJson","contributors","contributorOrcIds","contributorOrganizations","peerReviewers","peerReviewerOrcIds","recommendedReferentConceptIds","ohdsiForumPost","createdDate","modifiedDate","lastModifiedBy","replaces","notes","isReferenceCohort","censorWindowStartDate","censorWindowEndDate","collapseSettingsType","collapseEraPad","exitStrategy","exitDateOffSetField","exitDateOffSet","numberOfInclusionRules","initialEventLimit","initialEventRestrictionAdditionalCriteria","initialEventRestrictionAdditionalCriteriaLimit","inclusionRuleQualifyingEventLimit","numberOfCohortEntryEvents","numberOfDomainsInEntryEvents","domainsInEntryEvents","continousObservationWindowPrior","continousObservationWindowPost","numberOfConceptSets","demographicCriteria","demographicCriteriaAge","demographicCriteriaGender","useOfObservationPeriodInclusionRule","restrictedByVisit","hasWashoutInText","domainConditionOccurrence","domainMeasurement","eventCohort","domainObservation","domainVisitOccurrence","domainDeath","domainDrugExposure","criteriaLocationAgePrimaryCriteria","domainDeviceExposure","domainProcedureOccurrence","criteriaLocationFirstPrimaryCriteria","criteriaLocationAgeInclusionRules","criteriaLocationVisitTypePrimaryCriteria","criteriaLocationFirstInclusionRules","criteriaLocationGenderPrimaryCriteria","criteriaLocationConditionSourceConceptPrimaryCriteria","criteriaLocationGenderInclusionRules","criteriaLocationProviderSpecialtyInclusionRules","criteriaLocationVisitSourceConceptPrimaryCriteria","criteriaLocationConditionSourceConceptInclusionRules","criteriaLocationProviderSpecialtyPrimaryCriteria","domainDrugEra","domainConditionEra","criteriaLocationProcedureSourceConceptPrimaryCriteria","exitDrugCodeSetId","exitPersistenceWindow","exitSurveillanceWindow","domainObservationPeriod","criteriaLocationAgeAdditionalCriteria","criteriaLocationGenderAdditionalCriteria","criteriaLocationMeasurementSourceConceptPrimaryCriteria"
 2,"[W] COVID-19 diagnosis or SARS-CoV-2 test (1pos)","COVID-19 diagnosis or SARS-CoV-2 test (1pos)","COVID-19 diagnosis or SARS-CoV-2 test (1pos)","rao@ohdsi.org","Withdrawn","","Withdrawn by contributor before peer review","",1,"","","","","","439676, 37311061","","2021-09-22","2023-09-19",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",0,0,"First",FALSE,"All","First",2,2,"ConditionOccurrence, Measurement",0,0,2,0,0,0,0,0,0,1,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 3,"[P] Cough or Sputum","Cough or Sputum","Cough or Sputum","rao@ohdsi.org","Pending peer review","","All events of cough or sputum finding","#Symptoms, #respiratory, #lung",1,"Gowtham A. Rao","'0000-0002-4949-7236'","'OHDSI'","","","254761","https://forums.ohdsi.org/t/17895","2021-09-22","2023-09-28",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",14,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 4,"[P] Diarrhea","Diarrhea","Diarrhea","rao@ohdsi.org","Pending peer review","","All events of diarrhea including Functional Diarrhea","#Symptoms",1,"Gowtham A. Rao","'0000-0002-4949-7236'","'OHDSI'","","","196523","https://forums.ohdsi.org/t/17895","2021-09-23","2023-09-25",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",7,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
@@ -106,7 +106,7 @@
 214,"[P] Acquired Isolated Neutropenia or unspecified leukopenia","Acquired Isolated Neutropenia or unspecified leukopenia","Acquired Isolated Neutropenia or unspecified leukopenia","rao@ohdsi.org","Pending peer review","","all events of neutropenia indexed on diagnosis or lab results with no congenital or genetic neutropenia, and no other cell lines reduced at the same time","",1,"Gowtham A. Rao","'0000-0002-4949-7236'","'OHDSI'","","","435224","https://forums.ohdsi.org/t/17409","2022-11-11","2023-09-19",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",0,9,"All",FALSE,"All","All",3,2,"ConditionOccurrence, Measurement",0,0,10,1,0,0,0,0,0,1,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 215,"[P] Isolated Immune Thrombocytopenia","Isolated Immune Thrombocytopenia","Isolated Immune Thrombocytopenia","rao@ohdsi.org","Pending peer review","","events of Immune Thrombocytopenia (ITP) with no evidence of congenital or genetic thrombocytopenia, and no simultaneous neutropenia, pancytopenia, bone marrow involvement, anemia.","#DME",1,"'Gowtham A. Rao', 'Azza Shoaibi'","'0000-0002-4949-7236', '0000-0002-6976-2594'","'OHDSI'","","","433749, 4103532","","2022-11-11","2023-09-19",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",0,8,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,9,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 216,"[P] Isolated Immune Thrombocytopenia in absence of common thrombocytopenia causes","Isolated Immune Thrombocytopenia in absence of common thrombocytopenia causes","Isolated Immune Thrombocytopenia in absence of common thrombocytopenia causes","rao@ohdsi.org","Pending peer review","","events of Immune Thrombocytopenia (ITP) with no evidence of congenital or genetic thrombocytopenia, and no simultaneous neutropenia, pancytopenia, bone marrow involvement, anemia. Persons exit after 180 days or when they have normal platelet count. Also no evidence of common causes of thrombocytopenia including hypersplenism, antiphospholipid syndrome, paroxysmal noctural hemoglobinuria, hemolytic uremic syndrome, thrombotic microangiopathy, major autoimmune disorders, chronic liver disease, pregnancy HELLP, tumors of hematopoietic cells or nutritional deficiency","#DME",1,"'Gowtham A. Rao', 'Azza Shoaibi'","'0000-0002-4949-7236', '0000-0002-6976-2594'","'OHDSI'","","","433749, 4103532","","2022-11-11","2023-09-19",,"",,0,,,"ERA",1,"fixed duration relative to initial event","EndDate",0,20,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,20,1,0,0,0,0,1,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-217,"[W] Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)","Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)","Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)","rao@ohdsi.org","Pending peer review","","Earliest events of Immune Thrombotic microangiopathy or microangiopathic hemolytic anemia indexed on the diagnosis or its treatment or investigation. Events with congenital or genetic thrombocytopenia all time prior to 7 days post index are excluded. Also excluded are patients with Platelet count > 150. cohort exit is 7 days post end date or an occurrence of a normal platelet measure .","#DME",1,"'Gowtham A. Rao', 'Azza Shoaibi'","'0000-0002-4949-7236', '0000-0002-6976-2594'","'OHDSI'","","","313800, 4119134","","2022-11-11","2023-10-03",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",7,2,"All",FALSE,"All","First",4,4,"ConditionOccurrence, DrugExposure, Measurement, ProcedureOccurrence",0,0,5,1,0,0,0,0,0,1,1,0,,,,1,,,1,,,,,,,,,,,,,,,,,,,,,
+217,"[W] Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)","Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)","Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)","rao@ohdsi.org","Pending peer review","","Earliest events of Immune Thrombotic microangiopathy or microangiopathic hemolytic anemia indexed on the diagnosis or its treatment or investigation. Events with congenital or genetic thrombocytopenia all time prior to 7 days post index are excluded. Also excluded are patients with Platelet count > 150. cohort exit is 7 days post end date or an occurrence of a normal platelet measure .","#DME",1,"'Gowtham A. Rao', 'Azza Shoaibi'","'0000-0002-4949-7236', '0000-0002-6976-2594'","'OHDSI'","","","313800, 4119134","","2022-11-11","2023-10-09",,"","same as 741",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",7,2,"All",FALSE,"All","First",4,4,"ConditionOccurrence, DrugExposure, Measurement, ProcedureOccurrence",0,0,5,1,0,0,0,0,0,1,1,0,,,,1,,,1,,,,,,,,,,,,,,,,,,,,,
 218,"[P] Rhabdomyolysis","Rhabdomyolysis","Rhabdomyolysis","rao@ohdsi.org","Pending peer review","","All events of rhabdomyolysis, indexed on a diagnosis or an observation of of Rhabdomyolysis or Myoglobinuria or a diagnosis of Muscle, ligament and fascia disorders co-occurring with a measurement of creatine kinase that is 5 times above the normal range- within 7 days. With no such events in the last 180 days washout period. Restricted to events that overlap with an inpatient visit. Events are excluded if they had recent trauma such as burn, drowning, hypothermia, hyperthermia, hyperpyrexia, crush syndrome, sepsis, march myoglobinuria, exertional rhabdomyolysis or alcohol intoxication, in the last 14 days including index. cohort exit 0 days post end date.","#DME",1,"'Gowtham A. Rao', 'Azza Shoaibi'","'0000-0002-4949-7236', '0000-0002-6976-2594'","'OHDSI'","","","137967, 4345578","","2022-11-11","2023-09-19",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",0,13,"All",FALSE,"All","All",3,2,"ConditionOccurrence, Observation",0,0,14,1,0,0,0,1,1,1,,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,
 219,"[P] Sudden Cardiac arrest or cardiac death","Sudden Cardiac arrest or cardiac death","Sudden Cardiac arrest or cardiac death","rao@ohdsi.org","Pending peer review","","Earliest event of Sudden Cardiac arrest or Cardiac death, indexed on diagnosis or observation of cardiac arrest or cardiac death or a procedures of resuscitation. Restricting to events overlapping an inpatient or ER visit. Cohort exist is 1 day post cohort end date.","#DME",1,"'Gowtham A. Rao', 'Azza Shoaibi'","'0000-0002-4949-7236', '0000-0002-6976-2594'","'OHDSI'","","","321042","","2022-11-11","2023-10-03",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",1,1,"All",FALSE,"All","First",3,3,"ConditionOccurrence, Observation, ProcedureOccurrence",0,0,2,1,0,0,0,1,0,1,,0,1,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 220,"[P] Angioedema","Angioedema","Angioedema","rao@ohdsi.org","Pending peer review","","all events of angioedema, with no recent cardiac edema, cellulitis, erysipelas, dermatitis or eczema, lymphedema or insect bites","",1,"Gowtham A. Rao","'0000-0002-4949-7236'","'OHDSI'","","","139900","","2022-11-11","2023-09-25",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",30,7,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,8,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
@@ -567,12 +567,12 @@
 737,"[P] Neutropenic Fever, Inpatient or ER, indexed on fever or Infection, 90 days era","Neutropenic Fever, Inpatient or ER, indexed on fever or Infection, 90 days era","Neutropenic Fever, Inpatient or ER, indexed on fever or Infection, 90 days era","rao@ohdsi.org","Pending peer review","","All events of febrile neutropenia, indexed on the diagnosis of febrile neutropenia or a fever (diagnosis or measurement) cooccurring with neutropenia (diagnosis or measurement) within 1 day , or a diagnosis of clinically significant infection cooccurring with neutropenia (diagnosis or measurement) within 1 day. Restricted to events overlapping with in an inpatient or emergency room visit and excluding events with a normal neutrophil count (ANC) on index. Cohort exit is 3 days after end date. Recurrent events will be combined into event eras if they are within 90 days of each other.","#DME",1,"'Gowtham A. Rao', 'Azza Shoaibi'","'0000-0002-4949-7236', '0000-0002-6976-2594'","'OHDSI'","","","257011, 437663, 4170143, 4250734","https://forums.ohdsi.org/t/17876","2023-08-23","2023-09-19",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",0,2,"All",TRUE,"All","All",8,3,"ConditionOccurrence, Measurement, Observation",0,0,7,1,0,0,0,1,0,1,1,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,
 738,"[P] Autoimmune hemolytic anemia","Autoimmune hemolytic anemia","Autoimmune hemolytic anemia","rao@ohdsi.org","Pending peer review","","All events of Autoimmune hemolytic anemia events not including evans syndrome","#Disease, #DME",1,"'Gowtham A. Rao', 'Azza Shoaibi'","'0000-0002-4949-7236', '0000-0002-6976-2594'","'OHDSI'","","","441269","","2023-08-23","2023-10-03",,"",,0,,,"ERA",1,"fixed duration relative to initial event","EndDate",0,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 739,"[P] All events of Isolated Immune Thrombocytopenia (ITP), with a washout period of 365 days","All events of Isolated Immune Thrombocytopenia (ITP), with a washout period of 365 days","Isolated Immune Thrombocytopenia (ITP), with a washout period of 365 days","rao@ohdsi.org","Pending peer review","","all events of Immune Thrombocytopenia (ITP), excluding such events in prior 365 days as washout period, also excluded are 1. events with a diagnosis of congenital or genetic thrombocytopenia all time prior to 7 days post index, 2. Events with a platelet count of >100 or a diagnosis of thrombocytosis on day of index 3. Events with co-occurring neutropenia, pancytopenia, bone marrow involvement, anemia 7 days within index. Persons exit after 180 days or when a normal platelet count measure is observed.","#DME",1,"'Gowtham A. Rao', 'Azza Shoaibi'","'0000-0002-4949-7236', '0000-0002-6976-2594'","'OHDSI'","","","433749, 4103532","","2023-08-23","2023-09-19",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",180,9,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,9,1,0,0,0,0,1,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-740,"[W] Earliest event of Pulmonary arterial hypertension (PAH)","Earliest event of Pulmonary arterial hypertension (PAH)","Pulmonary arterial hypertension (PAH)","rao@ohdsi.org","Pending peer review","","Earliest occurrence of Pulmonary Arterial Hypertension (PAH) indexed on occurrence of PAH condition requiring right heart catheterization or echocardiogram 30 days before or 30 days after diagnosis/index. Cohort exit is the end of continuous observation.","",1,"'Joel Swerdel'","","'OHDSI'","","","4013643","","2023-08-23","2023-10-03",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,3,1,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
+740,"[W] Earliest event of Pulmonary arterial hypertension (PAH)","Earliest event of Pulmonary arterial hypertension (PAH)","Pulmonary arterial hypertension (PAH)","rao@ohdsi.org","Pending peer review","","Earliest occurrence of Pulmonary Arterial Hypertension (PAH) indexed on occurrence of PAH condition requiring right heart catheterization or echocardiogram 30 days before or 30 days after diagnosis/index. Cohort exit is the end of continuous observation.","",1,"'Joel Swerdel'","","'OHDSI'","","","4013643","","2023-08-23","2023-10-09",,"","duplicate of 747",0,,,"ERA",0,"end of continuous observation",,,0,"First",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,3,1,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
 741,"[P] Earliest event of Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)","Earliest event of Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)","Earliest event of Thrombotic microangiopathy (TMA) or Microangiopathic hemolytic anemia (MAHA)","rao@ohdsi.org","Pending peer review","","Earliest events of Immune Thrombotic microangiopathy or microangiopathic hemolytic anemia indexed on the diagnosis or its treatment or investigation. Events with congenital or genetic thrombocytopenia all time prior to 7 days post index are excluded. Also excluded are patients with Platelet count > 150. cohort exit is 7 days post end date or an occurrence of a normal platelet measure .","#DME",1,"'Gowtham A. Rao', 'Azza Shoaibi'","'0000-0002-4949-7236', '0000-0002-6976-2594'","'OHDSI'","","","313800, 4119134","","2023-08-23","2023-09-19",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",7,2,"All",FALSE,"All","First",4,4,"ConditionOccurrence, DrugExposure, Measurement, ProcedureOccurrence",0,0,5,1,0,0,0,0,0,1,1,0,,,,1,,,1,,,,,,,,,,,,,,,,,,,,,
 742,"[P] Parasomnia or Sleep dysfunction with arousal disturbance","Parasomnia or Sleep dysfunction with arousal disturbance","Parasomnia or Sleep dysfunction with arousal disturbance","rao@ohdsi.org","Pending peer review","","All events of Parasomnia or Sleep dysfunction with arousal disturbance with events collapse 1 day after","",1,"'Gowtham A. Rao', 'Azza Shoaibi'","'0000-0002-4949-7236', '0000-0002-6976-2594'","'OHDSI'","","","254761","https://forums.ohdsi.org/t/17895","2023-09-08","2023-09-21",,"",,0,,,"ERA",1,"fixed duration relative to initial event","EndDate",0,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 743,"[P] Diabetic ketoacidosis IP-ER (SNOMED concept)","Diabetic ketoacidosis IP-ER (SNOMED concept)","Diabetic ketoacidosis identified during the inpatient or emergency room SNOMED concept","rao@ohdsi.org","Pending peer review","","All condition occurrences of DKA during an ER or IP visit, with 30-day event persistence (SNOMED code only)","",1,"'James Weaver', 'Chris Knoll'","'0000-0003-0755-5191',''","'OHDSI'","","","196523","https://forums.ohdsi.org/t/17895","2023-09-08","2023-09-20",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",30,0,"All",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 744,"[P] Pulmonary Hypertension","Pulmonary Hypertension","Pulmonary Hypertension","rao@ohdsi.org","Pending peer review","","First occurrence of Pulmonary Hypertension","",1,"'Joel N. Swerdel'","'0000-0001-9491-2737'","'OHDSI'","","","312437, 4041664","https://forums.ohdsi.org/t/17895","2023-09-14","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-745,"[W] Inflammatory Bowel Disease","Inflammatory Bowel Disease","Inflammatory Bowel Disease","rao@ohdsi.org","Pending peer review","","First occurrence of Inflammatory Bowel Disease","",1,"'Joel N. Swerdel'","'0000-0001-9491-2737'","'OHDSI'","","","4074815, 81893, 201606",,"2023-09-14","2023-10-03",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+745,"[W] Inflammatory Bowel Disease","Inflammatory Bowel Disease","Inflammatory Bowel Disease","rao@ohdsi.org","Pending peer review","","First occurrence of Inflammatory Bowel Disease","",1,"'Joel N. Swerdel'","'0000-0001-9491-2737'","'OHDSI'","","","4074815, 81893, 201606",,"2023-09-14","2023-10-09",,"","duplicate of 745",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 746,"[P] Chronic Thromboembolic Pulmonary Hypertension","Chronic Thromboembolic Pulmonary Hypertension","Chronic Thromboembolic Pulmonary Hypertension","rao@ohdsi.org","Pending peer review","","First occurrence of Chronic Thromboembolic Pulmonary Hypertension","",1,"'Joel N. Swerdel'","'0000-0001-9491-2737'","'OHDSI'","","","378253","https://forums.ohdsi.org/t/17895","2023-09-14","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,3,1,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
 747,"[P] Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension","rao@ohdsi.org","Pending peer review","","First occurrence of Pulmonary Arterial Hypertension","",1,"'Joel N. Swerdel'","'0000-0001-9491-2737'","'OHDSI'","","","43530714","https://forums.ohdsi.org/t/17895","2023-09-14","2023-10-02",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,3,1,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
 748,"[P] Psoriatic arthritis","Psoriatic arthritis","Psoriatic arthritis","rao@ohdsi.org","Pending peer review","","First occurrence of Psoriatic arthritis","",1,"'Joel N. Swerdel'","'0000-0001-9491-2737'","'OHDSI'","","","25297, 4226263","https://forums.ohdsi.org/t/17895","2023-09-14","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",2,1,"ConditionOccurrence",0,0,3,1,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
@@ -597,8 +597,8 @@
 768,"[P] Earliest event of Sickle Cell Anemia","Earliest event of Sickle Cell Anemia","Sickle Cell Anemia","rao@ohdsi.org","Pending peer review","","First occurrence of Sickle Cell Anemia","#epi1073",1,"'Joel Swerdel','Eva-maria Didden'","'0000-0001-9491-2737','0000-0001-7401-8877'","'OHDSI'","","","255573","","2023-09-16","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 769,"[P] Scleroderma, first occurrence","Scleroderma, first occurrence","Scleroderma","rao@ohdsi.org","Pending peer review","","First occurrence of Scleroderma","#epi1073",1,"'Joel Swerdel','Eva-maria Didden'","'0000-0001-9491-2737','0000-0001-7401-8877'","","","","76685, 80809, 81893, 81931, 134442, 134618, 135215, 140168, 194992, 199856, 201254, 201606, 254443, 257628, 374919, 432295, 438688, 443394, 4137275, 4232076","","2023-09-16","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 770,"[P] Essential Hypertension, first occurrence","Essential Hypertension, first occurrence","Essential Hypertension","rao@ohdsi.org","Pending peer review","","First occurrence of Essential Hypertension","#epi1073",1,"'Joel Swerdel','Eva-maria Didden'","'0000-0001-9491-2737','0000-0001-7401-8877'","'OHDSI'","","","253954, 434557","","2023-09-16","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-771,"[W] Pulmonary Hypertension (Group 2 Left heart disease, encompassing)","Pulmonary Hypertension (Group 2 Left heart disease, encompassing)","Pulmonary hypertension associated with left heart disease (WHO Group 2)","rao@ohdsi.org","Pending peer review","","First occurrence of Pulmonary hypertension associated with left heart disease (WHO Group 2)","#epi1073",1,"'Joel Swerdel','Eva-maria Didden'","'0000-0001-9491-2737','0000-0001-7401-8877'","'OHDSI'","","","137809, 443392","","2023-09-16","2023-09-25",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,5,1,0,0,1,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-772,"[W] Pulmonary Hypertension (Group 3 Chronic lung disease, encompassing)","Pulmonary Hypertension (Group 3 Chronic lung disease, encompassing)","Pulmonary hypertension associated with lung diseases and/or hypoxia (WHO Group 3)","rao@ohdsi.org","Pending peer review","","First occurrence of Pulmonary hypertension associated with lung diseases and/or hypoxia (WHO Group 3)","#epi1073",1,"'Joel Swerdel','Eva-maria Didden'","'0000-0001-9491-2737','0000-0001-7401-8877'","'OHDSI'","","","433736","https://forums.ohdsi.org/t/17895","2023-09-16","2023-09-25",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,3,1,0,0,1,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+771,"[W] Pulmonary Hypertension (Group 2 Left heart disease, encompassing)","Pulmonary Hypertension (Group 2 Left heart disease, encompassing)","Pulmonary hypertension associated with left heart disease (WHO Group 2)","rao@ohdsi.org","Pending peer review","","First occurrence of Pulmonary hypertension associated with left heart disease (WHO Group 2)","#epi1073",1,"'Joel Swerdel','Eva-maria Didden'","'0000-0001-9491-2737','0000-0001-7401-8877'","'OHDSI'","","","137809, 443392","","2023-09-16","2023-10-09",,"","duplicate of 750",0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,5,1,0,0,1,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+772,"[W] Pulmonary Hypertension (Group 3 Chronic lung disease, encompassing)","Pulmonary Hypertension (Group 3 Chronic lung disease, encompassing)","Pulmonary hypertension associated with lung diseases and/or hypoxia (WHO Group 3)","rao@ohdsi.org","Pending peer review","","First occurrence of Pulmonary hypertension associated with lung diseases and/or hypoxia (WHO Group 3)","#epi1073",1,"'Joel Swerdel','Eva-maria Didden'","'0000-0001-9491-2737','0000-0001-7401-8877'","'OHDSI'","","","433736","https://forums.ohdsi.org/t/17895","2023-09-16","2023-10-09",,"","replaced by 751. removed prefix and santized.",0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,3,1,0,0,1,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 773,"[P] Congenital Heart Disease","Congenital Heart Disease","Congenital Heart Disease","rao@ohdsi.org","Pending peer review","","First occurrence of Congenital Heart Disease","#epi1073",1,"'Joel Swerdel','Eva-maria Didden'","'0000-0001-9491-2737','0000-0001-7401-8877'","'OHDSI'","","","4182210","","2023-09-16","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 774,"[P] Portal Hypertension, first occurrence","Portal Hypertension, first occurrence","Portal Hypertension","rao@ohdsi.org","Pending peer review","","First occurrence of Portal Hypertension","#epi1073",1,"'Joel Swerdel','Eva-maria Didden'","'0000-0001-9491-2737','0000-0001-7401-8877'","'OHDSI'","","","312648, 4028741","","2023-09-16","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
 775,"[P] First Inflammatory Bowel Disease","First Inflammatory Bowel Disease","Inflammatory Bowel Disease","rao@ohdsi.org","Pending peer review","","First occurrence of Inflammatory Bowel Disease","",1,"'Joel N. Swerdel'","'0000-0001-9491-2737'","'OHDSI'","","","4074815, 81893, 201606",,"2023-09-16","2023-10-03",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
@@ -620,11 +620,11 @@
 791,"[P] Multiple Myeloma","Multiple Myeloma","Multiple Myeloma","rao@ohdsi.org","Pending peer review","","","",1,"'Asieh Golozar'","'0000-0002-4243-155X'","","","","","","2023-09-16","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",2,2,"ConditionOccurrence, Observation",365,0,1,0,0,0,0,0,0,1,,0,1,,,,,,,1,,,,,,,,,,,,,,,,,,,,
 792,"[P] Metastatic Hormone-Sensitive Prostate Cancer Synchronous","Metastatic Hormone-Sensitive Prostate Cancer Synchronous","Metastatic Hormone-Sensitive Prostate Cancer Synchronous","rao@ohdsi.org","Pending peer review","","","#Pioneer2",1,"'Asieh Golozar'","'0000-0002-4243-155X'","'OHDSI'","","","377091, 4196708","https://forums.ohdsi.org/t/17895","2023-09-16","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",3,2,"ConditionOccurrence, Measurement",183,183,6,1,1,1,0,0,0,1,1,0,,,,,,,,1,1,,1,,,1,,,,,,,,,,,,,,
 793,"[P] Metastatic Hormone-Sensitive Prostate Cancer Metachronus","Metastatic Hormone-Sensitive Prostate Cancer Metachronus","Metastatic Hormone-Sensitive Prostate Cancer Metachronus","rao@ohdsi.org","Pending peer review","","","#Pioneer2",1,"'Asieh Golozar'","'0000-0002-4243-155X'","'OHDSI'","","","439676, 37311061","","2023-09-16","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,7,"First",FALSE,"All","First",3,2,"ConditionOccurrence, Measurement",183,0,8,1,1,1,0,0,0,1,1,0,,,,,,,,1,1,,1,,,1,,,,,,,,,,,,,,
-794,"[W] Hemorrhage of digestive system","Hemorrhage of digestive system","Hemorrhage of digestive system","rao@ohdsi.org","Pending peer review","","all events of Hemorrhage of digestive system. Persons exit on cohort end date","",1,"","'","'","","","","","2023-09-17","2023-10-04",,"",,0,,,"ERA",1,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,0,1,7,,,,,,
+794,"[P] Hemorrhage of digestive system","Hemorrhage of digestive system","Hemorrhage of digestive system","rao@ohdsi.org","Pending peer review","","all events of Hemorrhage of digestive system. Persons exit on cohort end date plus 14 days","",1,"Gowtham A. Rao","'0000-0002-4949-7236'","'OHDSI'","","","","","2023-09-17","2023-10-09",,"","this cohort definition is wrong",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",14,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 795,"[P] Antineoplastic drugs against colorectal cancer","Antineoplastic drugs against colorectal cancer","Antineoplastic drugs against colorectal cancer","rao@ohdsi.org","Pending peer review","","First exposure of drugs Antineoplastic drugs against colorectal cancer.","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","439676, 37311061","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,0,,,,1,,,,,,,,,,,,,,,,,,,,,,,,
 796,"[P] Potential curative surgery for colorectal cancer","Potential curative surgery for colorectal cancer","Potential curative surgery for colorectal cancer","rao@ohdsi.org","Pending peer review","","First event potential curative surgery for colorectal cancer.","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ProcedureOccurrence",0,0,1,0,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 797,"[P] Radiotherapy against colorectal cancer","Radiotherapy against colorectal cancer","Radiotherapy against colorectal cancer","rao@ohdsi.org","Pending peer review","","First exposure of radiotherapy, excluding procedures with that are probably not related to colorectal cancer.","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","317302, 320425","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ProcedureOccurrence",0,0,1,0,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
-798,"[P] Primary adenocarcinoma of the colon or rectum","Primary adenocarcinoma of the colon or rectum","Primary adenocarcinoma of the colon or rectum","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of the colon or rectum","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","377091, 4196708","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,1,0,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
+798,"[P] Primary adenocarcinoma of the colon or rectum","Primary adenocarcinoma of the colon or rectum","Primary adenocarcinoma of the colon or rectum","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of the colon or rectum","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","377091, 4196708","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,1,0,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
 802,"[P] Acute Respiratory Failure 2","Acute Respiratory Failure 2","Acute Respiratory Failure","rao@ohdsi.org","Pending peer review","","First event of acute respiratory failure","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","Evan Minty","","79908, 139803, 443904","https://forums.ohdsi.org/t/17769","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 803,"[P] Fascial dehiscence and evisceration","Fascial dehiscence and evisceration","Fascial dehiscence and evisceration","rao@ohdsi.org","Pending peer review","","First fascial dehiscence or evisceration","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","254761, 312437, 437663, 439926, 442752, 4041664, 4178904, 4272240, 43530714","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",2,2,"ConditionOccurrence, ProcedureOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 804,"[P] Anastomotic leak or dehiscence","Anastomotic leak or dehiscence","Anastomotic leak or dehiscence","rao@ohdsi.org","Pending peer review","","First event of anastomotic leak or dehiscence of large or small intestine","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","199074","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,2,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
@@ -635,42 +635,42 @@
 809,"[P] Surgical wound infection (narrow)","Surgical wound infection (narrow)","Surgical wound infection (narrow)","rao@ohdsi.org","Pending peer review","","First event surgical wound infection","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","443454","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,2,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 810,"[P] Distant metastasis following colorectal cancer (wide)","Distant metastasis following colorectal cancer (wide)","Distant metastasis following colorectal cancer (wide)","rao@ohdsi.org","Pending peer review","","First event distant metastasis following colorectal cancer","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","314666, 4329847","https://forums.ohdsi.org/t/15900","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 811,"[P] Local recurrence after colorectal cancer","Local recurrence after colorectal cancer","Local recurrence after colorectal cancer","rao@ohdsi.org","Pending peer review","","First event local recurrence after colorectal cancer","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","4183609, 4266367","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-812,"[P] Primary adenocarcinoma of the colon or rectum, MSI-H or dMMR, no surgery or oncological treatment","Primary adenocarcinoma of the colon or rectum, MSI-H or dMMR, no surgery or oncological treatment","Primary adenocarcinoma of the colon or rectum, MSI-H or dMMR, no surgery or oncological treatment","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of the colon or rectum with MSI-H or dMMR, no curative surgery or oncological treatment any time after","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","376713, 439847","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,12,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
+812,"[P] Primary adenocarcinoma of the colon or rectum, MSI-H or dMMR, no surgery or oncological treatment","Primary adenocarcinoma of the colon or rectum, MSI-H or dMMR, no surgery or oncological treatment","Primary adenocarcinoma of the colon or rectum, MSI-H or dMMR, no surgery or oncological treatment","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of the colon or rectum with MSI-H or dMMR, no curative surgery or oncological treatment any time after","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","376713, 439847","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,12,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
 813,"[P] Primary adenocarcinoma of the colon or rectum treated with potentially curative surgery","Primary adenocarcinoma of the colon or rectum treated with potentially curative surgery","Primary adenocarcinoma of the colon or rectum treated with potentially curative surgery","rao@ohdsi.org","Pending peer review","","First event of Primary adenocarcinoma of the colon or rectum treated with curative surgery within 90 days of the operation","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","443454","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ProcedureOccurrence",365,0,3,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
-814,"[P] Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment","Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment","Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment","rao@ohdsi.org","Pending peer review","","First event of Primary adenocarcinoma of the colon or rectum treated with no curative surgery but oncological treatment within 90 days of the operation","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","373503","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,4,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
+814,"[P] Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment","Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment","Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment","rao@ohdsi.org","Pending peer review","","First event of Primary adenocarcinoma of the colon or rectum treated with no curative surgery but oncological treatment within 90 days of the operation","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","373503","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,4,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
 817,"[P] Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment2","Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment2","Primary adenocarcinoma of the colon or rectum, no curative intended surgery and oncological treatment","rao@ohdsi.org","Pending peer review","","Primary adenocarcinoma of the colon or rectum, no curative intended surgery, and oncological treatment at any time after","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","192671","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ConditionOccurrence",365,0,4,1,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-818,"[P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR","Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR","Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of the colon or rectum, with a molecular subtype of MSI-L, MSI-indeterminate, MSS or pMMR","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","313217, 44784217","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,11,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
+818,"[P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR","Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR","Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of the colon or rectum, with a molecular subtype of MSI-L, MSI-indeterminate, MSS or pMMR","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","313217, 44784217","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,11,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
 819,"[P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, treated with curative intended surgery","Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, treated with curative intended surgery","Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, treated with curative intended surgery","rao@ohdsi.org","Pending peer review","","First event of Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, treated with curative intended surgery within 90 days of diagnosis","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","438624, 4027133","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ProcedureOccurrence",365,0,12,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 820,"[P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment, no curative surgery","Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment, no curative surgery","Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment, no curative surgery","rao@ohdsi.org","Pending peer review","","First event of Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, treated with oncological therapy, but no curative intended surgery","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,2,"DrugEra, ProcedureOccurrence",365,0,15,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,1,,,,,,,,,
-821,"[P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment","Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment","Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment","rao@ohdsi.org","Pending peer review","","First event of Primary adenocarcinoma of the colon or rectum with a MSI-L, MSI-indeterminate, MSS or pMMR subtype, and no surgery or oncological treatment anytime in the future.","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,14,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
+821,"[P] Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment","Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment","Primary adenocarcinoma of the colon or rectum, MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment","rao@ohdsi.org","Pending peer review","","First event of Primary adenocarcinoma of the colon or rectum with a MSI-L, MSI-indeterminate, MSS or pMMR subtype, and no surgery or oncological treatment anytime in the future.","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,14,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
 822,"[P] Primary adenocarcinoma of colon or rectum, MSI-H or dMMR, surgical treatment","Primary adenocarcinoma of colon or rectum, MSI-H or dMMR, surgical treatment","Primary adenocarcinoma of colon or rectum, MSI-H or dMMR, surgical treatment","rao@ohdsi.org","Pending peer review","","First event of Primary adenocarcinoma of the colon or rectum with the MSI-H or dMMR molecular subtype, receiving potential curative surgery","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","40481547","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ProcedureOccurrence",365,0,10,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 823,"[P] Primary adenocarcinoma of colon or rectum, MSI-H or dMMR, oncological treatment no surgery","Primary adenocarcinoma of colon or rectum, MSI-H or dMMR, oncological treatment no surgery","Primary adenocarcinoma of colon or rectum, MSI-H or dMMR, oncological treatment no surgery","rao@ohdsi.org","Pending peer review","","First event primary adenocarcinoma of the colon or rectum, with MSI-H or dMMR molecular subtype, treated with oncological treatment no curative surgery","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","439676, 37311061","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",2,2,"DrugExposure, ProcedureOccurrence",365,0,12,1,0,0,0,0,0,,,0,,,,1,,,1,,,,,,,,,,,,,,,,,,,,,
-824,"[P] Primary adenocarcinoma of colon or rectum,  MSI-H or dMMR","Primary adenocarcinoma of colon or rectum, MSI-H or dMMR","Primary adenocarcinoma of colon or rectum, MSI-H or dMMR","rao@ohdsi.org","Pending peer review","","First event Primary adenocarcinoma of the colon or rectum, with MSI-H or dMMR molecular subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,11,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
-825,"[P] Primary adenocarcinoma of colon","Primary adenocarcinoma of colon","Primary adenocarcinoma of colon","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of colon","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,1,0,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
+824,"[P] Primary adenocarcinoma of colon or rectum,  MSI-H or dMMR","Primary adenocarcinoma of colon or rectum, MSI-H or dMMR","Primary adenocarcinoma of colon or rectum, MSI-H or dMMR","rao@ohdsi.org","Pending peer review","","First event Primary adenocarcinoma of the colon or rectum, with MSI-H or dMMR molecular subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,11,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
+825,"[P] Primary adenocarcinoma of colon","Primary adenocarcinoma of colon","Primary adenocarcinoma of colon","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of colon","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,1,0,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
 826,"[P] Primary adenocarcinoma of colon, no surgery or oncological treatment","Primary adenocarcinoma of colon, no surgery or oncological treatment","Primary adenocarcinoma of colon, no surgery or oncological treatment","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of the colon, no curative surgery and no oncological treatment anytime after","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","373995","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ConditionOccurrence",365,0,4,1,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 827,"[P] Primary adenocarcinoma of colon surgical treatment","Primary adenocarcinoma of colon surgical treatment","Primary adenocarcinoma of colon surgical treatment","rao@ohdsi.org","Pending peer review","","First event of curative surgery for primary adenocarcinoma","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","378419","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ProcedureOccurrence",365,0,2,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 828,"[P] Primary adenocarcinoma of colon oncological treatment, no surgery","Primary adenocarcinoma of colon oncological treatment, no surgery","Primary adenocarcinoma of colon oncological treatment, no surgery","rao@ohdsi.org","Pending peer review","","First event of oncological treatment after primary adenocarcinoma, with no curative surgery","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","138525, 194133","https://forums.ohdsi.org/t/18223","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,2,"DrugExposure, ProcedureOccurrence",365,0,4,1,0,0,0,0,0,,,0,,,,1,,,1,,,,,,,,,,,,,,,,,,,,,
-829,"[P] Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR","Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR","Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of colon, with MSI-L or pMMR molecular subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","444362","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,11,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
+829,"[P] Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR","Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR","Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of colon, with MSI-L or pMMR molecular subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","444362","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,11,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
 830,"[P] Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR, surgically treated","Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR, surgically treated","Primary adenocarcinoma of colon, MSI-L, MSI-indeterminate, MSS or pMMR, surgically treated","rao@ohdsi.org","Pending peer review","","First event of potential curative surgery after a primary adenocarcinoma with MSI-L, MSS, pMMR molecular subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","","","","438409, 4047120","https://forums.ohdsi.org/t/15901","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ProcedureOccurrence",365,0,12,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 831,"[P] Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment, no surgery","Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment, no surgery","Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment, no surgery","rao@ohdsi.org","Pending peer review","","First event of oncological treatment of primary adenocarcinoma of colon with MSS, MSI-L or pMMR subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","314666, 4296653, 4329847","https://forums.ohdsi.org/t/15900","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,2,"DrugEra, ProcedureOccurrence",365,0,14,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,1,,,,,,,,,
-832,"[P] Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment","Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment","Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment","rao@ohdsi.org","Pending peer review","","First event of adenocarcinoma of colon with molecular subtype pMMR/MSI-L/MSS for patients not receiving surgery or oncological treatment","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","198263","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,14,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
-833,"[P] Primary adenocarcinoma of colon MSI-H or dMMR","Primary adenocarcinoma of colon MSI-H or dMMR","Primary adenocarcinoma of colon MSI-H or dMMR","rao@ohdsi.org","Pending peer review","","First event of a primary adenocarcinoma of colon with MSI-H / pMMR molecular profile","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","442597, 4152351","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,9,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
+832,"[P] Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment","Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment","Primary adenocarcinoma of colon MSI-L, MSI-indeterminate, MSS or pMMR, no surgery or oncological treatment","rao@ohdsi.org","Pending peer review","","First event of adenocarcinoma of colon with molecular subtype pMMR/MSI-L/MSS for patients not receiving surgery or oncological treatment","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","198263","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,14,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
+833,"[P] Primary adenocarcinoma of colon MSI-H or dMMR","Primary adenocarcinoma of colon MSI-H or dMMR","Primary adenocarcinoma of colon MSI-H or dMMR","rao@ohdsi.org","Pending peer review","","First event of a primary adenocarcinoma of colon with MSI-H / pMMR molecular profile","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","442597, 4152351","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,9,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
 834,"[P] Primary adenocarcinoma of colon MSI-H or dMMR, surgical treatment","Primary adenocarcinoma of colon MSI-H or dMMR, surgical treatment","Primary adenocarcinoma of colon MSI-H or dMMR, surgical treatment","rao@ohdsi.org","Pending peer review","","First event of potentially curative surgery for adenocarcinoma of colon following diagnosis of MSI-H dMMR subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","439926, 4272240","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ProcedureOccurrence",365,0,10,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 835,"[P] Primary adenocarcinoma of colon MSI-H or dMMR, oncological treatment, no surgery","Primary adenocarcinoma of colon MSI-H or dMMR, oncological treatment, no surgery","Primary adenocarcinoma of colon MSI-H or dMMR, oncological treatment, no surgery","rao@ohdsi.org","Pending peer review","","First event of oncological treatment for colorectal cancer following diagnosis of primary adenocarcinoma of colon with MSI-H or dMMR profile, no curative surgery","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","4096682",,"2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,2,"DrugEra, ProcedureOccurrence",365,0,14,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,1,,,,,,,,,
-836,"[P] Primary adenocarcinoma of colon MSI-H or dMMR, no surgery or oncological treatment","Primary adenocarcinoma of colon MSI-H or dMMR, no surgery or oncological treatment","Primary adenocarcinoma of colon MSI-H or dMMR, no surgery or oncological treatment","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of colon with MSI-H or dMMR profile, no curative surgery or oncological treatment at anytime past diagnosis","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","137977, 435656","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,12,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
-837,"[P] Primary adenocarcinoma of rectum","Primary adenocarcinoma of rectum","Primary adenocarcinoma of rectum","rao@ohdsi.org","Pending peer review","","First event of a primary adenocarcinoma of rectum","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","436222","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,1,0,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
-838,"[P] Primary adenocarcinoma of rectum MSI-H or dMMR","Primary adenocarcinoma of rectum MSI-H or dMMR","Primary adenocarcinoma of rectum MSI-H or dMMR","rao@ohdsi.org","Pending peer review","","First event of a primary adenocarcinoma of rectum with MSI-H or dMMR molecular subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","196360, 197508","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,9,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
-839,"[P] Primary adenocarcinoma of rectum, MSI-H or dMMR, no surgery or oncological treatment","Primary adenocarcinoma of rectum, MSI-H or dMMR, no surgery or oncological treatment","Primary adenocarcinoma of rectum, MSI-H or dMMR, no surgery or oncological treatment","rao@ohdsi.org","Pending peer review","","First event of a primary adenocarcinoma of rectum with MSI-H or dMMR molecular subtype, without any curative surgery or oncological treatment in the future","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","80809","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,12,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
+836,"[P] Primary adenocarcinoma of colon MSI-H or dMMR, no surgery or oncological treatment","Primary adenocarcinoma of colon MSI-H or dMMR, no surgery or oncological treatment","Primary adenocarcinoma of colon MSI-H or dMMR, no surgery or oncological treatment","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of colon with MSI-H or dMMR profile, no curative surgery or oncological treatment at anytime past diagnosis","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","137977, 435656","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,12,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
+837,"[P] Primary adenocarcinoma of rectum","Primary adenocarcinoma of rectum","Primary adenocarcinoma of rectum","rao@ohdsi.org","Pending peer review","","First event of a primary adenocarcinoma of rectum","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","436222","https://forums.ohdsi.org/t/17895","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,1,0,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
+838,"[P] Primary adenocarcinoma of rectum MSI-H or dMMR","Primary adenocarcinoma of rectum MSI-H or dMMR","Primary adenocarcinoma of rectum MSI-H or dMMR","rao@ohdsi.org","Pending peer review","","First event of a primary adenocarcinoma of rectum with MSI-H or dMMR molecular subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","196360, 197508","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,9,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
+839,"[P] Primary adenocarcinoma of rectum, MSI-H or dMMR, no surgery or oncological treatment","Primary adenocarcinoma of rectum, MSI-H or dMMR, no surgery or oncological treatment","Primary adenocarcinoma of rectum, MSI-H or dMMR, no surgery or oncological treatment","rao@ohdsi.org","Pending peer review","","First event of a primary adenocarcinoma of rectum with MSI-H or dMMR molecular subtype, without any curative surgery or oncological treatment in the future","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","80809","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,12,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
 840,"[P] Primary adenocarcinoma of rectum MSI-H or dMMR, oncological treatment, no surgery","Primary adenocarcinoma of rectum MSI-H or dMMR, oncological treatment, no surgery","Primary adenocarcinoma of rectum MSI-H or dMMR, oncological treatment, no surgery","rao@ohdsi.org","Pending peer review","","First event of oncological treatment for patient with primary adenocarcinoma of rectum with MSI-H or dMMR molecular subtype, without any curative surgery","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","318443, 764123","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",2,2,"DrugExposure, ProcedureOccurrence",365,0,12,1,0,0,0,0,0,,,0,,,,1,,,1,,,,,,,,,,,,,,,,,,,,,
 841,"[P] Primary adenocarcinoma of rectum, MSI-H or dMMR, surgical treatment","Primary adenocarcinoma of rectum, MSI-H or dMMR, surgical treatment","Primary adenocarcinoma of rectum, MSI-H or dMMR, surgical treatment","rao@ohdsi.org","Pending peer review","","First event of potentially curative surgery for patients diagnosed with primary adenocarcinoma of rectum with MSI-H / dMMR subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","201606","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ProcedureOccurrence",365,0,10,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
-842,"[P] Primary adenocarcinoma of rectum, MSI-L, MSI-indeterminate, MSS or pMMR","Primary adenocarcinoma of rectum, MSI-L, MSI-indeterminate, MSS or pMMR","Primary adenocarcinoma of rectum, MSI-L, MSI-indeterminate, MSS or pMMR","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of rectum, with MSI-L, MSI-indeterminate, MSS or pMMR subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","440383","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,11,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
+842,"[P] Primary adenocarcinoma of rectum, MSI-L, MSI-indeterminate, MSS or pMMR","Primary adenocarcinoma of rectum, MSI-L, MSI-indeterminate, MSS or pMMR","Primary adenocarcinoma of rectum, MSI-L, MSI-indeterminate, MSS or pMMR","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of rectum, with MSI-L, MSI-indeterminate, MSS or pMMR subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","440383","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,11,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
 843,"[P] Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment,  no surgery","Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment, no surgery","Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, oncological treatment, no surgery","rao@ohdsi.org","Pending peer review","","First event of oncology in patients diagnosed with primary adenocarcinoma of rectum with MSI-L, MSI-indeterminate, MSS or pMMR profile, with no subsequent potentially curative surgery","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","140168","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,2,"DrugEra, ProcedureOccurrence",365,0,14,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,1,,,,,,,,,
-844,"[P] Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, no surgery and no oncological treatment","Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, no surgery and no oncological treatment","Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, no surgery and no oncological treatment","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of tectum with MSI-L / MSS / pMMR profile, no surgery or oncological treatment","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","81893","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,13,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,,,,1,,,,,
+844,"[P] Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, no surgery and no oncological treatment","Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, no surgery and no oncological treatment","Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, no surgery and no oncological treatment","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of tectum with MSI-L / MSS / pMMR profile, no surgery or oncological treatment","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","81893","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ConditionEra",365,0,13,1,0,0,0,0,0,,,0,,,,,,,,,,,,,,,,,,,,1,,,,,,,,
 845,"[P] Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, treated with potentially curative surgery","Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, treated with potentially curative surgery","Primary adenocarcinoma of rectum MSI-L, MSI-indeterminate, MSS or pMMR, treated with potentially curative surgery","rao@ohdsi.org","Pending peer review","","First event of potentially curative surgery for primary adenocarcinoma of rectum with MSI-L / pMMR subtype","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","26942, 138723, 4144746","https://forums.ohdsi.org/t/17854","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",1,1,"ProcedureOccurrence",365,0,12,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 846,"[P] Primary adenocarcinoma of rectum oncological treatment, no surgery","Primary adenocarcinoma of rectum oncological treatment, no surgery","Primary adenocarcinoma of rectum oncological treatment, no surgery","rao@ohdsi.org","Pending peer review","","First event of oncological for patients with primary adenocarcinoma in rectum, with no subsequent potentially curative surgery","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","257011, 437663, 4170143, 4250734","https://forums.ohdsi.org/t/17876","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,2,"DrugExposure, ProcedureOccurrence",365,0,4,1,0,0,0,0,0,,,0,,,,1,,,1,,,,,,,,,,,,,,,,,,,,,
 847,"[P] Primary adenocarcinoma of rectum surgical treatment","Primary adenocarcinoma of rectum surgical treatment","Primary adenocarcinoma of rectum surgical treatment","rao@ohdsi.org","Pending peer review","","First event of potentially curative surgery following diagnosis of primary adenocarcinoma of rectum","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","435503, 439777, 441269, 4250490","https://forums.ohdsi.org/t/17856","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ProcedureOccurrence",365,0,2,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 848,"[P] Primary adenocarcinoma of rectum, no surgery or oncological treatment","Primary adenocarcinoma of rectum, no surgery or oncological treatment","Primary adenocarcinoma of rectum, no surgery or oncological treatment","rao@ohdsi.org","Pending peer review","","First event of primary adenocarcinoma of rectum, no future potentially curative surgery or oncological treatment","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","435503, 439777, 441269, 4250490","https://forums.ohdsi.org/t/17856","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ConditionOccurrence",365,0,4,1,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-850,"[W] Intestinal obstruction (broad 2)","Intestinal obstruction (broad 2)","Intestinal obstruction","rao@ohdsi.org","Pending peer review","","First event Intestinal obstruction","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","432881","","2023-09-18","2023-10-03",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+850,"[W] Intestinal obstruction (broad 2)","Intestinal obstruction (broad 2)","Intestinal obstruction","rao@ohdsi.org","Pending peer review","","First event Intestinal obstruction","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","432881","","2023-09-18","2023-10-09",,"","duplicated 805",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 851,"[P] Intraabdominal obstruction (broad)","Intraabdominal obstruction (broad)","Intraabdominal obstruction","rao@ohdsi.org","Pending peer review","","First event Intraabdominal obstruction","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","Anna Ostropolets","","435224","https://forums.ohdsi.org/t/17409","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 852,"[P] Surgical wound infection (broad)","Surgical wound infection (broad)","Surgical wound infection (broad)","rao@ohdsi.org","Pending peer review","","First event surgical wound infection","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","435224","https://forums.ohdsi.org/t/17409","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,3,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 854,"[P] Distant metastasis following colorectal cancer (medium)","Distant metastasis following colorectal cancer (medium)","Distant metastasis following colorectal cancer (medium)","rao@ohdsi.org","Pending peer review","","First event distant metastasis following colorectal cancer","#ColorectalCancer, #Cancer",1,"Andreas Weinberger Rosen","0000-0001-9990-8155","'OHDSI'","","","433749, 4103532","","2023-09-18","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,2,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
@@ -685,22 +685,22 @@
 863,"[P] Cognitive impairment, incident","Cognitive impairment, incident","Cognitive impairment, incident","rao@ohdsi.org","Pending peer review","","Earliest occurrence of Crohns disease indexed on diagnosis date, for the first time in history , with 365 days prior observation time. cohort exit is the end of continuous observation","",1,"Azza Shoaibi', 'Dave Kern'","0000-0002-6976-2594'","'OHDSI'","","","4297400, 439795",,"2023-09-18","2023-10-04",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
 864,"[P] Earliest event of Dementia","Earliest event of Dementia","Earliest event of Dementia","rao@ohdsi.org","Pending peer review","","Occurrences of dementia indexed on diagnosis or observation date with no required prior continuous enrollment subset to earliest observation where the patient was 18 years or older cohort exit is the end of continuous observation.","#Dementia",1,"Azza Shoaibi'","0000-0002-6976-2594'","'OHDSI'","","","4182210","","2023-09-18","2023-10-03",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"All",FALSE,"All","First",2,2,"ConditionOccurrence, Observation",0,0,1,1,1,0,0,0,0,1,,0,1,,,,,,,,1,,,,,,,,,,,,,,,,,,,
 865,"[P] Non-Emergent Major Non Cardiac Surgery among adults","Non-Emergent Major Non Cardiac Surgery among adults","Non-Emergent Major Non Cardiac Surgery among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty'","0000-0003-4631-9992'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",35,1,"ProcedureOccurrence",0,0,37,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,,,,,
-866,"[P] AAA repair among adults with new onset atrial fibrillation after surgery","AAA repair among adults with new onset atrial fibrillation after surgery","AAA repair among adults with new onset atrial fibrillation after surgery","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-867,"[P] Lower Extremity Bypass among adults","Lower Extremity Bypass among adults","Lower Extremity Bypass among adults","rao@ohdsi.org","Pending peer review","","","#surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-868,"[P] Carotid Endarterectomy among adults","Carotid Endarterectomy among adults","Carotid Endarterectomy among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty, Brian Bucher","0000-0003-4631-9992, 0000-0001-8376-9752","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-869,"[P] Lung Resection among adults","Lung Resection among adults","Lung Resection among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-870,"[P] Esophagectomy among adults","Esophagectomy among adults","Esophagectomy among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","132702","","2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-871,"[P] Pancreatectomy among adults","Pancreatectomy among adults","Pancreatectomy among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-872,"[P] Colectomy among adults","Colectomy among adults","Colectomy among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-873,"[P] Cystectomy among adults","Cystectomy among adults","Cystectomy among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-874,"[P] Nephrectomy among adults","Nephrectomy among adults","Nephrectomy among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty, Brian Bucher","0000-0003-4631-9992, 0000-0001-8376-9752","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-875,"[P] Coronary Artery Bypass Graft Surgery among adults","Coronary Artery Bypass Graft Surgery among adults","Coronary Artery Bypass Graft Surgery among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-876,"[P] Aortic or Mitral Valve Repair or Replacement among adults","Aortic or Mitral Valve Repair or Replacement among adults","Aortic or Mitral Valve Repair or Replacement among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
+866,"[P] AAA repair among adults with new onset atrial fibrillation after surgery","AAA repair among adults with new onset atrial fibrillation after surgery","AAA repair among adults with new onset atrial fibrillation after surgery","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+867,"[P] Lower Extremity Bypass among adults","Lower Extremity Bypass among adults","Lower Extremity Bypass among adults","rao@ohdsi.org","Pending peer review","","","#surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+868,"[P] Carotid Endarterectomy among adults","Carotid Endarterectomy among adults","Carotid Endarterectomy among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty, Brian Bucher","0000-0003-4631-9992, 0000-0001-8376-9752","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+869,"[P] Lung Resection among adults","Lung Resection among adults","Lung Resection among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+870,"[P] Esophagectomy among adults","Esophagectomy among adults","Esophagectomy among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","132702","","2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+871,"[P] Pancreatectomy among adults","Pancreatectomy among adults","Pancreatectomy among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+872,"[P] Colectomy among adults","Colectomy among adults","Colectomy among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+873,"[P] Cystectomy among adults","Cystectomy among adults","Cystectomy among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+874,"[P] Nephrectomy among adults","Nephrectomy among adults","Nephrectomy among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty, Brian Bucher","0000-0003-4631-9992, 0000-0001-8376-9752","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+875,"[P] Coronary Artery Bypass Graft Surgery among adults","Coronary Artery Bypass Graft Surgery among adults","Coronary Artery Bypass Graft Surgery among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+876,"[P] Aortic or Mitral Valve Repair or Replacement among adults","Aortic or Mitral Valve Repair or Replacement among adults","Aortic or Mitral Valve Repair or Replacement among adults","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty', 'Brian Bucher'","0000-0003-4631-9992', '0000-0001-8376-9752'","'OHDSI'","","","4301351",,"2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,3,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
 877,"[P] Non-Emergent MNCS (age 18 or greater), post op Afib (parox)","Non-Emergent MNCS (age 18 or greater), post op Afib (parox)","Non-Emergent MNCS (age 18 or greater), post op Afib (parox)","rao@ohdsi.org","Pending peer review","","","#Surgery, #NonEmergent",1,"Evan Minty'","0000-0003-4631-9992'","'OHDSI'","","","374954","","2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",35,1,"ProcedureOccurrence",0,0,39,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,,,,,
 878,"[P] Non-Emergent MNCS (age 18 or greater), post op Afib (any)","Non-Emergent MNCS (age 18 or greater), post op Afib (any)","Non-Emergent MNCS (age 18 or greater), post op Afib (any)","rao@ohdsi.org","Pending peer review","","","#Surgery",1,"Evan Minty'","0000-0003-4631-9992'","'OHDSI'","","","436100","https://forums.ohdsi.org/t/17784","2023-09-19","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",35,1,"ProcedureOccurrence",0,0,38,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,,,,,
 881,"[P] Acute myocardial infarction","Acute myocardial infarction","Acute myocardial infarction events","rao@ohdsi.org","Pending","","Acute myocardial infarction condition record during an inpatient or ER visit successive records with > 180 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Hypertension, #legendHypertension, #Diabetes, #legendDiabetes",1,"'Marc Suchard','Martijn Schuemie','Harlan Krumholz','Seng Chan You','RuiJun Chun','Nicole Pratt','Christian Reich','Jon Duke','David Madigan','George Hripcsak','Patrick Ryan'","0000-0001-9818-479X', '0000-0002-0817-5361', '0000-0003-2046-127X','','','0000-0001-8730-8910', '','','','',''","'OHDSI'","","","139900","https://forums.ohdsi.org/t/17895","2023-09-20","2023-09-24",,"",,0,,,"ERA",180,"fixed duration relative to initial event","StartDate",7,0,"All",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 882,"[P] Decreased libido","Decreased libido","Persons with decreased libido","rao@ohdsi.org","Pending","","The first condition record of decreased libido","#usedInStudy, #LEGEND, #Hypertension, #legendHypertension, #Symptoms",1,"'Marc Suchard','Martijn Schuemie','Harlan Krumholz','Seng Chan You','RuiJun Chun','Nicole Pratt','Christian Reich','Jon Duke','David Madigan','George Hripcsak','Patrick Ryan'","0000-0001-9818-479X', '0000-0002-0817-5361', '0000-0003-2046-127X','','','0000-0001-8730-8910', '','','','',''","'OHDSI'","","","377575","https://forums.ohdsi.org/t/17895","2023-09-20","2023-09-21",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
-884,"[P] Diarrhea2","Diarrhea2","Diarrhea events","rao@ohdsi.org","Pending","","Diarrhea condition record of any type successive records with > 30 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Hypertension, #legendHypertension",1,"'Marc Suchard','Martijn Schuemie','Harlan Krumholz','Seng Chan You','RuiJun Chun','Nicole Pratt','Christian Reich','Jon Duke','David Madigan','George Hripcsak','Patrick Ryan'","0000-0001-9818-479X', '0000-0002-0817-5361', '0000-0003-2046-127X','','','0000-0001-8730-8910', '','','','',''","'OHDSI'","","","196523",,"2023-09-20","2023-10-04",,"",,0,,,"ERA",30,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+884,"[P] Diarrhea including enteritis","Diarrhea including enteritis","Diarrhea events","rao@ohdsi.org","Pending","","Diarrhea condition record of any type successive records with > 30 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Hypertension, #legendHypertension",1,"'Marc Suchard','Martijn Schuemie','Harlan Krumholz','Seng Chan You','RuiJun Chun','Nicole Pratt','Christian Reich','Jon Duke','David Madigan','George Hripcsak','Patrick Ryan'","0000-0001-9818-479X', '0000-0002-0817-5361', '0000-0003-2046-127X','','','0000-0001-8730-8910', '','','','',''","'OHDSI'","","","196523",,"2023-09-20","2023-10-09",,"",,0,,,"ERA",30,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 888,"[P] Gastrointestinal bleeding","Gastrointestinal bleeding","Gastrointestinal bleeding events","rao@ohdsi.org","Pending","","Gastrointestinal hemorrhage condition record during an inpatient or ER visit successive records with > 30 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Hypertension, #legendHypertension",1,"'Marc Suchard','Martijn Schuemie','Harlan Krumholz','Seng Chan You','RuiJun Chun','Nicole Pratt','Christian Reich','Jon Duke','David Madigan','George Hripcsak','Patrick Ryan'","0000-0001-9818-479X', '0000-0002-0817-5361', '0000-0003-2046-127X','','','0000-0001-8730-8910', '','','','',''","'OHDSI'","","","196715","","2023-09-20","2023-09-20",,"",,0,,,"ERA",30,"fixed duration relative to initial event","StartDate",7,0,"All",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 889,"[P] Hyponatremia","Hyponatremia","Hyponatremia events","rao@ohdsi.org","Pending","","Hyponatremia condition record of any type successive records with > 90 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Hypertension, #legendHypertension",1,"'Marc Suchard','Martijn Schuemie','Harlan Krumholz','Seng Chan You','RuiJun Chun','Nicole Pratt','Christian Reich','Jon Duke','David Madigan','George Hripcsak','Patrick Ryan'","0000-0001-9818-479X', '0000-0002-0817-5361', '0000-0003-2046-127X','','','0000-0001-8730-8910', '','','','',''","'OHDSI'","","","199837","","2023-09-20","2023-09-20",,"",,0,,,"ERA",90,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 890,"[P] Hypotension","Hypotension","Hypotension events","rao@ohdsi.org","Pending","","Hypotension condition record of any type successive records with > 90 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Hypertension, #legendHypertension",1,"'Marc Suchard','Martijn Schuemie','Harlan Krumholz','Seng Chan You','RuiJun Chun','Nicole Pratt','Christian Reich','Jon Duke','David Madigan','George Hripcsak','Patrick Ryan'","0000-0001-9818-479X', '0000-0002-0817-5361', '0000-0003-2046-127X','','','0000-0001-8730-8910', '','','','',''","'OHDSI'","","","4133004, 43531681","https://forums.ohdsi.org/t/17769","2023-09-20","2023-09-20",,"",,0,,,"ERA",90,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
@@ -762,14 +762,14 @@
 990,"[P] Bone fracture","Bone fracture","Bone Fracture","rao@ohdsi.org","Pending","","Bone fracture condition record of any type successive records with > 90 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","75053",,"2023-09-20","2023-10-04",,"",,0,,,"ERA",90,"fixed duration relative to initial event","EndDate",1,0,"All",FALSE,"All","All",2,2,"ConditionOccurrence, ProcedureOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 991,"[P] Breast cancer Malignant tumor of breast","Breast cancer Malignant tumor of breast","Breast cancer Malignant tumor of breast","rao@ohdsi.org","Pending","","Malignant tumor of breast condition record of any type limited to earliest event per person","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","197925, 4245614","","2023-09-20","2023-09-24",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",365,0,1,0,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
 992,"[P] Diabetic ketoacidosis with inpatient or ER visit","Diabetic ketoacidosis with inpatient or ER visit","","rao@ohdsi.org","Pending","","Diabetic ketoacidosis condition record during an inpatient or ER visit","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","261687","https://forums.ohdsi.org/t/17895","2023-09-20","2023-09-24",,"",,0,,,"ERA",180,"fixed duration relative to initial event","StartDate",7,0,"All",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-993,"[W] Diarrhea including enteritis","Diarrhea including enteritis","","rao@ohdsi.org","Pending","","Diarrhea condition record of any type successive records with > 30 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","4209223, 4285898, 42537251","https://forums.ohdsi.org/t/17895","2023-09-20","2023-09-28",,"",,0,,,"ERA",30,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+993,"[W] Diarrhea including enteritis","Diarrhea including enteritis","","rao@ohdsi.org","Pending","","Diarrhea condition record of any type successive records with > 30 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","4209223, 4285898, 42537251","https://forums.ohdsi.org/t/17895","2023-09-20","2023-10-09",,"","duplicate 884",0,,,"ERA",30,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 994,"[P] Genitourinary infection","Genitourinary infection","Genitourinary infection","rao@ohdsi.org","Pending","","Condition record of any type of genital or urinary tract infection during an outpatient or ER vists","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","24660, 4083666","https://forums.ohdsi.org/t/17895","2023-09-20","2023-09-25",,"",,0,,,"ERA",30,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 996,"[P] Hypoglycemia","Hypoglycemia","Hypoglycemia","rao@ohdsi.org","Pending","","Hypoglycemia condition record of any type successive records with > 90 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","257007, 4320791","https://forums.ohdsi.org/t/17895","2023-09-20","2023-09-24",,"",,0,,,"ERA",30,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-997,"[W] Hypotension or low blood pressure","Hypotension or low blood pressure","Hypotension","rao@ohdsi.org","Pending","","Hypotension condition record of any type successive records with > 90 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","24969, 260134","https://forums.ohdsi.org/t/17895","2023-09-20","2023-09-25",,"",,0,,,"ERA",90,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+997,"[W] Hypotension or low blood pressure","Hypotension or low blood pressure","Hypotension","rao@ohdsi.org","Pending","","Hypotension condition record of any type successive records with > 90 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","24969, 260134","https://forums.ohdsi.org/t/17895","2023-09-20","2023-10-09",,"","duplicates 890",0,,,"ERA",90,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 998,"[P] Joint pain3","Joint pain3","","rao@ohdsi.org","Pending","","Joint pain condition record of any type successive records with > 90 days gap are considered independent episodes","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","4096682","https://forums.ohdsi.org/t/17895","2023-09-20","2023-09-20",,"",,0,,,"ERA",90,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 999,"[P] Lower extremity amputation3","Lower extremity amputation3","Lower extremity amputation","rao@ohdsi.org","Pending","","Procedure record of below knee lower extremity amputation during inpatient or outpatient visit","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","261600, 4078925","https://forums.ohdsi.org/t/17895","2023-09-20","2023-09-24",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",0,0,"All",TRUE,"All","All",1,1,"ProcedureOccurrence",0,0,1,1,0,0,0,0,0,,,1,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 1000,"[P] Nausea3","Nausea3","","rao@ohdsi.org","Pending","","Nausea condition record of any type successive records with > 30 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","319049, 4256228","https://forums.ohdsi.org/t/17895","2023-09-20","2023-09-20",,"",,0,,,"ERA",30,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1001,"[W] Peripheral edema","Peripheral edema","Peripheral edema","rao@ohdsi.org","Pending","","Edema condition record of any type successive records with > 180 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","319049, 4256228","https://forums.ohdsi.org/t/17895","2023-09-20","2023-10-03",,"",,0,,,"ERA",180,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1001,"[W] Peripheral edema","Peripheral edema","Peripheral edema","rao@ohdsi.org","Pending","","Edema condition record of any type successive records with > 180 day gap are considered independent episodes","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","319049, 4256228","https://forums.ohdsi.org/t/17895","2023-09-20","2023-10-09",,"",,0,,,"ERA",180,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1002,"[P] Photosensitivity","Photosensitivity","Photosensitivity","rao@ohdsi.org","Pending","","Condition record of drug-induced photosensitivity during any type of visit","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","254061","https://forums.ohdsi.org/t/17895","2023-09-20","2023-09-24",,"",,0,,,"ERA",90,"fixed duration relative to initial event","StartDate",1,0,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1003,"[P] Renal cancer","Renal cancer","Renal Cancer","rao@ohdsi.org","Pending","","Primary malignant neoplasm of kidney condition record of any type limited to earliest event per person","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","'OHDSI'","","","73754","https://forums.ohdsi.org/t/18236","2023-09-20","2023-09-24",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",365,0,1,0,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
 1004,"[P] Thyroid tumor","Thyroid tumor","Thyroid tumor","rao@ohdsi.org","Pending","","Neoplasm of thyroid gland condition record of any type limited to earliest event per person","#usedInStudy, #LEGEND, #Diabetes, #legendDiabetes",1,"Rohan Khera','Martijn Schuemie','Yuan Lu','Anna Ostropolets','RuiJun Chun','George Hripcsak','Patrick Ryan','Harlan Krumholz','Marc Suchard'","0000-0001-9467-6199', '0000-0002-0817-5361', '', '0000-0002-0847-6682', '', '','','0000-0003-2046-127X','0000-0001-9818-479X'","","","","4131909",,"2023-09-20","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
@@ -800,49 +800,49 @@
 1032,"[P] Earliest event of Type 2 Diabetes Mellitus (DM), with no type 1 or secondary DM","Earliest event of Type 2 Diabetes Mellitus (DM), with no type 1 or secondary DM","Earliest event of Type 2 Diabetes Mellitus (DM), with no type 1 or secondary DM","rao@ohdsi.org","Pending","","Earliest event of Type 2 Diabetes Mellitus (DM), indexed on diagnosis or Blood glucose lowering drugs excluding insulin or high Hemoglobin A1c (limited to treatments or measurement that are followed with Type 2 DM diagnosis within 365 days) excluding persons with Type 1 DM or secondary diabetes mellitus in the all time prior including index date","#JnJ, #Indication",1,"Patrick Ryan,","","'OHDSI'","","","4027396","","2023-09-20","2023-09-20",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",4,3,"ConditionOccurrence, DrugExposure, Measurement",0,0,5,1,0,0,0,0,0,1,1,0,,,,1,,,,,,,,,,,,,,,,,,,,,,,,
 1033,"[P] Earliest event of Human Immunodeficiency Virus I (HIV), with treatment, lab or 2nd diagnosis","Earliest event of Human Immunodeficiency Virus I (HIV), with treatment, lab or 2nd diagnosis","Earliest event of Human Immunodeficiency Virus I (HIV), with treatment, lab or 2nd diagnosis","rao@ohdsi.org","Pending","","Earliest event of Human Immunodeficiency Virus I (HIV), with HIV drugs or laboratory results any time after index date or second diagnosis post index cohort exit is the end of continuous observation","#JnJ, #Indication",1,"Rupa Makadia, Jamie Calusardo","","'OHDSI'","","","4027396, 4117779","","2023-09-20","2023-10-04",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"All",TRUE,"First","First",1,1,"ConditionOccurrence",0,0,3,1,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1034,"[P] All events of Respiratory syncytial virus infection, with 30 days washout","All events of Respiratory syncytial virus infection, with 30 days washout","All events of Respiratory syncytial virus infection, with 30 days washout","rao@ohdsi.org","Pending","","All events of Respiratory syncytial virus infection, with no such events in prior 30 days (washout). Persons exit the cohort at the start date + 30 day.","#JnJ, #Indication",1,"Nathan Hall, Rupa Makadia","","'OHDSI'","","","377889","","2023-09-20","2023-09-20",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",30,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1035,"[P] New users of Thiazide diuretics","New users of Thiazide diuretics","New users of Thiazide diuretics","rao@ohdsi.org","Pending peer review","","New users of Thiazide diuretics","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,0,90,0,,,,,,
-1036,"[P] New users of Beta blockers","New users of Beta blockers","New users of Beta blockers","rao@ohdsi.org","Pending peer review","","New users of Beta blockers","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,2,90,0,,,,,,
-1037,"[P] New users of SGLT2 inhibitor","New users of SGLT2 inhibitor","New users of SGLT2 inhibitor","rao@ohdsi.org","Pending peer review","","New users of SGLT2 inhibitor","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,3,90,0,,,,,,
-1038,"[P] New users of GLP-1 receptor antagonists","New users of GLP-1 receptor antagonists","New users of GLP-1 receptor antagonists","rao@ohdsi.org","Pending peer review","","New users of GLP-1 receptor antagonists","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,4,90,0,,,,,,
-1039,"[P] New users of DPP-4 inhibitors","New users of DPP-4 inhibitors","New users of DPP-4 inhibitors","rao@ohdsi.org","Pending peer review","","New users of DPP-4 inhibitors","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,5,90,0,,,,,,
-1040,"[P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors","rao@ohdsi.org","Pending peer review","","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,6,90,0,,,,,,
-1041,"[P] New users of JAK inhibitors","New users of JAK inhibitors","New users of JAK inhibitors","rao@ohdsi.org","Pending peer review","","New users of JAK inhibitors","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,7,90,0,,,,,,
-1042,"[P] New users of IL-23 inhibitors","New users of IL-23 inhibitors","New users of IL-23 inhibitors","rao@ohdsi.org","Pending peer review","","New users of IL-23 inhibitors","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-10-03",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,8,90,0,,,,,,
-1043,"[P] New users of Fluoroquinolone systemic","New users of Fluoroquinolone systemic","New users of Fluoroquinolone systemic","rao@ohdsi.org","Pending peer review","","New users of Fluoroquinolone systemic","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,9,30,0,,,,,,
-1044,"[P] New users of Cephalosporin systemetic","New users of Cephalosporin systemetic","New users of Cephalosporin systemetic","rao@ohdsi.org","Pending peer review","","New users of Cephalosporin systemetic","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,10,30,0,,,,,,
-1045,"[P] New users of Trimethoprim systemetic","New users of Trimethoprim systemetic","New users of Trimethoprim systemetic","rao@ohdsi.org","Pending peer review","","New users of Trimethoprim systemetic","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,11,30,0,,,,,,
-1046,"[P] New users of Thiazide diuretics nested in essential hypertension","New users of Thiazide diuretics nested in essential hypertension","New users of Thiazide diuretics nested in essential hypertension","rao@ohdsi.org","Pending peer review","","New users of Thiazide diuretics nested in essential hypertension","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,0,90,0,,,,,,
-1047,"[P] New users of dihydropyridine calcium channel blockers nested in essential hypertension","New users of dihydropyridine calcium channel blockers nested in essential hypertension","New users of dihydropyridine calcium channel blockers nested in essential hypertension","rao@ohdsi.org","Pending peer review","","New users of dihydropyridine calcium channel blockers nested in essential hypertension","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,1,90,0,,,,,,
-1048,"[P] New users of dihydropyridine calcium channel blockers","New users of dihydropyridine calcium channel blockers","New users of dihydropyridine calcium channel blockers","rao@ohdsi.org","Pending peer review","","New users of dihydropyridine calcium channel blockers","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,1,90,0,,,,,,
-1049,"[P] New users of Beta blockers nested in essential hypertension","New users of Beta blockers nested in essential hypertension","New users of Beta blockers nested in essential hypertension","rao@ohdsi.org","Pending peer review","","New users of Beta blockers nested in essential hypertension","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,2,90,0,,,,,,
-1050,"[P] New users of Beta blockers nested in Left Heart Failure","New users of Beta blockers nested in Left Heart Failure","New users of Beta blockers nested in Left Heart Failure","rao@ohdsi.org","Pending peer review","","New users of Beta blockers nested in Left Heart Failure","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,2,90,0,,,,,,
-1051,"[P] New users of SGLT2 inhibitor nested in Left Heart Failure","New users of SGLT2 inhibitor nested in Left Heart Failure","New users of SGLT2 inhibitor nested in Left Heart Failure","rao@ohdsi.org","Pending peer review","","New users of SGLT2 inhibitor nested in Left Heart Failure","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,3,90,0,,,,,,
-1052,"[P] New users of Beta blockers nested in Acute Myocardial Infarction","New users of Beta blockers nested in Acute Myocardial Infarction","New users of Beta blockers nested in Acute Myocardial Infarction","rao@ohdsi.org","Pending peer review","","New users of Beta blockers nested in Acute Myocardial Infarction","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,3,1,0,0,0,1,0,,,0,,,,1,,,,1,,,,,,,,,,,,2,90,0,,,,,,
-1053,"[P] New users of GLP-1 receptor antagonists nested in Type 2 diabetes mellitus","New users of GLP-1 receptor antagonists nested in Type 2 diabetes mellitus","New users of GLP-1 receptor antagonists nested in Type 2 diabetes mellitus","rao@ohdsi.org","Pending peer review","","New users of GLP-1 receptor antagonists nested in Type 2 diabetes mellitus","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,4,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,4,90,0,,,,,,
-1054,"[P] New users of SGLT2 inhibitor nested in Type 2 diabetes mellitus","New users of SGLT2 inhibitor nested in Type 2 diabetes mellitus","New users of SGLT2 inhibitor nested in Type 2 diabetes mellitus","rao@ohdsi.org","Pending peer review","","New users of SGLT2 inhibitor nested in Type 2 diabetes mellitus","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,4,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,3,90,0,,,,,,
-1055,"[P] New users of DPP-4 inhibitors nested in Type 2 diabetes mellitus","New users of DPP-4 inhibitors nested in Type 2 diabetes mellitus","New users of DPP-4 inhibitors nested in Type 2 diabetes mellitus","rao@ohdsi.org","Pending peer review","","New users of DPP-4 inhibitors nested in Type 2 diabetes mellitus","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,4,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,5,90,0,,,,,,
-1056,"[P] New users of GLP-1 receptor antagonists nested in obesity","New users of GLP-1 receptor antagonists nested in obesity","New users of GLP-1 receptor antagonists nested in obesity","rao@ohdsi.org","Pending peer review","","New users of GLP-1 receptor antagonists nested in obesity","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,4,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,4,90,0,,,,,,
-1057,"[P] New users of IL-23 inhibitors nested in Plaque psoriasis","New users of IL-23 inhibitors nested in Plaque psoriasis","New users of IL-23 inhibitors nested in Plaque psoriasis","rao@ohdsi.org","Pending peer review","","New users of IL-23 inhibitors nested in Plaque psoriasis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-10-03",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,8,90,0,,,,,,
-1058,"[P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Plaque psoriasis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Plaque psoriasis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Plaque psoriasis","rao@ohdsi.org","Pending peer review","","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Plaque psoriasis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,6,90,0,,,,,,
-1059,"[P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Psoriatic Arthritis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Psoriatic Arthritis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Psoriatic Arthritis","rao@ohdsi.org","Pending peer review","","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Psoriatic Arthritis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,4,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,6,90,0,,,,,,
-1060,"[P] New users of Fluoroquinolone systemic nested in Urinary Tract Infection","New users of Fluoroquinolone systemic nested in Urinary Tract Infection","New users of Fluoroquinolone systemic nested in Urinary Tract Infection","rao@ohdsi.org","Pending peer review","","New users of Fluoroquinolone systemic nested in Urinary Tract Infection","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,9,30,0,,,,,,
-1061,"[P] New users of Cephalosporin systemetic nested in Urinary Tract Infection","New users of Cephalosporin systemetic nested in Urinary Tract Infection","New users of Cephalosporin systemetic nested in Urinary Tract Infection","rao@ohdsi.org","Pending peer review","","New users of Cephalosporin systemetic nested in Urinary Tract Infection","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,10,30,0,,,,,,
-1062,"[P] New users of Trimethoprim systemetic nested in Urinary Tract Infection","New users of Trimethoprim systemetic nested in Urinary Tract Infection","New users of Trimethoprim systemetic nested in Urinary Tract Infection","rao@ohdsi.org","Pending peer review","","New users of Trimethoprim systemetic nested in Urinary Tract Infection","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,11,30,0,,,,,,
-1063,"[P] New users of Fluoroquinolone systemic nested in Acute Typical Pneumonia","New users of Fluoroquinolone systemic nested in Acute Typical Pneumonia","New users of Fluoroquinolone systemic nested in Acute Typical Pneumonia","rao@ohdsi.org","Pending peer review","","New users of Fluoroquinolone systemic nested in Acute Typical Pneumonia","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,3,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,9,30,0,,,,,,
-1064,"[P] New users of Cephalosporin systemetic nested in Acute Typical Pneumonia","New users of Cephalosporin systemetic nested in Acute Typical Pneumonia","New users of Cephalosporin systemetic nested in Acute Typical Pneumonia","rao@ohdsi.org","Pending peer review","","New users of Cephalosporin systemetic nested in Acute Typical Pneumonia","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,3,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,10,30,0,,,,,,
-1065,"[P] New users of Trimethoprim systemetic nested in Acute Typical Pneumonia","New users of Trimethoprim systemetic nested in Acute Typical Pneumonia","New users of Trimethoprim systemetic nested in Acute Typical Pneumonia","rao@ohdsi.org","Pending peer review","","New users of Trimethoprim systemetic nested in Acute Typical Pneumonia","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,3,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,11,30,0,,,,,,
-1066,"[P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Rheumatoid arthritis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Rheumatoid arthritis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Rheumatoid arthritis","rao@ohdsi.org","Pending peer review","","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Rheumatoid arthritis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,6,90,0,,,,,,
-1067,"[P] New users of JAK inhibitors nested in Ulcerative colitis","New users of JAK inhibitors nested in Ulcerative colitis","New users of JAK inhibitors nested in Ulcerative colitis","rao@ohdsi.org","Pending peer review","","New users of JAK inhibitors nested in Ulcerative colitis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,7,90,0,,,,,,
-1068,"[P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Ulcerative colitis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Ulcerative colitis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Ulcerative colitis","rao@ohdsi.org","Pending peer review","","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Ulcerative colitis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,6,90,0,,,,,,
-1069,"[P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Crohns disease","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Crohns disease","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Crohns disease","rao@ohdsi.org","Pending peer review","","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Crohns disease","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,6,90,0,,,,,,
-1070,"[P] New users of JAK inhibitors nested in Rheumatoid arthritis","New users of JAK inhibitors nested in Rheumatoid arthritis","New users of JAK inhibitors nested in Rheumatoid arthritis","rao@ohdsi.org","Pending peer review","","New users of JAK inhibitors nested in Rheumatoid arthritis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,7,90,0,,,,,,
+1035,"[P] New users of Thiazide diuretics","New users of Thiazide diuretics","New users of Thiazide diuretics","rao@ohdsi.org","Pending peer review","","New users of Thiazide diuretics","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,0,90,0,,,,
+1036,"[P] New users of Beta blockers","New users of Beta blockers","New users of Beta blockers","rao@ohdsi.org","Pending peer review","","New users of Beta blockers","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,2,90,0,,,,
+1037,"[P] New users of SGLT2 inhibitor","New users of SGLT2 inhibitor","New users of SGLT2 inhibitor","rao@ohdsi.org","Pending peer review","","New users of SGLT2 inhibitor","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,3,90,0,,,,
+1038,"[P] New users of GLP-1 receptor antagonists","New users of GLP-1 receptor antagonists","New users of GLP-1 receptor antagonists","rao@ohdsi.org","Pending peer review","","New users of GLP-1 receptor antagonists","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,4,90,0,,,,
+1039,"[P] New users of DPP-4 inhibitors","New users of DPP-4 inhibitors","New users of DPP-4 inhibitors","rao@ohdsi.org","Pending peer review","","New users of DPP-4 inhibitors","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,5,90,0,,,,
+1040,"[P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors","rao@ohdsi.org","Pending peer review","","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,6,90,0,,,,
+1041,"[P] New users of JAK inhibitors","New users of JAK inhibitors","New users of JAK inhibitors","rao@ohdsi.org","Pending peer review","","New users of JAK inhibitors","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,7,90,0,,,,
+1042,"[P] New users of IL-23 inhibitors","New users of IL-23 inhibitors","New users of IL-23 inhibitors","rao@ohdsi.org","Pending peer review","","New users of IL-23 inhibitors","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-10-03",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,8,90,0,,,,
+1043,"[P] New users of Fluoroquinolone systemic","New users of Fluoroquinolone systemic","New users of Fluoroquinolone systemic","rao@ohdsi.org","Pending peer review","","New users of Fluoroquinolone systemic","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,9,30,0,,,,
+1044,"[P] New users of Cephalosporin systemetic","New users of Cephalosporin systemetic","New users of Cephalosporin systemetic","rao@ohdsi.org","Pending peer review","","New users of Cephalosporin systemetic","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,10,30,0,,,,
+1045,"[P] New users of Trimethoprim systemetic","New users of Trimethoprim systemetic","New users of Trimethoprim systemetic","rao@ohdsi.org","Pending peer review","","New users of Trimethoprim systemetic","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,11,30,0,,,,
+1046,"[P] New users of Thiazide diuretics nested in essential hypertension","New users of Thiazide diuretics nested in essential hypertension","New users of Thiazide diuretics nested in essential hypertension","rao@ohdsi.org","Pending peer review","","New users of Thiazide diuretics nested in essential hypertension","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,0,90,0,,,,
+1047,"[P] New users of dihydropyridine calcium channel blockers nested in essential hypertension","New users of dihydropyridine calcium channel blockers nested in essential hypertension","New users of dihydropyridine calcium channel blockers nested in essential hypertension","rao@ohdsi.org","Pending peer review","","New users of dihydropyridine calcium channel blockers nested in essential hypertension","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,1,90,0,,,,
+1048,"[P] New users of dihydropyridine calcium channel blockers","New users of dihydropyridine calcium channel blockers","New users of dihydropyridine calcium channel blockers","rao@ohdsi.org","Pending peer review","","New users of dihydropyridine calcium channel blockers","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,0,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,1,0,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,1,90,0,,,,
+1049,"[P] New users of Beta blockers nested in essential hypertension","New users of Beta blockers nested in essential hypertension","New users of Beta blockers nested in essential hypertension","rao@ohdsi.org","Pending peer review","","New users of Beta blockers nested in essential hypertension","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,2,90,0,,,,
+1050,"[P] New users of Beta blockers nested in Left Heart Failure","New users of Beta blockers nested in Left Heart Failure","New users of Beta blockers nested in Left Heart Failure","rao@ohdsi.org","Pending peer review","","New users of Beta blockers nested in Left Heart Failure","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,2,90,0,,,,
+1051,"[P] New users of SGLT2 inhibitor nested in Left Heart Failure","New users of SGLT2 inhibitor nested in Left Heart Failure","New users of SGLT2 inhibitor nested in Left Heart Failure","rao@ohdsi.org","Pending peer review","","New users of SGLT2 inhibitor nested in Left Heart Failure","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,3,90,0,,,,
+1052,"[P] New users of Beta blockers nested in Acute Myocardial Infarction","New users of Beta blockers nested in Acute Myocardial Infarction","New users of Beta blockers nested in Acute Myocardial Infarction","rao@ohdsi.org","Pending peer review","","New users of Beta blockers nested in Acute Myocardial Infarction","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,3,1,0,0,0,1,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,2,90,0,,,,
+1053,"[P] New users of GLP-1 receptor antagonists nested in Type 2 diabetes mellitus","New users of GLP-1 receptor antagonists nested in Type 2 diabetes mellitus","New users of GLP-1 receptor antagonists nested in Type 2 diabetes mellitus","rao@ohdsi.org","Pending peer review","","New users of GLP-1 receptor antagonists nested in Type 2 diabetes mellitus","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,4,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,4,90,0,,,,
+1054,"[P] New users of SGLT2 inhibitor nested in Type 2 diabetes mellitus","New users of SGLT2 inhibitor nested in Type 2 diabetes mellitus","New users of SGLT2 inhibitor nested in Type 2 diabetes mellitus","rao@ohdsi.org","Pending peer review","","New users of SGLT2 inhibitor nested in Type 2 diabetes mellitus","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,4,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,3,90,0,,,,
+1055,"[P] New users of DPP-4 inhibitors nested in Type 2 diabetes mellitus","New users of DPP-4 inhibitors nested in Type 2 diabetes mellitus","New users of DPP-4 inhibitors nested in Type 2 diabetes mellitus","rao@ohdsi.org","Pending peer review","","New users of DPP-4 inhibitors nested in Type 2 diabetes mellitus","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,4,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,5,90,0,,,,
+1056,"[P] New users of GLP-1 receptor antagonists nested in obesity","New users of GLP-1 receptor antagonists nested in obesity","New users of GLP-1 receptor antagonists nested in obesity","rao@ohdsi.org","Pending peer review","","New users of GLP-1 receptor antagonists nested in obesity","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,4,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,4,90,0,,,,
+1057,"[P] New users of IL-23 inhibitors nested in Plaque psoriasis","New users of IL-23 inhibitors nested in Plaque psoriasis","New users of IL-23 inhibitors nested in Plaque psoriasis","rao@ohdsi.org","Pending peer review","","New users of IL-23 inhibitors nested in Plaque psoriasis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-10-03",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,8,90,0,,,,
+1058,"[P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Plaque psoriasis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Plaque psoriasis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Plaque psoriasis","rao@ohdsi.org","Pending peer review","","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Plaque psoriasis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,6,90,0,,,,
+1059,"[P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Psoriatic Arthritis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Psoriatic Arthritis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Psoriatic Arthritis","rao@ohdsi.org","Pending peer review","","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Psoriatic Arthritis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,4,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,6,90,0,,,,
+1060,"[P] New users of Fluoroquinolone systemic nested in Urinary Tract Infection","New users of Fluoroquinolone systemic nested in Urinary Tract Infection","New users of Fluoroquinolone systemic nested in Urinary Tract Infection","rao@ohdsi.org","Pending peer review","","New users of Fluoroquinolone systemic nested in Urinary Tract Infection","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,9,30,0,,,,
+1061,"[P] New users of Cephalosporin systemetic nested in Urinary Tract Infection","New users of Cephalosporin systemetic nested in Urinary Tract Infection","New users of Cephalosporin systemetic nested in Urinary Tract Infection","rao@ohdsi.org","Pending peer review","","New users of Cephalosporin systemetic nested in Urinary Tract Infection","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,10,30,0,,,,
+1062,"[P] New users of Trimethoprim systemetic nested in Urinary Tract Infection","New users of Trimethoprim systemetic nested in Urinary Tract Infection","New users of Trimethoprim systemetic nested in Urinary Tract Infection","rao@ohdsi.org","Pending peer review","","New users of Trimethoprim systemetic nested in Urinary Tract Infection","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,11,30,0,,,,
+1063,"[P] New users of Fluoroquinolone systemic nested in Acute Typical Pneumonia","New users of Fluoroquinolone systemic nested in Acute Typical Pneumonia","New users of Fluoroquinolone systemic nested in Acute Typical Pneumonia","rao@ohdsi.org","Pending peer review","","New users of Fluoroquinolone systemic nested in Acute Typical Pneumonia","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,3,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,9,30,0,,,,
+1064,"[P] New users of Cephalosporin systemetic nested in Acute Typical Pneumonia","New users of Cephalosporin systemetic nested in Acute Typical Pneumonia","New users of Cephalosporin systemetic nested in Acute Typical Pneumonia","rao@ohdsi.org","Pending peer review","","New users of Cephalosporin systemetic nested in Acute Typical Pneumonia","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,3,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,10,30,0,,,,
+1065,"[P] New users of Trimethoprim systemetic nested in Acute Typical Pneumonia","New users of Trimethoprim systemetic nested in Acute Typical Pneumonia","New users of Trimethoprim systemetic nested in Acute Typical Pneumonia","rao@ohdsi.org","Pending peer review","","New users of Trimethoprim systemetic nested in Acute Typical Pneumonia","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,3,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,11,30,0,,,,
+1066,"[P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Rheumatoid arthritis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Rheumatoid arthritis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Rheumatoid arthritis","rao@ohdsi.org","Pending peer review","","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Rheumatoid arthritis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,6,90,0,,,,
+1067,"[P] New users of JAK inhibitors nested in Ulcerative colitis","New users of JAK inhibitors nested in Ulcerative colitis","New users of JAK inhibitors nested in Ulcerative colitis","rao@ohdsi.org","Pending peer review","","New users of JAK inhibitors nested in Ulcerative colitis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,7,90,0,,,,
+1068,"[P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Ulcerative colitis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Ulcerative colitis","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Ulcerative colitis","rao@ohdsi.org","Pending peer review","","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Ulcerative colitis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,6,90,0,,,,
+1069,"[P] New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Crohns disease","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Crohns disease","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Crohns disease","rao@ohdsi.org","Pending peer review","","New users of Tumor Necrosis Factor alpha (TNFa) inhibitors nested in Crohns disease","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,6,90,0,,,,
+1070,"[P] New users of JAK inhibitors nested in Rheumatoid arthritis","New users of JAK inhibitors nested in Rheumatoid arthritis","New users of JAK inhibitors nested in Rheumatoid arthritis","rao@ohdsi.org","Pending peer review","","New users of JAK inhibitors nested in Rheumatoid arthritis","#HowOften, #Target, #Study, #Symposium",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-09-21",,"",,0,,,"ERA",0,"end of continuous drug exposure",,,1,"First",FALSE,"All","First",1,1,"DrugExposure",365,0,2,1,0,0,0,0,0,,,0,,,,1,,,,1,,,,,,,,,,,,,,7,90,0,,,,
 1071,"[P] persons at risk at start of year 2012-2022 with 365d prior observation","persons at risk at start of year 2012-2022 with 365d prior observation","persons at risk at start of year 2012-2022 with 365d prior observation","rao@ohdsi.org","Pending peer review","","persons at risk at start of year 2012-2022 with 365d prior observation","#Target, #Study, #Symposium, #baseCohort",1,"'Patrick Ryan'","","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-21","2023-10-02",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,0,"All",TRUE,"All","All",11,1,"ObservationPeriod",365,0,0,1,1,1,1,0,0,,,1,,,,,,,,,,,,,,,,,,,,,,,,,1,1,1,
 1072,"[P] CMV Anterior Uveitis","CMV Anterior Uveitis","Cytomegalovirus CMV Anterior Uveitis","rao@ohdsi.org","Pending peer review","",,"#Opthalmology, #OhdsiWorkGroup",1,"'Edward Lee','Kiana Tavakoli','Rupesh Agrawal','Karen Armbrust','Kareem Moussa','Jessica Shantha','Edmund Tsui','Brian Toy'","'','0000-0002-9612-5697','','','','','','','',''","'Roski Eye Institute, Keck School of Medicine, USC','Shiley Eye Institute, University of California San Diego','National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore', 'Minneapolis VA Health Care System, University of Minnesota','UC Davis','UCSF','UCLA Stein Eye Institute, David Geffen School of Medicine at UCLA','Roski Eye Institute, Keck School of Medicine, USC'","","","436100",,"2023-09-21","2023-09-22",,"",,0,,,"ERA",0,"end of continuous observation",,,6,"First",FALSE,"All","First",5,3,"ConditionOccurrence, Measurement, Observation",0,0,11,1,0,0,0,0,0,1,1,0,1,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1073,"[P] Serious Infection, opportunistic infections and other infections of interest event","Serious Infection, opportunistic infections and other infections of interest event","Serious Infection, opportunistic infections and other infections of interest event","rao@ohdsi.org","Pending peer review","","Incidence of Serious Infection, opportunistic infections and other infections of interest event.","#Infection",1,"Joel Swerdel'","0000-0002-6976-2594'","'OHDSI'","","","81893",,"2023-09-22","2023-09-22",,"",,0,,,"ERA",90,"fixed duration relative to initial event","StartDate",30,0,"All",FALSE,"All","All",3,1,"ConditionOccurrence",0,0,4,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1074,"[P] Serious Infection","Serious Infection","Serious Infection","rao@ohdsi.org","Pending peer review","","Incidence of Serious Infection.","#Infection",1,"Joel Swerdel'","0000-0002-6976-2594'","'OHDSI'","","","81893",,"2023-09-22","2023-09-22",,"",,0,,,"ERA",90,"fixed duration relative to initial event","StartDate",30,0,"All",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1075,"[P] FDA AESI Narcolepsy","FDA AESI Narcolepsy","Narcolepsy","rao@ohdsi.org","Pending peer review","","Narcolepsy","#AESI, ,#FDA, #Study, #Symposium, #Covid19SubjectsAesiIncidenceRate",1,"'Azza Shoaibi','Gowtham Rao','Rupa Makadia', 'Patrick Ryan'","'0000-0002-6976-2594', '0000-0002-4949-7236','',''","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-22","2023-09-22",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1076,"[P] FDA AESI Anaphylaxis","FDA AESI Anaphylaxis","Anaphylaxis","rao@ohdsi.org","Pending peer review","","Anaphylaxis","#AESI, ,#FDA, #Study, #Symposium, #Covid19, #Covid19SubjectsAesiIncidenceRate",1,"'Azza Shoaibi','Gowtham Rao','Rupa Makadia', 'Patrick Ryan'","'0000-0002-6976-2594', '0000-0002-4949-7236','',''","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-22","2023-09-22",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1077,"[W] FDA AESI Anaphylaxis v2","FDA AESI Anaphylaxis v2","Anaphylaxis v2","rao@ohdsi.org","Pending peer review","","Anaphylaxis v2","#AESI, ,#FDA, #Study, #Symposium, #Covid19, #Covid19SubjectsAesiIncidenceRate",1,"'Azza Shoaibi','Gowtham Rao','Rupa Makadia', 'Patrick Ryan'","'0000-0002-6976-2594', '0000-0002-4949-7236','',''","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-22","2023-10-03",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1077,"[P] FDA AESI Anaphylaxis v2","FDA AESI Anaphylaxis v2","Anaphylaxis v2","rao@ohdsi.org","Pending peer review","","Anaphylaxis v2","#AESI, ,#FDA, #Study, #Symposium, #Covid19, #Covid19SubjectsAesiIncidenceRate",1,"'Azza Shoaibi','Gowtham Rao','Rupa Makadia', 'Patrick Ryan'","'0000-0002-6976-2594', '0000-0002-4949-7236','',''","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-22","2023-10-09",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1078,"[P] FDA AESI Bells Palsy","FDA AESI Bells Palsy","Bells Palsy","rao@ohdsi.org","Pending peer review","","Bells Palsy","#AESI, ,#FDA, #Study, #Symposium, #Covid19, #Covid19SubjectsAesiIncidenceRate",1,"'Azza Shoaibi','Gowtham Rao','Rupa Makadia', 'Patrick Ryan'","'0000-0002-6976-2594', '0000-0002-4949-7236','',''","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-22","2023-09-22",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1079,"[P] FDA AESI Encephalomyelitis","FDA AESI Encephalomyelitis","Encephalomyelitis","rao@ohdsi.org","Pending peer review","","Encephalomyelitis","#AESI, ,#FDA, #Study, #Symposium, #Covid19, #Covid19SubjectsAesiIncidenceRate",1,"'Azza Shoaibi','Gowtham Rao','Rupa Makadia', 'Patrick Ryan'","'0000-0002-6976-2594', '0000-0002-4949-7236','',''","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-22","2023-09-22",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1080,"[P] FDA AESI Guillain Barre Syndrome","FDA AESI Guillain Barre Syndrome","Guillain Barre Syndrome","rao@ohdsi.org","Pending peer review","","Guillain Barre Syndrome","#AESI, ,#FDA, #Study, #Symposium, #Covid19, #Covid19SubjectsAesiIncidenceRate",1,"'Azza Shoaibi','Gowtham Rao','Rupa Makadia', 'Patrick Ryan'","'0000-0002-6976-2594', '0000-0002-4949-7236','',''","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-22","2023-09-22",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
@@ -857,83 +857,83 @@
 1089,"[P] FDA AESI Non-hemorrhagic Stroke","FDA AESI Non-hemorrhagic Stroke","Non-hemorrhagic Stroke","rao@ohdsi.org","Pending peer review","","Non-hemorrhagic Stroke","#AESI, ,#FDA, #Study, #Symposium, #Covid19, #Covid19SubjectsAesiIncidenceRate",1,"'Azza Shoaibi','Gowtham Rao','Rupa Makadia', 'Patrick Ryan'","'0000-0002-6976-2594', '0000-0002-4949-7236','',''","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-22","2023-09-22",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1090,"[P] FDA AESI Pulmonary Embolism","FDA AESI Pulmonary Embolism","Pulmonary Embolism","rao@ohdsi.org","Pending peer review","","Pulmonary Embolism","#AESI, ,#FDA, #Study, #Symposium, #Covid19, #Covid19SubjectsAesiIncidenceRate",1,"'Azza Shoaibi','Gowtham Rao','Rupa Makadia', 'Patrick Ryan'","'0000-0002-6976-2594', '0000-0002-4949-7236','',''","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-22","2023-09-22",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1091,"[P] FDA AESI Thrombosis with Thrombocytopenia (TWT)","FDA AESI Thrombosis with Thrombocytopenia (TWT)","Thrombosis with Thrombocytopenia (TWT)","rao@ohdsi.org","Pending peer review","","Thrombosis with Thrombocytopenia (TWT)","#AESI, ,#FDA, #Study, #Symposium, #Covid19, #Covid19SubjectsAesiIncidenceRate",1,"'Azza Shoaibi','Gowtham Rao','Rupa Makadia', 'Patrick Ryan'","'0000-0002-6976-2594', '0000-0002-4949-7236','',''","'Johnson and Johnson', 'OHDSI'","","","",,"2023-09-22","2023-09-22",,"",,0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,2,"All",FALSE,"All","All",11,1,"ConditionOccurrence",0,0,16,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1093,"[P] Abdominal Aoritc Aneurysm repair - post op new Afib (any)","Abdominal Aoritc Aneurysm repair - post op new Afib (any)","Abdominal Aoritc Aneurysm repair - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) AAA repair (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-1094,"[P] Lower Extremity Bypass - post op new Afib (any)","Lower Extremity Bypass - post op new Afib (any)","Lower Extremity Bypass - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Lower Extremity Bypass (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation.","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-1095,"[P] Carotid Endarterectomy - post op new Afib (any)","Carotid Endarterectomy - post op new Afib (any)","Carotid Endarterectomy - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Carotid Endarterctomy (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-1096,"[P] Lung Resection - post op new Afib (any)","Lung Resection - post op new Afib (any)","Lung Resection - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Lung Resection (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation.","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-1097,"[P] Esophagectomy - post op new Afib (any)","Esophagectomy - post op new Afib (any)","Esophagectomy - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Esophagectomy (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-1098,"[P] Pancreatectomy - post op new Afib (any)","Pancreatectomy - post op new Afib (any)","Pancreatectomy - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Pancreatectomy (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-1099,"[P] Colectomy - post op new Afib (any)","Colectomy - post op new Afib (any)","Colectomy - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Colectomy (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-1100,"[P] Cystectomy - post op new Afib (any)","Cystectomy - post op new Afib (any)","Cystectomy - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Cystectomy (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-1101,"[P] Nephrectomy - post op new Afib (any)","Nephrectomy - post op new Afib (any)","Nephrectomy - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Nephrectomy (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-1102,"[P] Coronary Artery Bypass Graft Surgery - post op new Afib (any)","Coronary Artery Bypass Graft Surgery - post op new Afib (any)","Coronary Artery Bypass Graft Surgery - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit)CABG (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
-1103,"[P] Aortic or Mitral Valve Repair or Replacement - post op new Afib (any)","Aortic or Mitral Valve Repair or Replacement - post op new Afib (any)","Aortic or Mitral Valve Repair or Replacement - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Aortic Or Mitral Repair or Replacement (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,1,,,,
+1093,"[P] Abdominal Aoritc Aneurysm repair - post op new Afib (any)","Abdominal Aoritc Aneurysm repair - post op new Afib (any)","Abdominal Aoritc Aneurysm repair - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) AAA repair (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+1094,"[P] Lower Extremity Bypass - post op new Afib (any)","Lower Extremity Bypass - post op new Afib (any)","Lower Extremity Bypass - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Lower Extremity Bypass (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation.","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+1095,"[P] Carotid Endarterectomy - post op new Afib (any)","Carotid Endarterectomy - post op new Afib (any)","Carotid Endarterectomy - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Carotid Endarterctomy (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+1096,"[P] Lung Resection - post op new Afib (any)","Lung Resection - post op new Afib (any)","Lung Resection - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Lung Resection (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation.","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+1097,"[P] Esophagectomy - post op new Afib (any)","Esophagectomy - post op new Afib (any)","Esophagectomy - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Esophagectomy (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+1098,"[P] Pancreatectomy - post op new Afib (any)","Pancreatectomy - post op new Afib (any)","Pancreatectomy - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Pancreatectomy (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+1099,"[P] Colectomy - post op new Afib (any)","Colectomy - post op new Afib (any)","Colectomy - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Colectomy (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+1100,"[P] Cystectomy - post op new Afib (any)","Cystectomy - post op new Afib (any)","Cystectomy - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Cystectomy (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+1101,"[P] Nephrectomy - post op new Afib (any)","Nephrectomy - post op new Afib (any)","Nephrectomy - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Nephrectomy (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+1102,"[P] Coronary Artery Bypass Graft Surgery - post op new Afib (any)","Coronary Artery Bypass Graft Surgery - post op new Afib (any)","Coronary Artery Bypass Graft Surgery - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit)CABG (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
+1103,"[P] Aortic or Mitral Valve Repair or Replacement - post op new Afib (any)","Aortic or Mitral Valve Repair or Replacement - post op new Afib (any)","Aortic or Mitral Valve Repair or Replacement - post op new Afib (any)","rao@ohdsi.org","Pending peer review","","Non emergent (No ED visit) Aortic Or Mitral Repair or Replacement (requiring inpatient stay) among adults, first occurrence Afib (any) that occurs 14d after index (date of surgery), no prior atrial fibrillation","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,4,"First",FALSE,"All","First",2,1,"ProcedureOccurrence",0,0,4,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,1,,,,,,,
 1104,"[P] RBC Transfusion (adult relevant, no auto 1yr clean window)","RBC Transfusion (adult relevant, no auto 1yr clean window)","RBC Transfusion (adult relevant, no auto 1yr clean window)","rao@ohdsi.org","Pending peer review","","RBC transfusion with no prior transfusion","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","",,"2023-09-25","2023-09-25",,"",,0,,,"ERA",0,"end of continuous observation",,,1,"First",FALSE,"All","First",1,1,"ProcedureOccurrence",0,0,2,1,0,0,0,0,0,,,0,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
 1105,"[P] Clostridium difficile - first episode","Clostridium difficile - first episode","Clostridium difficile - first episode","rao@ohdsi.org","Pending peer review","","Clostridium difficile with no history of clostridium difficle","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","4307981",,"2023-09-25","2023-10-04",,"",,0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",2,2,"ConditionOccurrence, Measurement",0,0,2,1,0,0,0,0,0,1,1,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
 1106,"[P] Non-Emergent Major Non Cardiac Surgery no prior Opioid","Non-Emergent Major Non Cardiac Surgery no prior Opioid","Non-Emergent Major Non Cardiac Surgery no prior Opioid","rao@ohdsi.org","Pending peer review","","Persons having any of major non cardiac surgery","#Surgery, #WorkGroup",1,"Evan Minty","0000-0003-4631-9992","'OHDSI'","","","","","2023-09-25","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,3,"First",FALSE,"All","First",35,1,"ProcedureOccurrence",0,0,38,1,1,0,0,1,0,,,0,,,,,,,1,,1,,,,,,,,,,,,,,,,,,,
 1150,"Emergency room only or Emergency room and inpatient visits (0Pe, 0Era)","Emergency room only or Emergency room and inpatient visits (0Pe, 0Era)","Emergency room visits (0Pe, 0Era)","rao@ohdsi.org","Accepted","3.4.0","All events of Emergency Room visits or Emergency room or inpatient visit. This cohort is deemed validated as it represents data convention and did not need to go thru peer review process","#standard, #Visits",1,"Gowtham A. Rao","'0000-0002-4949-7236'","'OHDSI'","","","","","2023-10-04","2023-10-04",,"",,0,,,"ERA",0,"fixed duration relative to initial event","EndDate",0,0,"All",FALSE,"All","All",1,1,"VisitOccurrence",0,0,1,0,0,0,0,0,0,,,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,
 1151,"[P] Autism","Autism","Autism","rao@ohdsi.org","Pending peer review","","","#autism",1,"Gowtham A. Rao","'0000-0002-4949-7236'","'OHDSI'","","","439776","","2023-10-05","2023-10-05",,"",,0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1152,"Deep Vein Thrombosis DVT 10","Deep Vein Thrombosis DVT 10","Deep Vein Thrombosis DVT","rao@ohdsi.org","Prediction","","All events of Deep Vein Thrombosis (DVT), indexed on a condition occurrence of Deep Vein Thrombosis (DVT). Requiring a clean window of 30 days, cohort exit is 1 day after start date.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4133004",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1153,"Seizure 10","Seizure 10","Seizure","rao@ohdsi.org","Prediction","","First Seizure record in 42 days continues for 1 day","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","377091",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1154,"Heart failure 10","Heart failure 10","Heart failure","rao@ohdsi.org","Prediction","","First Heart failure continues until observation end","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","316139",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1155,"Non-hemorrhagic Stroke 10","Non-hemorrhagic Stroke 10","Non-hemorrhagic Stroke","rao@ohdsi.org","Prediction","","All events of Ischemic (Non-hemorrhagic) Stroke, indexed on a condition occurrence of Ischemic (Non-hemorrhagic), limited to events with overlapping inpatient visit with no such events in prior 365 days (clean window). Persons exit the cohort at the start date + 1 day.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","443454",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1156,"Hemorrhagic stroke 10","Hemorrhagic stroke 10","Hemorrhagic stroke","rao@ohdsi.org","Prediction","","All events of Hemorrhagic stroke, indexed on a condition occurrence of Hemorrhagic stroke, limited to events with overlapping inpatient visit with no such events in prior 365 days (clean window). Persons exit the cohort at the start date + 1 day.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","439847",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1157,"peripheral vascular disease 10","peripheral vascular disease 10","peripheral vascular disease","rao@ohdsi.org","Prediction","","First peripheral vascular disease continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","321052",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1158,"Aspirin 10","Aspirin 10","Aspirin","rao@ohdsi.org","Prediction","","aspirin exposures w 0d prior obsv 30d gap","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1112807",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1159,"Angina 10","Angina 10","Angina","rao@ohdsi.org","Prediction","","First Angina in 30 days continues for 1 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","77670",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",1,"fixed duration relative to initial event","EndDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1160,"Atrial Fibrillation 10","Atrial Fibrillation 10","Atrial Fibrillation","rao@ohdsi.org","Prediction","","First Atrial Fibrillation continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","313217",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
-1161,"Major depressive disorder with NO occurrence of certain psychiatric disorder 10","Major depressive disorder with NO occurrence of certain psychiatric disorder 10","Major depressive disorder with NO occurrence of certain psychiatric disorder","rao@ohdsi.org","Prediction","","Earliest occurrence of major depressive disorder indexed on diagnosis date requiring no occurrence anytime prior including day 0 of Bipolar disorder, Schizoaffective, Schizophrenia not including paraphrenia, Dementia or Psychotic disorder cohort exit is the end of continuous observation.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","440383",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",TRUE,"All","First",1,1,"ConditionOccurrence",0,0,6,1,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
-1162,"Coronary artery disease (CAD) 10","Coronary artery disease (CAD) 10","Coronary artery disease (CAD)","rao@ohdsi.org","Prediction","","First coronary artery disease (CAD) continues until observation end","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","318443",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",2,2,"ConditionOccurrence, Observation",0,0,1,0,0,0,0,0,0,1,,0,1,,,,,,,1,,,,,,,,,,,,,,,,,,,,
-1163,"Acute Kidney Injury 10","Acute Kidney Injury 10","Acute Kidney Injury","rao@ohdsi.org","Prediction","","All events of Acute Kidney Injury (AKI) indexed on a diagnosis of Acute kidney injury or a Dialysis procedure at a medicare certified esrd facility for acute kidney injury without esrd,. Applying a washout period of 30 days between observed events excluding events/patients with 1. a diagnosis of End-Stage Kidney Disease in the 365 days before AKI occurrence 2. patients receiving chronic dialysis defined as more than 3 recorded events of dialysis in 365 days before AKI occurrence 3. kidney Transplant any time prior . patients exit the cohort 7 days post index.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","197320",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",7,4,"All",FALSE,"All","All",2,2,"ConditionOccurrence, ProcedureOccurrence",0,0,7,1,0,0,0,0,1,1,,1,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
-1164,"Asthma 10","Asthma 10","Asthma","rao@ohdsi.org","Prediction","","First Asthma continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","317009",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1165,"Alcoholism 10","Alcoholism 10","Alcoholism","rao@ohdsi.org","Prediction","","First record of Alcoholism until observation end","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4218106",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",3,3,"ConditionOccurrence, Observation, ProcedureOccurrence",0,0,1,0,0,0,0,0,0,1,,0,1,,,,,,1,,,,,,,,,,,,,,,,,,,,,
-1166,"Smoking 10","Smoking 10","Smoking","rao@ohdsi.org","Prediction","","First Smoking condition or observtion or procedure record continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4209423",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",3,3,"ConditionOccurrence, Observation, ProcedureOccurrence",0,0,1,0,0,0,0,0,0,1,,0,1,,,,,,1,,,,,,,,,,,,,,,,,,,,,
-1167,"sleep apnea 10","sleep apnea 10","sleep apnea","rao@ohdsi.org","Prediction","","First sleep apnea record continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","313459",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1168,"skin ulcer 10","skin ulcer 10","skin ulcer","rao@ohdsi.org","Prediction","","First skin ulcer record in 365 days continues for 30 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4262920",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",30,1,"All",FALSE,"All","All",3,3,"ConditionOccurrence, Observation, ProcedureOccurrence",0,0,1,1,0,0,0,0,1,1,,1,1,,,,,,1,,,,,,,,,,,,,,,,,,,,,
-1169,"Chronic hepatitis 10","Chronic hepatitis 10","Chronic hepatitis","rao@ohdsi.org","Prediction","","First Chronic hepatitis continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4212540",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1170,"hyperlipidemia 10","hyperlipidemia 10","hyperlipidemia","rao@ohdsi.org","Prediction","","First hyperlipidemia continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","432867",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1171,"hypothyroidism 10","hypothyroidism 10","hypothyroidism","rao@ohdsi.org","Prediction","","First hypothyroidism continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","140673",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1172,"Heart valve disorder 10","Heart valve disorder 10","Heart valve disorder","rao@ohdsi.org","Prediction","","First Heart valve disorder continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4281749",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1173,"Low back pain 10","Low back pain 10","Low back pain","rao@ohdsi.org","Prediction","","First Low back pain continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","194133",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1174,"neuropathy 10","neuropathy 10","neuropathy","rao@ohdsi.org","Prediction","","First neuropathy continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4301699",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1175,"Psychotic disorder 10","Psychotic disorder 10","Psychotic disorder","rao@ohdsi.org","Prediction","","First Psychotic disorder continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","436073",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1176,"Sepsis 10","Sepsis 10","Sepsis","rao@ohdsi.org","Prediction","","First Sepsis record in 180 days continues for 7 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","132797",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",7,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,1,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1177,"Acute Respiratory failure 10","Acute Respiratory failure 10","Acute Respiratory failure","rao@ohdsi.org","Prediction","","First Acute Respiratory failure record in 365 days continues for 14 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","319049",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",14,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,1,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1178,"Gastroesophageal reflux disease 10","Gastroesophageal reflux disease 10","Gastroesophageal reflux disease","rao@ohdsi.org","Prediction","","First Gastroesophageal reflux disease continues until observation end","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","318800",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1179,"obesity 10","obesity 10","obesity","rao@ohdsi.org","Prediction","","First obesity measurement or condition or observation continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","433736",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",5,3,"ConditionOccurrence, Measurement, Observation",0,0,3,0,0,0,0,0,0,1,1,0,1,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1180,"Inflammatory Bowel Disease 10","Inflammatory Bowel Disease 10","Inflammatory Bowel Disease","rao@ohdsi.org","Prediction","","First Inflammatory Bowel Disease continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","201606",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1181,"STEROIDS 10","STEROIDS 10","STEROIDS","rao@ohdsi.org","Prediction","","STEROIDS record with 60 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1551099",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,60,0,,,,,,
-1182,"Opioids 10","Opioids 10","Opioids","rao@ohdsi.org","Prediction","","Opioids with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1174888",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1183,"ANTIEPILEPTICS 10","ANTIEPILEPTICS 10","ANTIEPILEPTICS","rao@ohdsi.org","Prediction","","ANTIEPILEPTICS exposure with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","797399",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1184,"Osteoarthritis 10","Osteoarthritis 10","Osteoarthritis","rao@ohdsi.org","Prediction","","First Osteoarthritis continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","80180",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1185,"Osteoporosis 10","Osteoporosis 10","Osteoporosis","rao@ohdsi.org","Prediction","","First Osteoporosis continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","80502",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1186,"Urinary tract infectious 10","Urinary tract infectious 10","Urinary tract infectious","rao@ohdsi.org","Prediction","","First Urinary tract infectious record in 30 days continues for 1 day","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","81902",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,1,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1187,"acetaminophen exposure 10","acetaminophen exposure 10","acetaminophen exposure","rao@ohdsi.org","Prediction","","acetaminophen exposure with 30 day persistence window","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1125315",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1188,"Anemia 10","Anemia 10","Anemia","rao@ohdsi.org","Prediction","","Anemia record or measurement continues for 21 days unless normal measurement","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4144746",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",365,"fixed duration relative to initial event","StartDate",21,3,"All",FALSE,"All","All",3,2,"ConditionOccurrence, Measurement",0,0,4,1,0,0,0,0,0,1,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1189,"Anxiety 10","Anxiety 10","Anxiety","rao@ohdsi.org","Prediction","","First Anxiety continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","441542",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",2,2,"ConditionOccurrence, Observation",0,0,1,0,0,0,0,0,0,1,,0,1,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1190,"HORMONAL CONTRACEPTIVES 10","HORMONAL CONTRACEPTIVES 10","HORMONAL CONTRACEPTIVES","rao@ohdsi.org","Prediction","","HORMONAL CONTRACEPTIVES with 30 day persistence window","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","21602473",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1191,"Chronic kidney disease or end stage renal disease 10","Chronic kidney disease or end stage renal disease 10","Chronic kidney disease or end stage renal disease","rao@ohdsi.org","Prediction","","First chronic kidney disease or end stage renal disease continues until observation end","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","46271022",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",5,3,"ConditionOccurrence, Observation, ProcedureOccurrence",0,0,3,0,0,0,0,0,0,1,,0,1,,,,,,1,,,,,,,,,,,,,,,,,,,,,
-1192,"Chronic obstructive pulmonary disease (COPD) 10","Chronic obstructive pulmonary disease (COPD) 10","Chronic obstructive pulmonary disease (COPD)","rao@ohdsi.org","Prediction","","First chronic obstructive pulmonary disease (COPD) continues until observation end","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","255573",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1193,"Type 1 diabetes and no prior specific nonT1DM diabetes 10","Type 1 diabetes and no prior specific nonT1DM diabetes 10","Type 1 diabetes and no prior specific nonT1DM diabetes","rao@ohdsi.org","Prediction","","Earliest Type 1 diabetes with no prior type 2 or secondary diabetes continues until end of observation.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","201254",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,3,1,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1194,"Type 2 Diabetes Mellitus with no type 1 or secondary DM 10","Type 2 Diabetes Mellitus with no type 1 or secondary DM 10","Type 2 Diabetes Mellitus with no type 1 or secondary DM","rao@ohdsi.org","Prediction","","Earliest Type 2 diabetes with no prior type 1 or secondary diabetes continues until end of observation.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","201820",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,5,1,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1195,"Dyspnea 10","Dyspnea 10","Dyspnea","rao@ohdsi.org","Prediction","","All events of Dyspnea with no Dyspnea in prior 30 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","312437",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",0,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1196,"Edema 10","Edema 10","Edema","rao@ohdsi.org","Prediction","","All events of Edema with no Edemain prior 30 days and cohort ends 3 days after index.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","433595",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",3,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,1,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1197,"Acute gastrointestinal bleeding 10","Acute gastrointestinal bleeding 10","Acute gastrointestinal bleeding","rao@ohdsi.org","Prediction","","First gastrointestinal bleed in 45 days continues for 7 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","192671",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",7,1,"All",FALSE,"All","All",2,2,"ConditionOccurrence, ProcedureOccurrence",0,0,1,1,0,0,0,0,1,1,,1,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
-1198,"Hypertension 10","Hypertension 10","Hypertension","rao@ohdsi.org","Prediction","","First Hypertension continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","316866",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1199,"Pneumonia 10","Pneumonia 10","Pneumonia","rao@ohdsi.org","Prediction","","First Pneumonia record in 180 days continues until for 30 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","255848",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",30,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,1,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1200,"Rheumatoid Arthritis 10","Rheumatoid Arthritis 10","Rheumatoid Arthritis","rao@ohdsi.org","Prediction","","First Rheumatoid Arthritis record continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","80809",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",2,2,"ConditionOccurrence, Observation",0,0,1,0,0,0,0,0,0,1,,0,1,,,,,,,,,,,,,,,,,,,,,,,,,,,
-1201,"Antibiotics Aminoglycosides 10","Antibiotics Aminoglycosides 10","Antibiotics Aminoglycosides","rao@ohdsi.org","Prediction","","any Antibiotics Aminoglycosides with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","915981",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1202,"Antibiotics Carbapenems 10","Antibiotics Carbapenems 10","Antibiotics Carbapenems","rao@ohdsi.org","Prediction","","any Antibiotics Carbapenems with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1709170",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1203,"Antibiotics Cephalosporins 10","Antibiotics Cephalosporins 10","Antibiotics Cephalosporins","rao@ohdsi.org","Prediction","","any Antibiotics Cephalosporins with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1786621",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1204,"Antibiotics Fluoroquinolones 10","Antibiotics Fluoroquinolones 10","Antibiotics Fluoroquinolones","rao@ohdsi.org","Prediction","","any Antibiotics Fluoroquinolones with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1797513",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1205,"Antibiotics Glycopeptides and lipoglycopeptides 10","Antibiotics Glycopeptides and lipoglycopeptides 10","Antibiotics Glycopeptides and lipoglycopeptides","rao@ohdsi.org","Prediction","","any Antibiotics Glycopeptides and lipoglycopeptides with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1707687",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1206,"Antibiotics Macrolides 10","Antibiotics Macrolides 10","Antibiotics Macrolides","rao@ohdsi.org","Prediction","","any Antibiotics Macrolides with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1734104",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1207,"Antibiotics Monobactams 10","Antibiotics Monobactams 10","Antibiotics Monobactams","rao@ohdsi.org","Prediction","","any Antibiotics Monobactams with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1715117",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1208,"Antibiotics Oxazolidinones 10","Antibiotics Oxazolidinones 10","Antibiotics Oxazolidinones","rao@ohdsi.org","Prediction","","any Antibiotics Oxazolidinones with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1736887",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1209,"Antibiotics Penicillins 10","Antibiotics Penicillins 10","Antibiotics Penicillins","rao@ohdsi.org","Prediction","","any Antibiotics Penicillins with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1713332",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1210,"Antibiotics Polypeptides 10","Antibiotics Polypeptides 10","Antibiotics Polypeptides","rao@ohdsi.org","Prediction","","any Antibiotics Polypeptides with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","948582",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,0,30,0,,,,,,
-1211,"Antibiotics Rifamycins 10","Antibiotics Rifamycins 10","Antibiotics Rifamycins","rao@ohdsi.org","Prediction","","any Antibiotics Rifamycins with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1735947",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,1,30,0,,,,,,
-1212,"Antibiotics Sulfonamides 10","Antibiotics Sulfonamides 10","Antibiotics Sulfonamides","rao@ohdsi.org","Prediction","","any Antibiotics Sulfonamides with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1836430",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,2,30,0,,,,,,
-1213,"Antibiotics Streptogramins 10","Antibiotics Streptogramins 10","Antibiotics Streptogramins","rao@ohdsi.org","Prediction","","any Antibiotics Streptogramins with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1789517",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,3,30,0,,,,,,
-1214,"Antibiotics Tetracyclines 10","Antibiotics Tetracyclines 10","Antibiotics Tetracyclines","rao@ohdsi.org","Prediction","","any Antibiotics Tetracyclines with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1738521",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,4,30,0,,,,,,
-1215,"Any cancer (excl. prostate cancer and benign cancer) 10","Any cancer (excl. prostate cancer and benign cancer) 10","Any cancer (excl. prostate cancer and benign cancer)","rao@ohdsi.org","Prediction","","First cancer (excluding prostate and benign) continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","438112",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",4,3,"ConditionOccurrence, Measurement, Observation",0,0,1,0,0,0,0,0,0,1,1,0,1,,,,,,,,,,,,,,,,,,,,,,,,,,,1
+1152,"[P] Deep Vein Thrombosis DVT 10","Deep Vein Thrombosis DVT 10","Deep Vein Thrombosis DVT","rao@ohdsi.org","Prediction","","All events of Deep Vein Thrombosis (DVT), indexed on a condition occurrence of Deep Vein Thrombosis (DVT). Requiring a clean window of 30 days, cohort exit is 1 day after start date.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4133004",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1153,"[P] Seizure 10","Seizure 10","Seizure","rao@ohdsi.org","Prediction","","First Seizure record in 42 days continues for 1 day","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","377091",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1154,"[P] Heart failure 10","Heart failure 10","Heart failure","rao@ohdsi.org","Prediction","","First Heart failure continues until observation end","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","316139",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1155,"[P] Non-hemorrhagic Stroke 10","Non-hemorrhagic Stroke 10","Non-hemorrhagic Stroke","rao@ohdsi.org","Prediction","","All events of Ischemic (Non-hemorrhagic) Stroke, indexed on a condition occurrence of Ischemic (Non-hemorrhagic), limited to events with overlapping inpatient visit with no such events in prior 365 days (clean window). Persons exit the cohort at the start date + 1 day.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","443454",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1156,"[P] Hemorrhagic stroke 10","Hemorrhagic stroke 10","Hemorrhagic stroke","rao@ohdsi.org","Prediction","","All events of Hemorrhagic stroke, indexed on a condition occurrence of Hemorrhagic stroke, limited to events with overlapping inpatient visit with no such events in prior 365 days (clean window). Persons exit the cohort at the start date + 1 day.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","439847",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",TRUE,"All","All",1,1,"ConditionOccurrence",0,0,2,1,0,0,0,1,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1157,"[P] peripheral vascular disease 10","peripheral vascular disease 10","peripheral vascular disease","rao@ohdsi.org","Prediction","","First peripheral vascular disease continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","321052",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1158,"[P] Aspirin 10","Aspirin 10","Aspirin","rao@ohdsi.org","Prediction","","aspirin exposures w 0d prior obsv 30d gap","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1112807",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1159,"[P] Angina 10","Angina 10","Angina","rao@ohdsi.org","Prediction","","First Angina in 30 days continues for 1 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","77670",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",1,"fixed duration relative to initial event","EndDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1160,"[P] Atrial Fibrillation 10","Atrial Fibrillation 10","Atrial Fibrillation","rao@ohdsi.org","Prediction","","First Atrial Fibrillation continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","313217",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
+1161,"[P] Major depressive disorder with NO occurrence of certain psychiatric disorder 10","Major depressive disorder with NO occurrence of certain psychiatric disorder 10","Major depressive disorder with NO occurrence of certain psychiatric disorder","rao@ohdsi.org","Prediction","","Earliest occurrence of major depressive disorder indexed on diagnosis date requiring no occurrence anytime prior including day 0 of Bipolar disorder, Schizoaffective, Schizophrenia not including paraphrenia, Dementia or Psychotic disorder cohort exit is the end of continuous observation.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","440383",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",TRUE,"All","First",1,1,"ConditionOccurrence",0,0,6,1,0,0,0,0,0,1,,0,,,,,,,,1,,,,,,,,,,,,,,,,,,,,
+1162,"[P] Coronary artery disease (CAD) 10","Coronary artery disease (CAD) 10","Coronary artery disease (CAD)","rao@ohdsi.org","Prediction","","First coronary artery disease (CAD) continues until observation end","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","318443",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",2,2,"ConditionOccurrence, Observation",0,0,1,0,0,0,0,0,0,1,,0,1,,,,,,,1,,,,,,,,,,,,,,,,,,,,
+1163,"[P] Acute Kidney Injury 10","Acute Kidney Injury 10","Acute Kidney Injury","rao@ohdsi.org","Prediction","","All events of Acute Kidney Injury (AKI) indexed on a diagnosis of Acute kidney injury or a Dialysis procedure at a medicare certified esrd facility for acute kidney injury without esrd,. Applying a washout period of 30 days between observed events excluding events/patients with 1. a diagnosis of End-Stage Kidney Disease in the 365 days before AKI occurrence 2. patients receiving chronic dialysis defined as more than 3 recorded events of dialysis in 365 days before AKI occurrence 3. kidney Transplant any time prior . patients exit the cohort 7 days post index.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","197320",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",7,4,"All",FALSE,"All","All",2,2,"ConditionOccurrence, ProcedureOccurrence",0,0,7,1,0,0,0,0,1,1,,1,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
+1164,"[P] Asthma 10","Asthma 10","Asthma","rao@ohdsi.org","Prediction","","First Asthma continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","317009",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1165,"[P] Alcoholism 10","Alcoholism 10","Alcoholism","rao@ohdsi.org","Prediction","","First record of Alcoholism until observation end","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4218106",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",3,3,"ConditionOccurrence, Observation, ProcedureOccurrence",0,0,1,0,0,0,0,0,0,1,,0,1,,,,,,1,,,,,,,,,,,,,,,,,,,,,
+1166,"[P] Smoking 10","Smoking 10","Smoking","rao@ohdsi.org","Prediction","","First Smoking condition or observtion or procedure record continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4209423",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",3,3,"ConditionOccurrence, Observation, ProcedureOccurrence",0,0,1,0,0,0,0,0,0,1,,0,1,,,,,,1,,,,,,,,,,,,,,,,,,,,,
+1167,"[P] sleep apnea 10","sleep apnea 10","sleep apnea","rao@ohdsi.org","Prediction","","First sleep apnea record continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","313459",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1168,"[P] skin ulcer 10","skin ulcer 10","skin ulcer","rao@ohdsi.org","Prediction","","First skin ulcer record in 365 days continues for 30 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4262920",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",30,1,"All",FALSE,"All","All",3,3,"ConditionOccurrence, Observation, ProcedureOccurrence",0,0,1,1,0,0,0,0,1,1,,1,1,,,,,,1,,,,,,,,,,,,,,,,,,,,,
+1169,"[P] Chronic hepatitis 10","Chronic hepatitis 10","Chronic hepatitis","rao@ohdsi.org","Prediction","","First Chronic hepatitis continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4212540",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1170,"[P] hyperlipidemia 10","hyperlipidemia 10","hyperlipidemia","rao@ohdsi.org","Prediction","","First hyperlipidemia continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","432867",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1171,"[P] hypothyroidism 10","hypothyroidism 10","hypothyroidism","rao@ohdsi.org","Prediction","","First hypothyroidism continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","140673",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1172,"[P] Heart valve disorder 10","Heart valve disorder 10","Heart valve disorder","rao@ohdsi.org","Prediction","","First Heart valve disorder continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4281749",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1173,"[P] Low back pain 10","Low back pain 10","Low back pain","rao@ohdsi.org","Prediction","","First Low back pain continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","194133",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1174,"[P] neuropathy 10","neuropathy 10","neuropathy","rao@ohdsi.org","Prediction","","First neuropathy continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4301699",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1175,"[P] Psychotic disorder 10","Psychotic disorder 10","Psychotic disorder","rao@ohdsi.org","Prediction","","First Psychotic disorder continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","436073",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1176,"[P] Sepsis 10","Sepsis 10","Sepsis","rao@ohdsi.org","Prediction","","First Sepsis record in 180 days continues for 7 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","132797",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",7,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,1,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1177,"[P] Acute Respiratory failure 10","Acute Respiratory failure 10","Acute Respiratory failure","rao@ohdsi.org","Prediction","","First Acute Respiratory failure record in 365 days continues for 14 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","319049",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",14,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,1,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1178,"[P] Gastroesophageal reflux disease 10","Gastroesophageal reflux disease 10","Gastroesophageal reflux disease","rao@ohdsi.org","Prediction","","First Gastroesophageal reflux disease continues until observation end","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","318800",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1179,"[P] obesity 10","obesity 10","obesity","rao@ohdsi.org","Prediction","","First obesity measurement or condition or observation continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","433736",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",5,3,"ConditionOccurrence, Measurement, Observation",0,0,3,0,0,0,0,0,0,1,1,0,1,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1180,"[P] Inflammatory Bowel Disease 10","Inflammatory Bowel Disease 10","Inflammatory Bowel Disease","rao@ohdsi.org","Prediction","","First Inflammatory Bowel Disease continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","201606",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1181,"[P] STEROIDS 10","STEROIDS 10","STEROIDS","rao@ohdsi.org","Prediction","","STEROIDS record with 60 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1551099",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,60,0,,,,
+1182,"[P] Opioids 10","Opioids 10","Opioids","rao@ohdsi.org","Prediction","","Opioids with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1174888",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1183,"[P] ANTIEPILEPTICS 10","ANTIEPILEPTICS 10","ANTIEPILEPTICS","rao@ohdsi.org","Prediction","","ANTIEPILEPTICS exposure with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","797399",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1184,"[P] Osteoarthritis 10","Osteoarthritis 10","Osteoarthritis","rao@ohdsi.org","Prediction","","First Osteoarthritis continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","80180",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1185,"[P] Osteoporosis 10","Osteoporosis 10","Osteoporosis","rao@ohdsi.org","Prediction","","First Osteoporosis continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","80502",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1186,"[P] Urinary tract infectious 10","Urinary tract infectious 10","Urinary tract infectious","rao@ohdsi.org","Prediction","","First Urinary tract infectious record in 30 days continues for 1 day","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","81902",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",1,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,1,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1187,"[P] acetaminophen exposure 10","acetaminophen exposure 10","acetaminophen exposure","rao@ohdsi.org","Prediction","","acetaminophen exposure with 30 day persistence window","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1125315",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1188,"[P] Anemia 10","Anemia 10","Anemia","rao@ohdsi.org","Prediction","","Anemia record or measurement continues for 21 days unless normal measurement","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","4144746",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",365,"fixed duration relative to initial event","StartDate",21,3,"All",FALSE,"All","All",3,2,"ConditionOccurrence, Measurement",0,0,4,1,0,0,0,0,0,1,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1189,"[P] Anxiety 10","Anxiety 10","Anxiety","rao@ohdsi.org","Prediction","","First Anxiety continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","441542",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",2,2,"ConditionOccurrence, Observation",0,0,1,0,0,0,0,0,0,1,,0,1,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1190,"[P] HORMONAL CONTRACEPTIVES 10","HORMONAL CONTRACEPTIVES 10","HORMONAL CONTRACEPTIVES","rao@ohdsi.org","Prediction","","HORMONAL CONTRACEPTIVES with 30 day persistence window","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","21602473",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1191,"[P] Chronic kidney disease or end stage renal disease 10","Chronic kidney disease or end stage renal disease 10","Chronic kidney disease or end stage renal disease","rao@ohdsi.org","Prediction","","First chronic kidney disease or end stage renal disease continues until observation end","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","46271022",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",5,3,"ConditionOccurrence, Observation, ProcedureOccurrence",0,0,3,0,0,0,0,0,0,1,,0,1,,,,,,1,,,,,,,,,,,,,,,,,,,,,
+1192,"[P] Chronic obstructive pulmonary disease (COPD) 10","Chronic obstructive pulmonary disease (COPD) 10","Chronic obstructive pulmonary disease (COPD)","rao@ohdsi.org","Prediction","","First chronic obstructive pulmonary disease (COPD) continues until observation end","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","255573",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1193,"[P] Type 1 diabetes and no prior specific nonT1DM diabetes 10","Type 1 diabetes and no prior specific nonT1DM diabetes 10","Type 1 diabetes and no prior specific nonT1DM diabetes","rao@ohdsi.org","Prediction","","Earliest Type 1 diabetes with no prior type 2 or secondary diabetes continues until end of observation.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","201254",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,3,1,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1194,"[P] Type 2 Diabetes Mellitus with no type 1 or secondary DM 10","Type 2 Diabetes Mellitus with no type 1 or secondary DM 10","Type 2 Diabetes Mellitus with no type 1 or secondary DM","rao@ohdsi.org","Prediction","","Earliest Type 2 diabetes with no prior type 1 or secondary diabetes continues until end of observation.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","201820",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,2,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,5,1,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1195,"[P] Dyspnea 10","Dyspnea 10","Dyspnea","rao@ohdsi.org","Prediction","","All events of Dyspnea with no Dyspnea in prior 30 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","312437",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",0,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,0,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1196,"[P] Edema 10","Edema 10","Edema","rao@ohdsi.org","Prediction","","All events of Edema with no Edemain prior 30 days and cohort ends 3 days after index.","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","433595",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",3,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,1,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1197,"[P] Acute gastrointestinal bleeding 10","Acute gastrointestinal bleeding 10","Acute gastrointestinal bleeding","rao@ohdsi.org","Prediction","","First gastrointestinal bleed in 45 days continues for 7 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","192671",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","StartDate",7,1,"All",FALSE,"All","All",2,2,"ConditionOccurrence, ProcedureOccurrence",0,0,1,1,0,0,0,0,1,1,,1,,,,,,,1,,,,,,,,,,,,,,,,,,,,,
+1198,"[P] Hypertension 10","Hypertension 10","Hypertension","rao@ohdsi.org","Prediction","","First Hypertension continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","316866",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",1,1,"ConditionOccurrence",0,0,1,0,0,0,0,0,0,1,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1199,"[P] Pneumonia 10","Pneumonia 10","Pneumonia","rao@ohdsi.org","Prediction","","First Pneumonia record in 180 days continues until for 30 days","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","255848",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"fixed duration relative to initial event","EndDate",30,1,"All",FALSE,"All","All",1,1,"ConditionOccurrence",0,0,1,1,0,0,0,0,1,1,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1200,"[P] Rheumatoid Arthritis 10","Rheumatoid Arthritis 10","Rheumatoid Arthritis","rao@ohdsi.org","Prediction","","First Rheumatoid Arthritis record continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","80809",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",2,2,"ConditionOccurrence, Observation",0,0,1,0,0,0,0,0,0,1,,0,1,,,,,,,,,,,,,,,,,,,,,,,,,,,
+1201,"[P] Antibiotics Aminoglycosides 10","Antibiotics Aminoglycosides 10","Antibiotics Aminoglycosides","rao@ohdsi.org","Prediction","","any Antibiotics Aminoglycosides with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","915981",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1202,"[P] Antibiotics Carbapenems 10","Antibiotics Carbapenems 10","Antibiotics Carbapenems","rao@ohdsi.org","Prediction","","any Antibiotics Carbapenems with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1709170",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1203,"[P] Antibiotics Cephalosporins 10","Antibiotics Cephalosporins 10","Antibiotics Cephalosporins","rao@ohdsi.org","Prediction","","any Antibiotics Cephalosporins with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1786621",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1204,"[P] Antibiotics Fluoroquinolones 10","Antibiotics Fluoroquinolones 10","Antibiotics Fluoroquinolones","rao@ohdsi.org","Prediction","","any Antibiotics Fluoroquinolones with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1797513",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1205,"[P] Antibiotics Glycopeptides and lipoglycopeptides 10","Antibiotics Glycopeptides and lipoglycopeptides 10","Antibiotics Glycopeptides and lipoglycopeptides","rao@ohdsi.org","Prediction","","any Antibiotics Glycopeptides and lipoglycopeptides with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1707687",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1206,"[P] Antibiotics Macrolides 10","Antibiotics Macrolides 10","Antibiotics Macrolides","rao@ohdsi.org","Prediction","","any Antibiotics Macrolides with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1734104",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1207,"[P] Antibiotics Monobactams 10","Antibiotics Monobactams 10","Antibiotics Monobactams","rao@ohdsi.org","Prediction","","any Antibiotics Monobactams with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1715117",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1208,"[P] Antibiotics Oxazolidinones 10","Antibiotics Oxazolidinones 10","Antibiotics Oxazolidinones","rao@ohdsi.org","Prediction","","any Antibiotics Oxazolidinones with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1736887",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1209,"[P] Antibiotics Penicillins 10","Antibiotics Penicillins 10","Antibiotics Penicillins","rao@ohdsi.org","Prediction","","any Antibiotics Penicillins with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1713332",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1210,"[P] Antibiotics Polypeptides 10","Antibiotics Polypeptides 10","Antibiotics Polypeptides","rao@ohdsi.org","Prediction","","any Antibiotics Polypeptides with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","948582",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,0,30,0,,,,
+1211,"[P] Antibiotics Rifamycins 10","Antibiotics Rifamycins 10","Antibiotics Rifamycins","rao@ohdsi.org","Prediction","","any Antibiotics Rifamycins with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1735947",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,1,30,0,,,,
+1212,"[P] Antibiotics Sulfonamides 10","Antibiotics Sulfonamides 10","Antibiotics Sulfonamides","rao@ohdsi.org","Prediction","","any Antibiotics Sulfonamides with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1836430",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,2,30,0,,,,
+1213,"[P] Antibiotics Streptogramins 10","Antibiotics Streptogramins 10","Antibiotics Streptogramins","rao@ohdsi.org","Prediction","","any Antibiotics Streptogramins with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1789517",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,3,30,0,,,,
+1214,"[P] Antibiotics Tetracyclines 10","Antibiotics Tetracyclines 10","Antibiotics Tetracyclines","rao@ohdsi.org","Prediction","","any Antibiotics Tetracyclines with 30 day persistence","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","1738521",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous drug exposure",,,0,"All",FALSE,"All","All",1,1,"DrugExposure",0,0,1,0,0,0,0,0,0,,,1,,,,1,,,,,,,,,,,,,,,,,,4,30,0,,,,
+1215,"[P] Any cancer (excl. prostate cancer and benign cancer) 10","Any cancer (excl. prostate cancer and benign cancer) 10","Any cancer (excl. prostate cancer and benign cancer)","rao@ohdsi.org","Prediction","","First cancer (excluding prostate and benign) continues until end of observation","#Prediction",1,"'Jenna Reps'","'0000-0002-2970-0778'","'Johnson and Johnson', 'OHDSI'","","","438112",,"2023-10-09","2023-10-09",,"","Prediction phenotypes",0,,,"ERA",0,"end of continuous observation",,,0,"First",FALSE,"All","First",4,3,"ConditionOccurrence, Measurement, Observation",0,0,1,0,0,0,0,0,0,1,1,0,1,,,,,,,,,,,,,,,,,,,,,,,,,,,1
diff --git a/inst/OrcidLog.csv b/inst/OrcidLog.csv
index 9584d742..c972cdba 100644
--- a/inst/OrcidLog.csv
+++ b/inst/OrcidLog.csv
@@ -11,7 +11,7 @@
 "0000-0002-0847-6682","Anna","Ostropolets","",24,0
 "0000-0002-2970-0778","Jenna","Reps","",64,0
 "0000-0002-4243-155X","Asieh","Golozar","",8,0
-"0000-0002-4949-7236","Gowtham","Rao","",529,14
+"0000-0002-4949-7236","Gowtham","Rao","",530,14
 "0000-0002-6976-2594","Azza","Shoaibi","",67,0
 "0000-0002-9612-5697","Brian","Toy","",1,0
 "0000-0003-0755-5191","James","Weaver","",2,0
diff --git a/inst/cohorts/794.json b/inst/cohorts/794.json
index 7fdd542c..1e736cb6 100644
--- a/inst/cohorts/794.json
+++ b/inst/cohorts/794.json
@@ -52,16 +52,15 @@
 	},
 	"InclusionRules" : [],
 	"EndStrategy" : {
-		"CustomEra" : {
-			"DrugCodesetId" : 0,
-			"GapDays" : 1,
-			"Offset" : 7
+		"DateOffset" : {
+			"DateField" : "EndDate",
+			"Offset" : 14
 		}
 	},
 	"CensoringCriteria" : [],
 	"CollapseSettings" : {
 		"CollapseType" : "ERA",
-		"EraPad" : 1
+		"EraPad" : 0
 	},
 	"CensorWindow" : {}
 }
\ No newline at end of file
diff --git a/inst/doc/HowToUsePhenotypeLibraryRPackage.pdf b/inst/doc/HowToUsePhenotypeLibraryRPackage.pdf
index cc63f12bd1f4696a5a6a4bca65330987a7986db0..9f8b4e84d075123cc376ad604c89080bd6d4dbb5 100644
GIT binary patch
delta 37240
zcmV(^K-It6gAApC43H%PFfx;&4Jd!jS4(r-HW0q+S8$RGbr6CF0g@h1r*0g_?j)`&
zySc=f4kS_%rnNqz?0l@Kj}H#Hk`GP|nB;NMP1V
z=54kb3g(tEECot3CnTZb$_jr{w1N_BI10IRuU18=(^Qv<(O?l7Glcuxup^r#j%sQf
zD5x06WuC+jL*=nU?+VEqi#{@4F0yu9Lkj4Pg7&Ox;gqswwu616*
zE}Plab1%=%-`(yDw27ApNXW%DUX1Mt*tQ~#Ja52coG@Qi&iWyi!##gzv?J4U&B*ws
zrqTJkMUA>%^$IX2h+&f2@&(#>w6^sbKz&y1rtC^MTX*y&+p9OwRZr`>nO?Olf?oDd>SKq!J>(d-o``jc+H8wtIe0TWxG*c)|T_Q+`-A_y?tr!6xQm?BlS>swf7@8ZEY?}
zAqcJO|Md^Uku-lz^ct2kSjuE#O7sLiq(@=%7c2o>;O0Vv=gv-%=_QJda1{YFd|m6M
zDQjlDYY@)L)K+wx>mtjSx-8>o;vcfr9B65k;Kbg3_R~zja)Www6vfe}I4|sN49wX)
znV!eRG*8ysN6jASLiy4?jV39^<8->nw`AB$f4BF82AzK!w{XwZPPTFv_a3M9{s4fA
zn<1wF5O1^1d;!}mhxPU=teGhfQ
z$+rcQra+4y;#G-hursmB-q&7lIeO~>_j#i8d=YD`qpgP>`tDPS)@PNgBcP7@Q42&Z
z5#3X_atzlNZX3&)%X#R&iZ33
z5vdQ{m$8oY)ZV$3j&AAiKkiWTCbggCc!hu2@1{aG101?(8RzxHE0$e1_aAqtaSf;T
zraZ{^oo*g5)9;~=9)>tpvK)h5F7nL&4QY9}|M-77wL*3jV^eJ1KN29&yDvJkLj#sDG{T_$4#|+p%>QpBMMqjVG&h9_%P@}dx
zGhO!c9naa12dAVxwOIvcIS|H+#J=E*1H)(kafh1MubAaBTlKRX&(HC}q&6OU3BK(F
z7V{o*+f{k?SoHlP;(`%L!|EBijUsDFnEwcW1J#J#hLem1Cj&S+HItzYD1XgZ>u=jQ
z691mRLTJA@K+K4GtGF%Db(3z3?lzlv?{H`r3t6IV7MA2C>7=;>`nT_pL&cUX=V9k?
z`@t3;!+CLL_#<6s=D5zgBiDX^93P#YhrW}NH1Z;6JauBviK$CmKX%52^Lg;{_3<$D
z!of@YaQws`e#=@gY+Yx9XMd9gldrHp&*XfZ&9L*2d@f#}SPpW;Mb19Ry0VkSWYJ9K
zb)^KKtW+)J_R@{nPa=O`v`Ky+e*l|?l#(ma*^e%$HuBw?8&xpY5kG2Q9ZAP>WKqZ$y)r2S4Dku
zr81#5HSZ@otBM^&^C4rkZ^L-S70(uD*AR^#dC7Z1
zX_MrVNl2JnC&`VF?6{-9nR4}ISsZcv-uF_I?7LoXS8WsT@eq9r7aJ&2_4SInGUQ;j)XB>uJs!k9&?k-`k;IK0!JO&Qulp)_-?rxcg8UZQJXN;_2D=_Tn#hgLafgJwGCn6KKmTN*a56#GRk!x$@
z(gb6$p|IzITauuOtXHpE!dyaqSm~u&Js%miMvR(+8B-UF(JoWhS+MCT>W3sv8@XTH
z(8mAcB%)vMPLLm-taZl?Q4Gq2jW+pxiigDWd(;N++JC>q?q_QR)ux@T9GpC1wXxJY
zn1kQt07g*#GX-`SP@hoPn4t%O0crF=7$1^8-LJ0hK4=T!*ay1a;79QZ04$5ID1N@-
zC)jm}+0zSSra2FF@0YC9Rgs47;H!pWdVS=1B%pUGA^%*UXPWUX?q<0;UN+7GXvT5V
z?qR#0*niE~S{Qh)3)^P8qk1))V^ddl{k>YQ)T+exi~oM1P@(mo(tj`VqWmXdH+>Xl
z)r^@jB()wiBd>o53B-zNpL94}2wp;gX^y*X4jqxWsv-Z#rTT7l8(p4#fAql^?Q<~h
zI;LQMxIW%O3RvwJPOBU2WcUFTn31W#Sb+WwSATPC$t4_a@qp!Av&?h5dp%D6szE!
z-hXALJ%5WG1P!duQsf5so@s?*L?j7X8VA5Y&#naa-k2$X?hUC_86awKZWx7wu~8hz
zu73S!2_z1nNibk%f`N9LzNQEi8w{qRE|EqxY(89l`i0=wxxrupJI%gX*2ZEOF6ut}
z;M{INRkM-MLBJKLq;3oaJRzxP3pms)N+I)q
zlkAasAE(JdfY^&t1jM?5!C(S}n>&#nH1-;@X3vlmzw6-AJyxODL|v8GRydK_Wq(t+
z5Y^f-H+EnpA&TI7rK^T(;DO#x7<+$;_~;$07+jEQp-Q^O;=(54Af+m1E^2R?%J@Painggs
zf{3m)aB$>Eo;!xFOT{42KOd^_hsAtr2
zB@fr}Yt5cfqh%)LO)ZLpJ;xwGRY$R*$*Q)%^$nyi|ETxP-N|4U7o!*P($NinG(qvzN>Q$NpRMCU}>w;a+4fIvVGev25b4b=C$
z`)eUov&2s}YvDQ)y%^jUr)~E=ld*9^f-pMNR-=S{KYrlBB~6JR$9ooi8pW{M>jqNy
z(CH}_Hbk~)_b*M`wcsAHU4Pm=#76g|_k9L$lOJGnH>4jDjOl%-!1jyJgT{8>hdQ;q
zQ|X`S^=QXs!lxvr&-l8YEu?)C7pn@dPOXP@p3N!%Fg%ydwXC_6HP@*pzM&ftQ@A>;
z?-=bO0oXc%g8-5eu(p0bGTOHv2mz`81xs5f2MT3wWOH6
z3?0F0Ajr%D1pEYc5w^8+cd#%sclsTJnU?lzujd;RRmQu6+{{7f7bwD1h@bl94&sQ{V#6hU}k_n)WEK$4z@P`BmhvFJ2}~L
z(bK!Sy3(0BJ37(XI+)SfS^vXN#oWRX;A-n&1pt3K0Ih-lG{zZZ0&b_1Iq+WrelH3@
z#=;l~as>W%60`l6(gxg0uoGDB^lyJ+;6^z8j%ocbbATfd_#bJ^4ITgSl~GWT0oWK?
zfSiCJLy$4p(8s=4%z=zIs7}#|56vS1y`nH?dfgk
z`rj*N2y%Ax_^UVnS+=n)$kD>l$?;zifdEqrYv6D8j=$H;0`!keR!~k-OjLhag;oYU
zcpzF?TX1(kbWUzg|5*QyCnzEV9z}Kz0231vfB`(Dq97AtTN@iNYe&T2?Gv#8_sPlD
z!JYp9%(WHB))nOWf90kYAQRKyoi}l|qgMr4*gFFyMgGScEJFMvGXpvS7yv+f0MO0Y
zoc?#Zf2QTPnDMt5+y-w?J6nG{fT^LiBhcHz6bSx6^mH_I0Ro&HoPpk+e=GhIAu_T9
zOe~C@z=ICnEQtR^mjs#G0yzIA1~d6z)&GnDc7`?<*6#md`Ck_5z~5XcaYytEVN*W@{GSvTPWd1P|1sU6#Sb)p`Oss4GLk9;#cSHv8
z95Au60z4VPBW(h7`)7Yp0Q7VqTPLs!z|Psp8(?bdfcSec*;oPeg1<%oLTmtfp+ATn
zKrj3UaRBH={vb{Oz39IYI|G1T>iS*S`9<0^AVeeLSCn8vH_WO1R{%ry#
z`lmfC;1x1=w=)NV{;~keEdGLErj~y}aOr<2vVm)~{=Lio=)sM$`2!ij27h9+f|nTt
z-ktvzFoSb}oNbJLA9ZGbabN^D!}bqLa7^33ycik5mDzv&QG;{X8G^60|5!>E#{ZH2
z=R&f8%drDGSlIrxG>qW3+5h1L?vTB+E%?GR`fDv1!P39l$OtC>r)t*U2D*S#r{BtWZ{5eej=S}qw
zR(5i*wF0VJn1J7tf0@V{g7=l1HUs!dV+6~=U;q1??tdg8`*R!r*h(z0&W#8
zGq`)~%#6Rc6`S{exElZKb@R_{3O@Az7yo`*0Dyl$H=r@%@`9}~_ZQ3LhM-~}(cGyL
zSTat!<1$P>4XId|<zY5u*of|6{lRSs1*aW%X{sI4>Gc6UI>N9=aG7e>ASVcORO*dg
zcPEM#b#ji1#!;7NO4CK@Fu`2trWOlgIx|mxr9h_ADQ><|Dt?i6cxEmJq+?E)g|$`6
zl!44rg+4U>uxAOOazZ`%iekMIzQMgR!Fzu#VP8Fn9}NNg@FzN!L^d?V-F}uwR?Iq6
zJi()^sJfJuN}Y-NzAUN3J&NBtGlDF=x=PttgkSRlaK2RvV&e@svClASX9-8pk_1mI
z`c(}jQ+6u+nv=^6c&rr{Ybqu*#PRaSbKK3aGi>-=TLf>z21jmm)Qa?B6Ng3az2Sd1
z!yk*8ns*m;<1s|g^N1yUI*Ejx4nIIxS8L07)v~?}^kwiHDpaPp-(40pFfRqa`!%0r
zt<$-ZsQols(AXr*?m+fo=cM<|(hLTtn_9u)r!))`bX;3$ku%SAjVq
z#Cl8La;X6rp8nqzcWR*_m}uOMWeraH;irNPIe9@zl!q
z1HMD<{J`Lo4Y6mI!Mv@T3AB>oIaxf-h+^I9mTPr?ByuGKP9{2du97~XEunvyU9QPN
z{;ZkM5=Sx-_J@ho^SJq9mmNxZi0{-8>#HN)sk0p4po@8?xS|$R-K(wO-2D(+;Lm{1
zQdr~UdTKqiSM+8sB4!G{W(NrKm^C!xf~bvURJ6NjAq4Dpzu=T1@lpz?J+$0Z7eDFn
z>?)=R4lJ{2rBR6s1bz8_1%-dqTUhf36spxofrE#VWj8B&AEwfPhp=*;U6U_uQeYH9mnS*%cg+g>_T8&mG^IX88s8kx2XxSMzN#1{l^VRoiJJq1Q
z|2bHg+GHuX4>hklu*r>g+gwX|))tmwwv0O%#>v!A*0L0je;~Jb0{S`99Rmf_z2>7e
zJ^qynr^?pNf3RTqmNjl*^#QPihI%G+{>9j-9{DxUg0KT0k>l~~BakOjR|jv-6kT7|
zK|45(_=|6#rh)Vu!ySLP_|uyYsLBjZY;jY|E}uW>-Wy){Wuyw|V49l;Zre9RZR^NP
za%|~WkreDo9q(r(`XNAb?r^f}8Wg4w@{s@fVMV&Jl%+B;Zk{U^J8&d{mn*V%rXi+u
z^0b&w^lnKrDZNGX@kHoy>`IEPdj&BCrs(3)f1896UNnnru{wV=-_d50MBP$}m)Say
zq+~3_U&UkKVhY(&rYI%&E;rNC}$4yS%qla-KK!q#@<-K8eG{qNr
zaLUI_xw*wy%0jFgSH$cD7X@uQd7jcRqb*GSQRuh|XP@mUSVTZcQidh{_B#
zBrR>FA8V=2)O8F&n;0GEJaFilAQJaPo3srSLup6D`htHmefs_hx=V;NxkTXb`O3*P
z^^%R*?ALNYv{?+UlD(?BB(CfU;>YZLG1;$;`IkzYeNh>6iCm;|S_j-I_W*9H-BL1rCJvT5%a?wU(DM`NIrhwvhcPa-D+Z+m3~G1
z@H@~Vc^iL<$fnKv!R{n=bh-Ef#ZJhpiUA>5ue$H0F3s4VZc)n0;N^d(Z#z@qZD^5pkbDLiU8TOB;~s1R5FS;r
z;2}$u_e1h<1sN@51fSldG5W85?rpErJqug&B+HS!FAuIPaf3zuM{3t|{Ar+U?{Y2E
zl>FNu>G
z@!1c*hn?aau^ikOo6b!i70!Oe&o|CsN)i2*1SIN1&?k~WAC;XS8;zCTdSLQ
z%G-U)BlvX!oSC^{=Gtqd^2jCGwI%VpqOG7ee=2&?_Z!vSbPYQ9XuZlSd>!Ya&rcn3
zRL9~8Tbb&kB9G;5`6M%=$K6Vw&znM#d@!yT;MwpT>Vj_Vsak)|bgz9CjPsT7W2>AT
z4HMy#X2i!abhi*f(`8PC-0FXD=^bp{%PQb2Jxt-#3gp1;(Q>@1~w{*A=(opuV`
zPytj@AIUfMcW>2C++LV5C0ULd-_HipRs~*!zcr1RHb&k28b4DmpJ+AG;!EZNJDh|p
z^$6>`iOCx%ciUT#(An32)Aqq~pM-!%f|M)ghweG>Yy2i2(r&JJ0Q!I1*-th8zm%Ij
zcouHTaNFylPSvwdXlrEq{D(J4P
z7Wl5PY@jS>zVfcfN>BCUs?-n0HTm
zgECB!dO3iN2R#aLq�LHh^Rf8{Z#i%+H0sObpOb&yn!Hxh$cn+-fz8S-CP678+!G^4b{b@{eP*~=RHeJfgmFs_Qng^P2LF%zrzC$*v(Duj&XkUIw
z@(aOTGU)p~Pya3bb^X4#&ATbgw4;|NAI1!#gAU7W-#BCvHgHEKZm2n5mYt$Usv?A6
zJvB3VpPrgNFC=&doLWti718>>#QW#lk$Coom*Cr@2AX~I$}S<$_(}{}#@!7^QM^FB
zNEv@&&CP>TXXW}_A3wWpl(_`d@q@%MdQM)vTlsm9K(GG2UCR0;f;qtx$aaO#n+Y`W
zL065SOca$m$w$M4KEqjTjm-uL73B<%nXv8Ia~YP4Wj`DXj=&r)#&rv3$DvwOTeka1
zC>b$jx*oVqs=6bvgC4uW(sUnbA;fz-UzvYQ1Nv$)FLhOZ7z5MVQ4#@On}T6caOmvbXlvUw7M@EG3>mg1$Fnm>*c9|@}$58&DVVSyyW)rJaBdDnVg8-d5-%=XS
z-h*Q@J!I7W``274M%Klo@(fl9__2S2X&%v@@G$;{`&I-h+?%H8j)!C+wBVszXPEg!
z;^TmTJ+-fgk@_m=
zOdP1u&5(xJdopj|lzY#pP5zDdV`c4fij7T7KoLYWb3{rc(6{b@keLoDz?~@xl6h}7`vLZJ%
zglX#7kV~5K4aFvKBL@^1?}(gxi(wTj-%sHf_Ek>>_NR(udBpgODaKBmU2nlHmzS4*
zPS(#cpI|K$%!HEHmghwA&3c}VC6)dPp~jHN=9iz1t%@AQ+Y&@enT>yWhyAXBz7+dr
z1g1REarz(0uL|pPjXKY~#uK~=tzQmvX~-i7UR=8{zsIa7IdMtd#%=iwnS{68#g(^_
z1>B|Q1{)BUz_eL~a%c14z+vc>DhCs`aMC|j)fvFdt0D`HknuLgR>Hw+li1$ZjiSU0
zN<_z)D3sfUQaP6$1xtUVWc%HEyy1kZGseL*)y%Z(?(}C!!)Pq&xSfu_haRxo7Cx`~
ziKh}Q))nC^U-sS$s%D@3l7k1YG+H;teax*`qn(|@QOp)gR<<)HjZ&kWgzcUA`-H>l
znCjkqbFHS!*lO8;i_JuJAo5XTkDCZic+sx~{_|9Jd!l<irztRc`5we9qgQawU^x1z@!&BH@j*Yj)!3AyPmJ#YEnee<9sAiq;Q`Gt~3
z&2jb)T_197AXR_4Es&y+ecR_b$+X@tJXP8H@h-{$x2I@rLA2W5FDA-@%g|~qq%ltX
zwz|xNtP5)6ut}*`tfnKNI=Xb0T!l%#=ECZ-@WKvn(B3;sn_3MP-``ZZ#AvC3>-%Nw
zT(D&TwmfqDa8^37AVpM{pj?NnsQ1loc#?xMigryw=yHFT&i!#tO~7|oR-l!xUk<{O
z2q_g{OBRER07Ha<#GC}L<&vz#fKPSIf%5!F=tb|Vv4j;FGw5KQ^F_(Y_eBFr)6>Ta
zriL~if0`?Ucv^2uU|Tad@fswHPk_5Lp^
z=gnM!=bPOI0z76HOrE(s-
z=00#VoLGS^i-<_g3aqU!@_?bF!5~K&*u5NP
z(iEUR50Z@M5YijES|qaK1mrQNKK)h=|MkUu(L6~jH3@`|KzU~lVpHy&oftroA5kMx
zQ)XZDfRF}ljgK{sY8dJBaP@K8;c%DyPw_|n1p&uQLWKGLjgwMFU1n_@3BsLK7Abv&
zmBfEDe&kr|wDAr>!3WxU=k8WMmYqIKjBJkT%Zbe|j&FfTj>E^5^GsOnebG@0+)Gtx
z!Sg|@S(%ryV|0-bbsVr%Jzq%y4HtUE#5|o}@}7;cBLtkgAkB7zNTY6aqsNi@N0;pp
ze(dfV?S*~fnQoIKMc}f{=#nRRe?W!fS8^IqgbY6|7NZ=)8QiPg(W)-nd!?%2O#UmMpe=>DXWMS*(infP
zlbGx~N%rPY`Omlmiwhz%dgtx3xL=dekuQ|#Gc9tPws*T=OEflT@H+@40#8ZA3+!eaX;mXvEW({Q)_Y
za#Q&{Rt2??v)6Pd4IMKwM=F=4kCcD>Z@0^@=pcPE>$ek{RTI^UotnOMeDLCJX_89n
zS#DF|Ar($*dQie0N7ZC#<)y6qB)TG%po+rN%i_fO#-LjQ>PBV*2X_hbtW=@LJTZ|^
zl4pKLF|&_#kV|?5?d$M3DSvLDk<1)9nV~r|jiZcjC}G~?NU5ZIQN1+nm6WL5
zjGf4T7UmX1R`0Y$)LvV!(WGdGAh2914QjEXmZQ8HP&M6cgtiu}uPL|MlFzpAgQ9HN
z*`I?!#G@V@)zW8?)lL(uoR*i8UPo%y(Fug+bm2RZ
zODWIrr=p
zcy|{dlZuSld?$UX^n!vyI(PB*~1StV^lAw~3jDBF9%f
zn^6$~g+9Y@5qmNA+p
z$2Iv~lIDABrs)_z(fa72H5SPCBk%(6-x5_A&c
z#=rMj#@r0knA?7!)vUdGm*G`nABz6anC}DiW{%c>28tF6ZK(v4LRYzj8S*N9;x>yx
zrjOfK&82Gu>*(78WKlNMVZqP#5OjQ;$HPEu&5mJ}4s7Dj7j@L5JK~k&c^mc95nsI;
zlUK@s-T~&%-e-SK_PlvANTnYHAoSE6kXvuwZBP<=arwW`reInw@5dHE;CpPmStI^_
ziA+VBQ7XoX*({QbWLnVYc#5+Qaf&d0aOP}ELIqNs9Kxil9Z66lbt(ipR(^Shq5ZZJ
zVyYU^)XX`8V7PEcd7HT~eF!}b3E5ga|N3D>8fx-GZhn7cBX}F=8htVBJ_^m%=V)%kx~itW-c0>-I
z1oMyuFv2YK4&cU#edsn=pU0w2S<~GtLW<9>C1e@do)ypj!5Z{4@p*Q7)n2^@*HbuH;tp{2KS!*J+u6)T{aHl~j1r
zVH#KUmSvOMinPT6w#s^j)l^H)Rp5V~`8rqFIxGSb)!cf4p`_qm&b4FV6G8^B;#pwF
zTb(*v<9TcnpYElP&QM>;cO)+`K7^j{Q%61bCM^0aB)FgufjS7%-Xb`quA*5onZG6l
zRpj!tc1y*4{D@FlQQSV^X1{WEoX+^Gi*S4%cfko+dV^H7|Lo3tFm6@#XbXQfxmOV_
z1~B7cD0}I}c=|h#!Zh
z%hU}gZzXbJOTbeJ>)L-~iCc87mi=BQ#r9UXqy2%A&Fk4oG(WJ^aTnpG9`_6?QNL{P7fhUv$Xq{SWx9_ooY
zb+Ueoji%1v-_&{N#%%67`uwSR#pSxJEYsI{2(+gT=Tp-2b$pAu&SdK7VIXx&`I0Zv
z(!zu{eojjbPmHTK37__(4u-)FqGBrRoe6}X`s9#_Z&3;dj3AmVud^+(1q-1pB6sU*
zJ-sF-6H9tu3h>^-V=W-oAzT-!qUW{!n(02b=Ot{bj0IcAJd3+D94-GXJNz)oJz;9E
zE#He7kobRxj=BRGO?l#wYyAA3uVXL7>?y(x+Nm*8Ro=!)B&MV;iNTi%6n?cTfZgY3
z$i`SXy94Enyn71ZHTD>AVeCQ`@g${dwi$d3@1N
zV|oBnc)SyDSBZ$m{s~cy>e~9iz0l!tK4JnwdXk6?^OKF<%X_+l?PrH0q?rH5KT!jt
z=1PCLmXZaW((cFA7~R`Tvsfa;IuD-n{vY=fVy;%v6d~Y({6Q=spTfO1xPi{hqgh6*
z&@5y<*i`#M_?#v1JK+nV*^>=sIg{1TN>D0|#f5SO2}?-L9PVc-)O7{N&N(>0TirWo
z73dLUhuzU0Eavtd%ZPuesmE(SzVf(ybd+qc<gpJWVSY|K7JCxxTrvf>BpunTZT^)bV
zQVdC&ErG!|?&F~BH;%n-{Jj%iJk&q`4El2Phlv`ZLR9d?MFgK%(&do7@@=WFv`%$e
zz|b46AO1D!N<3{jzQ;IqSc!EBzb=doBcU_&_9m~1SUzAGVth;9~-0q%T2sfjYXaw
zT8BO6RFIGbPu(|Bz&HC*%=NiMObWYo8JKrhsA!9wvI@NZy6zOF97G~!j7BKi&V40=
z@o1mUTQf+C`5D_5$iI!s9baMLGN92kBK+i?=`GOrVAdxz0hgAK#AR%%f0vOku;zbEV(nd`f@so}>QGZJar
zJd(&|%$5?ma-VxEWKC2Wh)Wk-*+&EOs^P?Nt6jW_5oFw+a65R;xJ8u*xq}#!1b^7q
zZ=G|7G!~-TX>y!4sBB;CmpFf_*x`Etw>!{PVkq5QypDJgMnlQ^rhtsJ7nSEM<<}I#
zypxN8a|;YvY8fz4aV6ocnCi$ZU*Kh7+vE07n@wucdne3-cKoMLM>~iL`<+{yK!Buk
zU}}X~gC~1s(3&*4-&=n&TBs2AlO>q;w=TF*(+AiRp%owUPa*mI=C*(0ma5~nbxGb7
z$9UiGJW>Ev)-b4PrU8P*4zy)1Uz#@(fJ{SvlvGBX1{sNIT$EwCH~Z72zG9}(g${`q
zFZVEb0qULo=JD7x(84NE`f4W;Vs1L`{Bz*1@2{kI3sMTwieQ>6KeV7o6dV@qrInW=
z-40BV%+0>YFeMKY+sS{-o!&aoLSFpdr<=R{DE{sI<0qItS)&zWT+$#5!1
zbg|0`NDy7bAbU723X`y#tNN^Vfv+
zXf#NTc>WM|eAO`7d{wF)(G45tgplvIr_(@JHPacoAB;@Bw_8so53rWntGQV_Mc;o}#EU9MdE!1u-w
zl#E`sFI=>>?}vXWRRqyj?JO4F2m*ySNm*Oxx);wp+e^L>a->_WQL#C75_(n3qW5W$zvv+H76^;vstk8gNwB9s-v
z+`Bhim^F|yXlSdlc22+E3A~BRlz`EK)lMiUxRzk{aSBZ=l*{1VNBV(a+MMGb&Z<2?
z0V=>L7SnF!QY#snmNRPNyA3D(@FZ!}!&&977!_(;oqSS?&eDM_wP0OYSsTw(Lr){z
zTmFAFQ7&mGO-Wc%gxFN3j=Z9InaoT*o63tYZ7LfBy++KdL|JTcJvIiv3RQa8AE5mW
zM?TVcFPg-GyE>h4QGS{hmAa!!9#9k3iv9{wHP8#j}^uxQNQnx?s`>MIvg
z@)d>x9IBsnquoEhpP5J5m9cnWQpPaehZA!oo!->z#VCc*D%p*^@Ka2VMmKBP
zr6e*z5`1{cKAFtwou|JBc`mz{jzQu2
zs8oizGnO+Bz2p%Ah$r@IQ>7b++3w|b$-2b?q?Fjv6>n|Cc9Xr6+%i}WtqXshZqa3~
zes0x*mCDys@-bD_7IyR_9b}&>;o2yf|i
z8|iG$e5ONhBdXI!B4syU<^m-mKdSKy1ba`D54l2PH(^w{w6%;%)G6b`F?6e%B55rY
zV%p=rs66So@u=n-y2lR~oieXOt#8wuSc0~4g%^VS*B8GdeycOqJ%4``5K|XM#yeIH
z!M~^#^;|;T#|p2;cIjT_vSMm{m)=+7ofDNjR#X&tXPl)#EOm{1cf-nU3ajnm^58lAtdo=|?X_5!21C4D*k$m9
zWSD{lF@J6-teZL`}keU)>>oD?$
zN>vW(dBMTCo2F*IbeVyx&)qjWD9Xl}>-&JGNQm9InIR2PH$6A|^v`Vy4Vad+S2iPXi@qOZz80)dEvFziu}!
z`#ZYKu%r6Mj!a*nopEGcBhzkF^sf98Bda7kueQj%pyGzI5fezHL8M}F?Rj!&R(?1{
zmKBQTo%oyfehn*vr`ZMOuehFyLWFw2oWfsdjiK}3S@?f2yTW1YCAKsA_s*{EKYZFA
z(+T8R8NSV3P*6{&A6OXVTN0|}icbnHD}|!nV9TDR?dH29Y6se?D@|^QLY2{KWJ9lL
zY`|K1A_pgqjpDTnah~RHYSd3ln{1HEamCv5JxwAu_z0QVT4Wn?rw|O)koX7l9+In8He&E$L);nZ1Le
z%m6|_y}!lvSOUFtsyy|qS8_>({EN~3!59j0Xb`;3S0%zUaHc!1XfqAKq@mt;qJHQAV?jH#{{zqKnG0m{SdJi=l
zbBffGyfQz3?5UTg4(aq^rymU1m!wB~3kj(@	l)sUa^sTU*|vw8~omiZFFWxlV=X
zUQtxMdUoa2Kp}oJk|+_9C>cF0icofJ8xMzW(6D7kr8zTihu$Srs@_~oUL$^r#vQ}Z
zSyOy@YCr3+2a*hUP9yHiwvDLZ4(?~n_xaeluSD{H%V{M-Mhawcid4OqcKU
zNravBL+E|(bX#$k{zhAwinOHRne+bL$mXzrMEY$f(@d5mN9^SC3cW5-_C#am@T051
zVgoOotB0;!Ak4#O-G)_yT5&48M`gO;rZ>=e$7+MSGS!+t^F(CV5o(j112AFa1%$mT
z-|t$6cqvym&V)9NS2&&W4@P{w)L^I|=0TUA_9^{13TMs6X(QwOX3+j8qf#oAIBMm8
z#Y=S>pe&USH+wF_asY!tP3ds)n3d1_v$n-l|H4}ww?fePGs{;{a7CJOR})0~Hdmz9Z(I`3~$+w=n`Tds!7^
zQb_nJ#7pbTxuW0CLLO2!@$qV-R5}27T3zsGd8}DK*L7y@l)E~UJy;r~UdLSDi
zV|AV>h>tNeCl-Si3=5rfA-Wg5u-8p@_h`98I2SYCVDJ+ZbQULC0B})#kYX@@o>(-|
z9*TkzspfRmzkB)Vy`sUT+B*bN+J&i(x^4F#FUq{+P0xMd5)SK>yn)Snn
zUkz3=KVaU#Yr5SZofdOn>~+Ov&;42rS5sc=pv6)+8so)(sP9;mTi0Q2rH|s5|JdBP
zowK)&`eKeg3Tl=P#8hV!8n^O)Dq1z`{Q5?-Z4;jZGka${dgGOz$l=iJ@%qs~%V?NN
zPB7hU30Z}!nLC;>^jY38*zZI5dC3Z3QZKvnDenO&1&Dm_<
z_*~W}SDd;#8vL%6>09|T%35W7WgxPPEy(AfQ(Oe#ByTz^0_9rPDyD+D@GM$Ot43)Y
zqFhN#1e!9C$oS4Ij+&f*{_RNhD}kl`@Zpn~o8Zaq4Hq^)Nj}p3P7tQ<=bss~nb0#2
zUz(rthK?$CHWuvUa!(9vWVllZDJstmu+f(gpVtqhzwM|tiV1#0Yms{vcy8^i4VJT+
zRJiqB_@;}yw7l*Addv~*yDz~0(6`zg(&LvK(x&^(M=2Tck%I$&I?;uM^V-oTMf~iR
z_|pVNPE_mngwS`*OW3%oU1IWIRD5|%okxUxxvb#%;;?(Jg3uU7EPsg6YciAHb9WUb
z%J-l2L~cx|QhaFluG|P4`64?jMb~}PKj`p6YT{5Ro~QXe3t(kuj8;b?17(Lt1U_cM0+|>Rye>&u(qM{z#V!Q@OL7t)|26d~R~)XE
z2Q+^qdNTrbZ3ZY%SidF-&CpNy%rKF)Zcld)FC>o9w6oHta}=6(1wm^e@lY0?dVg$t
z&!T9UBuGmmY_I!@M0v*%g*xTg8-fl8D=2WTz5
zq5RV0J+}$0l73pryQ^f1Hhw8Ic_;zbos6r{?D$y&j!fQTy&0Yw5ngjHG?62UJ4QQ^
z+(0hLq+^dFD2H`Z;#Bq$6I2Lfkw|zZE`NB3|JL*C4B88hmW_hpc8Wc$;EH$SWukl*K^dt!9rOMD{;RwDq(EGxjP
zHm%BNv(jiVSNN%x@8^@8gy?3=>)Hz|-xi`S_iG%?6DG*+1YHVJJ2;InTh#
zVykyw221Bo^e6pFkN+0663w)|&lTUtZpj@?%obHu2O~@#GO^Jh$t!4-r};|o_&uxq
zBD)|E@6CNEUc0q{fA03jbrA8Dz6l;<+Sp~1wM(fYf$(9#qUmmjl|Ukr!I&8LwdJpW
z0fC8agtfx~dr4YitD8L`xctYuYCyWJ0sIG8lk_oEn5kt5fEVmnKl~NR$KA=G)?zn3
zBxD!CtQE$A0XD2xfrwO=WTYa*&0-Zk@_2P&$8TbbzplBYJmPZMH0>7sx4))uo_^_|
z2~>53EaO0oI?>qt9>^#p#Fd2vMbcD%y{i_Ia#~NHFj1m5O|TK*Hq>zKF*&v5DyuwZ
zT<`0Zwq|(rCOv_vGMZYU826o*syhC7oHPLyH`2^NdD1UC7El!Eda84@Kl<
z6A7O!JskmxTCbOE`ubKx8R6NQ6@FGkUPCQflW9$`M4AoDvkk%_ymD^)!BBJ+DhZGA6DGsem4_ou7LRLNrUr?vCj(qV>
zPyL|`36>b?_W6SZ-Q**i*e3`d=tC{;eoZVkambY~uFwfva2XJp-8j@f(~|(k*P2bz
zd?OwNmBEA+5*-|46=x7N1&XKFRf?i=P7kK#d%1lIy6&sA#w{JTaio2J{EV3`V+RT9
zWi&^S-bqBds3Kg>%&MZcDhx$5`9_p1Eg#}zj8)@D=WnrPd)Be1SbtHQa6D^V5^
zk=yZ+91c2X_@d)n>SHN;6zNNG@zKkA-$Xt&zqoPEt?VG$Yq}xg=8Ip~RCw#5p?Jk1
zb1FV-pHw&L?>bIm*$$0=6R6Ea&C-9#9(_O5le^d%hsi+jv5Rc)7m;ffd(~4Gv8p!m
z7&=i_gFzz)Hqsy}8s08=wwxP`bc(l0IGmq?sx5alnBzEPZZZAjGshl3s
zJM%Z#KY35YPaia;qD
zrF7d36G^46s1_9leFwxZbE5H5i-jH<@attL0YJvpO{`N0DTxpq%Zplz{}>@2(J2qnqg;U|=T!L$7o
z3axGwa6l@A{Z21AWkT`kL95~n6w}-T5i3uY(|Z(fsOAYB)3Z?Ni=_QPQ`)H)l@T#X
zf0|e)_MTa1Db|LM-xU^~L4xOY<~ZKZRQhJ*O+J}_O?98juT9md2Yu8Et37o-+(jgL^mndIMr527T9WoRM=n--43O8GWIBgj_J_59PjKoCAF|;Vs2-6455AF9;YPVYyXo`6
zkBL&$F2nP`%MZi=8adA4OnuN?16gIwfl8bGPMB43-&Cd&^hP|HttM9^LFanr{gi)8
zf?d0h1ddkKXao4MUMuF%O=`7hV4k+eH1s1yy+M#2!2X7q@*&qoP>~JcTOA4sc1>M>
zJNXk_u@Q-xF3A9ugC#`UTsOEM?Hs3v+2<7cq^4)wmPdTcpAUtFU$iL2yE*<%Y|S2(
zW)95caCXByh~H8-xVEv_F1fdc0{pYwh`6aeU2w>N_bLFVt{+i22w!VHy&kV
zWJoeLlc%I)(qxrH|LsvImk3@$F~&O}K?@uW&3~X$`)ptwmp_wL>AJ{y88-u!Me(>l`=R!hD7bWDGcM
z(U32=g>i%GM~m7#FL1P;Mndv`0>k4k2*{x{#zTX!H$#VEU6{(*?t-KrdiQ96zz}0Y
zBu!eVFVc&BGO?}Ee*|R89L*7QSHq}WC&;8?I)AQqz?$|r$bL|Ozo<}PS$-l-%2WD`
z7iPN!{egUvNw8cV{)Vq6-G!k3F=aG1!a_Q$6NU8gM6;CGFGY6>+AsotIKS@oZuk@H
z*2uVxwj~`~P?9OT+vG=?S}}}vQLt(pdOQSsbJ$FU2NrrtL;;IPf|6+Sc+$-+R>Iev
z|0_jkm@Z1_6WBu)eFK^lO7CjcPT1c%E?5GUN3IUR;rmzWPmas0exR>YqZLz?s<&s$
zyC*-hYf1xUM?!ATA|ADW%9@z}1GQHm^)SR=eE$<&?FsIar_Q=FvNU4kcbdnWTb#-f#@
zCXQ{6+dZJO_Ng)hgKZ<
zXuTqZR3{lU%?;N;bE9t2Jn$*oGM!e6t2R%B;9Kk2q-da)uO_IWDFwc)jyWYY)xl2=
z-h}>lwoZqonn$~T0u1R4BFRcWr8ohc4fnwcLdzf-=1yFhqWHHGC&~2g17xByLbje|
zEk>!Z_#GBx4I%1v!65438Ge51^c<#267YAlV)t+j_-*CA&vXR??#${mJSed~J$oN}sv5_xq5x1FKo&=4gB?Eq7l
zD*lnK&rRHh&g%gP!4GNV)fe`gw>EGN8B=Lw=|jjO=R77TF>r1iPg_!n;PMyL%P1B&
zch7ZC@cF&Cjc(6%)Q=mz?WtPIE_#G^R}{9EDXu^<10iWe$?uFY2XCem_F9MG=f-G!
z%L}=&Ftv7n9KPwJLqMzTg6HS(8BF_I5mGu*}#t&$DI-z4$Sl=NpA(tsa9;9bOE~`YRv}
zm0W0U_&~hSq3k;21-=xegha>5a+lu3`GVut@+lN`o=Rd
z_C#7k8?`nX$h*W0(d;QQGA37?;f=cRP+BK^ngDCZvOtZS3{rz7#(WKLM=Ya;s{dcF
zRy_$6Vd9i$k=u6zIo(Q1enZ_yh`>aw{G5n?Hf|v+QU5g5OrGi#v!``P9
zk47H7{F!?lqo2#h^4&#wqu=cdF7&{EOyuo?$U!0XW>`hZgIKBa!bk3TyD0!=buj@m
zSN8V?LNxVt?%TXZ%$~RxIm3~hRimST#}Mk4`J4#k=2)>jxOxST3+uC%$!dDm1T-Co
zXjEkSxl8CO#F8$eq<+|I1Fw~{r+qXoBiabH`V~}p%!dr0ZHusS^Sj0FbN;@6#P1<$
zLfQ?rSk;Q)F0s80Egb#ov?{c@Pkyt{ulYvHaV>J;%LJ*_H^L9O?Ch}~hA}>WR2&^s
z(A}xZRe7W-Ojpitp<6bR$+XQ%ZEGTF@hy|0Mz&;%*F*=SHo&c>v9hKuFl_y*%N2n2
z^Q-x7jH&cFU
zvN9(I=!iI40KbOPC#f#4%AyVuQW?ZvaADr}HMYp9D(99;`bg;{$#k^>YnR0qS;qUP
zKkRUxPp7DhO{k-HrlbdcI_xw5Y`ILT&uk=CT_<7gwt3
zB@7u{U)nwwcQ|q=Q0oRxCHB{!xSY&DZL4mOSNpt9b3&4LVQJhT-wywB7
zSqjeb6i4{*24;EAA5h4pSNy%8+O_jXX?qJ=T*~QK`l!*;!BY!=+}5uMCo=l*jFsq-
zuo&P|6y6yDBLmNB<8NWrX^L{w=g=oI?kv;*LV%IEZJz5nBc?9)NV%6oGf#ZuLD(v0
zkiz@M5T(6>K{4F_(Evb`nr6F$HZAW}ttr_AML=?5n4=Da7}nbA_1s4M&zK@pXGX1@
zf=xbx$K${omMHbo
zq8bq1yW!AJ#$~?q4j@63i8}
z)n34d&$@*hLORT-U0uh)A)Z(xk$;R+dkcA6SqEaeKe7@lf_BCtz6DfW;xdw&s^eA8
zMjew>SY%><(;7hL1N_X2WV}2OE${qN$0+G`1v_t|REddFOJP+L8fi5I^
zm+3T8Jd%=v;myYuOEAbRt+FK7-Ff|_qZJ?tWU*-0#GE&EnPqp^fnVT@QY)~0tjOyl
z>1Qj5y4t}i%D=2bFe!Eu!<l@qp9x
z{3R3vNeL4%yvPsEM5V_0$0G(}K<)zE74b)L1dpjXi;ca&%?6)jP-rEUwB@48FwtZNXJ{(q2u;E=jJs94KSba{dKEiW8
z(q!q^23N7piKr!|(m_6CPY$fsJ5xxGwS^6+pxbxkmDe4z4@sC1v^txA#3?JjANa&H
z|Hf3WNopAb%=bLnzr?Kv5*F}{ktL#4asG!h5}Tx_=W+SE{ZTYDyBacIhHyV4)2Wkx
zVDmvNVoZM*FD?FUl5%%@vDaRhI-X&bco`I@tO9Dcj(h^Sg{TWm)v^-`5*Wh->V~`gMhpo5r
z?~>JRJ_S!kBiI9`W~g??IXnBPaY37Zi;I(T#LaybL^6j)Y@hI3q77>m4Y4z}=rd`E
zr#2S#L^G{Y?EoCfOTB8>YQsO#*gp}WefetxV&WH6nE=U5@qKTKnd2NFWDjPeVi7}Sspyelkal6Ght);IoiUH
z!FDcL@@pX8YqDf=LY1dZ$bnC|E*u;v*3|Zi>pYM3%b!*&Oq;;OaPG$Lv5CzPZQjneex(_>Cbv`|h8gcP|n38G1?8ed2
zC7sgL*3QiPYT!ZvaIAmC`cL`OGOW0^Mii)qp8dxs3q=HEEvtxPCrICnylez6yJ
z6#T3r)qUe_mKEYiDmDOTYUHGV83NBqzS-MX3U{?*vs{4-@Oj$g
ziE8J7?6qI*z9-d?KcEGFZq#g_K+80!&#Gu%dTksQ<(9T<&Q1)%03AHneHGX{h<+lq
zc#tbr8RFZ?V7o2|=A`jG-Zh{I(Vx$Dp6(u5n76?r-K>4Xu`w&AoE|}-;x5?^V_QLc
zm%_GJ;>p$P#FJ471s71P%s_#Z&-tM>IrBPPvH*b2{wbGL_{Lg)%cfQ#h${T+OT{3-q>%&!OjM>@Hup>g_s4u`>Q>F3pcK>yyb7h`Q2pcie{0C
z)nhwreB(nk7e7vJte9dj!eST1k?95%^IW^{*HY^l>B(qxaR@R^jz^d!AhC{FJ-e2i
zGR`a(M1_Tc^Chx^As?TW*hE`H8389SvGcd1JQ>9HOAM{t??f2U!DLi)Lhe=vXH|OOXx{%bY+GtdYaCIW)x-(bi5BmIx4NIASzI3Imdv_5n>TcME?e5oqT;qQy
zDzvwIZi9a(|Kt;?-_vlpqqf_i6&~+BA3`FrEs)<&M!V-gY!L~QQqh+sa}dA;DVg3N
z(rrID@agx<`Tw8WB(vCGeF7YS7klfxcEi9G_~VB`z|=$<&hVZ~Q1h}$hl(6sCf>GZ
z;IB1*Y^D1E_aX}oa%rd%el!P^&{9=|RYF=ncrMaLS>EXn#>dhQtU=G$PvBp9xet*N
z5V$(5A~#r_5$_wu_Xj34ci2#*LCZ2m(Q>Ww1SohOJqzJqMt3!>3h=5o>`KkIq00jJ
zWmauxyecKPh6i(AgM)|GW%fM@S(yrbK|s)dnDNH5T<#ss*)535qkFI}q71C59=SEj
znIXw%27VOqu&+7_a}OGoSpmca>M+m}z~ZNuXC8H3BDBvZwA^dAGE17KY5mF2O=ADD=vYnvMfZ1{}LiMvvo@OaNKbjy(l=LyxbO_b;oR+;e
z7W|IHp_mYEaVRT_(bNNX@GbL!Pvew-oqnd%ZSlI(!ABL76+SE_F9vS2Q7X$V9j=fh
z+eDPF4a8iorHu}Jhkt@Kn)a?dR+pHtE?)iM239)!^@YrsNm3P;dUca+WO=RACy1%}
zP0CaIK%*}2Hr@!FZr4tz=kAJc5i3Wg-v564(_?=F4t7BP9@P=Bj`FQobQAu6FYT2u
z8&8z@CP@kGeS5`|(Img&or0Z+6re>CNHUWvj+YEa*FQ8g6##A}7yK
z@VcE;X0JiZm5IF5T%r~z9jWC`oG1i+*R5vs(nFtMM=k(Z?EZ_sbvipoPyBpyaY`^0
zHnm`?Rt66SF<3S3w@r2!L*j9NhjYY3FwA3(QdU)nl)hq4yHt$6@AyU+{d0NDzg0Or
z_}+ZB>AZ-&%S=1uH+&evZYCFClO@~!$`13$WE5+Y2a#9yWhfgK*~ycJ)OEtHL;QI{
ze=-7Vo_DQu@I&6;`fCiva&$WUhJ`VE*ttyw$tYe6al)uJNHnt~!^JLtotRH`GXs`$
zb7IGQtap$v7N@AQ$*8fpP-tXXH#RKhHdwCEEK)IHzK}*UimLpi>3q5=@|^s`VEsr*
z9`y;Y`}>1cW4{y3OPDP-cG4rHsN>$MoDBR7o$l7KHU&o0vnWRqWnUMf(A&bMi>C&q
z>7s*^!@@KZ({=2{@nSuHw8O}~k4Ct6qsMDskI4R@FC@iQY3duotRIzmLIcb&;U53P
zAM*K%qGAl??pycS&%%fZCw62XVWs~zNs^Ug(vGM`rd27afM|IvqUT737x3Qn3tP`Z
zZm-nG75p^fv~^vv`{X`1W2rz{L&vUj(oQFr!F|vV+*@pes|5#tTE(rH0{{h}k>l@N
zhrc-#T?AT0z6^`~_m5ZL9lhz5YR2FDF?(n07ih{HO*4|*u){k2c1>MD&S4_mQ{6H;
z?kB)}I3CVnFSoed?at-K2Wf!s?%Eia8lOz7Ti(%xMN(YJj-{8ZDcdGHQS5#1Gv?B>
zBD3CzJmoBfV~9n64GduiwQq!dMT{MWe1kcqmSucz#_4f@c_O&%dL5W{V#c)jB8lh*
z6GsErPIitl?fyuO=0m
z)>N+tb{J!kZ{G{tsMVV6j9fR)a3@iK>BfyBEszAolU9Ik|B32kakhK~mXP?=g^AVS
z;a=dO2Uy#zGG?9fnFpe+bdvFILqbAt)MOvE{&B;f^y|&lS%!N0tv=8?y)I5qWX(D7!qY~f4wr)0xE<@1KzZ-!?%
zz2U%r^^3dk*1{ksn1?O%o2Av6Um`+Ids@_&Rd`~p47e$#wpnAq&2!E+w^F|D2A0OqnLgy4HDniW-%Pp@^IGG2SCi!cAR%
zI+2j|m^*=4MxJn$cHLEAv-$YPomN@IXp%mZIuma$n&A~LE)qD7__VXSg4EWLzxm8MCcPi!EvI*>q3ry^ibJw
zOLPQDSt|nKG`EDNkDwW^Y&z3#D8R-4^>>BDNe0oYWr+rcg5>V&@8|Xs!U~-kyZu|*
zY3D#a3X7xfZok%$D-nyNax_Gn$p4)VLf`u{)-bokEzs|2rd1j7lZOSR6uOfw$frg>
zI4L6h?VF~xVkT3Qveq4<^l#38^ZE?O<-vWY2JB(c_Sr>|eJP3iJs2|j#35x)8f3>-H(Ww%!m^#GphGD7SV=E8RcDJv*L!&R0Yw*c<&3&|g?sH)}4!3U_
z4K+xZy$66AATbzRWG6~k?vQLtBT1l3C_EJh3HCrq_6xhS6@PrIy4;`%pd+PG56kRs
z=FcF5NF-fU4%+tuX8BwTfRxKhFhH7}?31Li<@L2A6o7453%4vh$OrN8<o2}~qg@P;X}b@tXoPJgPS8|n9`|*6
z^aid=MF#Lu(2obV5+0{X=^Uy(=1G+$PZYgq7oc`W~W-);?@sYb7JGv
z;^~)-us?@}6Y)yut7Tzy=n0d**2rP=hh1J{i^TAOsS-RLctAIlx=KoG@_Aa(Fa?BO
zZ-1Sp-l^1F_x8(<@RY5~Guf+2rmcd2ybSy>3mjKBI+NvSpSaw3i1>(6hL{7|qe2Ti
z>tXFt0A-LeVJL%tn}`yj7m$0RwjTM`fg*U}JuCkdy`-!YmKni
ze|bjh_pEB7DCiW0(MJ!2F@gO+MVon3Jus-WQT=2!jWv3z4gaBU)~M2B4aW0(;E#$le<8i`jhL
z@#Y7tbqYePpKeGkHUS=X3m!w)O;(##HQsJCp3>@lPwNb5?(2qEVH5#YjX
zEvgV3W#M@^QriG3;kg@iC
zL&4NdvtcfO9_Uz^QaRbCjltEzFlbwuL;rg!`!jt
zp}m8uDHFDDFa#dopI>_CwJosMy>)o$X->KO$T`!6d!AC4q!2*s>g0S-dYMuk>Ww@71~VMq1{75aatC{|Z=kUdP*ZNGp4Tfk(Hf
zVBqN#5}1MO$hFz|G>si<<`?mbWF5sxpV24`%1Rg8PAm^@>E4*1+$P1Sxy>W-W
zkL#VV+!vUBu|t0R$lG_>Q?8uPNzvvhm3LA~NY3X~kLrHHxB`|64_UiUA;fc}TH_FjTBAI8*h
zPg=%8nfz&{H2xxXT3oc+f~>@H%Xl0dzj-Zy%Z(?_HW<`%O-AQ}>F#=Fm-nzq9YjI?
zDxp<;oJtD8@q=3iW#dXsTl#pEnr`wm>4|(%H+`Z8lRudQXLuV1
z&EULNgoC~Cgxn7G2rGNkI>--eEW^6hTj$X}#>#LR&z+YS00h+gV^bH<3=A0@o&2eP
zlVvA;?l_G?7zL-3e5`$cZiunMrEW;aPq>)
z$p!MEe6sBQ85TYlnnAAj5nemWj6(2#9IqY{VJ9tA?+^8C7vJhh7*mC@gxdJT_B6PF
z7ox7MXxpA8Wy4tVng$o{iG<0XtO#a^z;+&L@z=JVh%rFMrVOsz4@48)+{Hg09Bm~c
zRLy|RDtP4WtplnLl&vG$r2$IXRIRewV^^RHsx1R%;;8YkRZap2#)^WuGH;N7uYL8T
zWk2&Yo_tJEtJ#6N$sXHDy=e%iBEo~Pjd0T+5}Z)Pq>cy?!&sdyRl4XvyvgLpR@?ODbtN1;s_V)DxEEyX
zWFAI2E9PeokGC~DZSV`WW7FIcD=T4Zf6P+?pv0zlXy;H10iCMocQU7_+Vs>k1ivRkg1^;FwEljkpZ)y5{Cb(YaZmw(->AX79E
zxk-kd%%@hxn}$ndnhCjo7RBmNJ6uVeWy3T@pg3pPn9_efj{Z}W#rU~xCZuFit-}TQ
z!qMj{N??-?uV3&CpDVA}sukyi^Q$8X8n=*ew_DJJ?6L5>u5Uct~(*g|I(oyj8SQd&Rd-LU>UX^@4NPndw6F#4&b>G9FiXv
z4GE3ocI$+)zsd_}jmg))89r|aYJ1}Trc`Jte$X8KiJ#GQJAcrEG{QDjlCFNd#_te*gT-W85)BJuiEL;re+JnPl-GQ)ny{i?g@0~_K3lc2)?sht_jra{6C5Q;NK6Ct)fOm
zvk(92DX2H;&>R9Y1&R51UeW2aiu)TyDBQ#{EYq1j>kz(wXf;0Lh6#*cEGl04W#LBZ
z7wUyc>^A7dp<`HIfj_xlXZp-BW8p5mg?*A#eeQRMe!EutWtiBcO9z+_16zWP1Q
z0Sq-aBZ<#RY5dveuh(Z$U+^sWzo+uk$1cUJWFg#S{3_l)6YeO3_q
zY3F6h#9B1DI%{2&$FM_$K`-{utfFn2DWGm;!suVm6NE|M}evifJG>!>Tz(5;4v
zeuH1@keC8pdMnL>;CQI4)kbUeY|d`FyjoJiasd^wIT_8bd&qkb5zjTN1gGP3-~hb}
ze3u!2Mo>(enfTW_gGrH+3iV*tiO=xiB(DQB_jOVx;vMp3c2ZPg0xRMeNi=ts3*NTZ
z+{+4RDl512YlPt)wzaS-U@-#4%qMY)TDn}LncOvPKDdn93@SHnA0pILJUML*pCZkhpBm~av%8d`zIwkJ?zSsU1n3lls=4p^&FQ&7E|3WMZjSw5^o`kZAX6^+hF
z+)RisIzGm=nS12m9ObLdM=W~w&*N%~3A}iV(K%w1J+3}uo$<+|yj3H$;=;#Ta@W{)
z7eMSCChrInCV1ogk@8ANM4L7*3Ca|ICb>v$D-ARgV*?NaAmFb%z1an)cszBfq_iQK
z?dC7%liJrhPCmKT`M<$bpE(AxKt`u-HtBz)eemk>%@=fjxcwZFuz*h?s9L!Ea~s0C
zCW)Y=p1im7hCr`c(Z5KWmk5BK)uFPOQ60K#WcK3&Xi*|?F#uH#6hVle(u7=pe*`+E
zDCg^2Whg|xqqIoqL-fgRI-n9H0OFo>oXzVhNGdBEAgdl*XzLbcCOAO?fcxzDCkKdVmEK_U{LT|(73_|kKK*bjvv{2SiMiB3J;&^c}
zPa-8QKG7{r|66w}uUz1r69+xtLBH6YfClLbIiX>R7^8{j7-%H_P@%kkRIBkZ*0>4~
zY}3uW*j37E*3d8o)~`mC0S0iIl^(p8RnUORp`Xo`EJ#V_-`&fi?F@}GydHg$;HPzEEG!sR5z%cqq1J^a*Wom4QK&Y$q7
z6DrtDb%EnJjSTJin^YZttO#z{FspoKT5qp1AvDo1n}u;_wZkukaqcCuZQ9}yG4l}i
zCR>)?93^o?12RzuX&7(>@X7w}R_NpI)a>$i2+ek^bsAe@_=GJ;;6B#m{Y{6_5V8e2
zO7?m+`6qf`xM^YCFGLGNE&SQsl-4z=Cd9V)6{&t3j2cK0YBg?u-(bU77n;PRAMboE
zfB+2s^>`u`y-GJGzc)4s&&}H&%(ZJdZDjTe9?N4$(9jAMJhwUGJ-dsKcB$|K&q4f@
zN2c;Lf2`Q~B=S&fe85gQ;Nz&-<~;aE2t)okZ5`$asL~tgB^>)i)kJN-^tki;M(Q=>
zLsR@M50Kywx574masJAw9>@K8NN1+uU7cCL9eK0OSd}l`5atu@RjUrVz=aAd$9#15
z1c@bT2H041g9ug64HIb%iu2n+q>;)Eusrb-KKCdUkwg`!hmXAtHlFGCU_2KdZ&=k$
zw8QGqHXPlrFW#hCoyaLwqfKK{ksLh$MkxjcdFYn;?jhEHa^Noe{&vB1)nze?&))-P
zz*00W1vc{g5AME-8J=*Gg;)ZH-?qYUKzeYmLA{R#?h0M~AYs!}UxM5_7PhQG?8qPU
z>+%ZG1%1P(*P5kFn(of$w%KEUoWz?DYv9hT$lr)c(^AQamM}5+Cmv5xu3YT21uuxK
zY}NFAr~P4n&CWla&kYTDVgDf1aY=2P?`*cjf*wbR$=Qy4SvndrBOi}?kdCmy^p|zq
zDSh3ej3IUVS4zI#Q@FpU+&Pt=`}|VQ<@o9MO4EYlBt)@wv3|Yr(9!sn@{HuG-wwzn
z^JsLIXq^#Anard_x99nG_TvC*LXmR2JzR>~>}@E2E1Id*$Fn|j_|evx`4<#)IH-ux
zI`loC1nPDNrF#bZe)RP_xtpB-cg89u2&$r+y3K)1E2|2
zYE!6j*umAZ0YgoL^K6%y4vJv2l80lvEw+sCbe>lb*HA7WbTXnV`L_P7zc4Z6hbA-p
zB)ms|I+^=pe?K#7;qipw9R$)Qa;L;AFb6^u2RNo+Pe42i`<|94zFEk95#6=0y|q^n
zWD@5~>((k>oBB<|{)Zlx!u&}Xq7<#H&&zg)>T%MI>374*%a5Z%Yu|myelayMP%|>K
z(=x~-t`3|Uy#}hUrGCX5p#=JC@dHfl2tH7Mq>v9_-P+WWdJBxBsf=95UtvOe*^y{|94GFdHWa{sE|FDVLB^s{{>#O|LFxjb*uImT5@slp}}<
z#hbC_KMzlEqWm?apR?e@e5q8sM1Op5F9&vql1T?5)n1|gWy?{Hc#%Q*cQkSc!ECgD
z1gjJ}db@NsANvO$W>a>_H*>opc73vgP~T`cP@ODrxO1)D)F)Z`P?#{&u?w1=EaQh&Cn!C!{4xg$cOyF!VdMM6A%QKt5BI9+C&*E-K
zR%-}U!?m16KyywW*`)HlK(9CQtVT-aI7`}>HPe#tXL~%xD`+O!IO6C3ZEMX9#b8?v-c#}hEp_kreuQRe{qbe}!?>2db>C~u+2HgDdVmO-y9L9}71EATA
z%i=~#a^eELI}VO1-$U`Nz6vO+ebbWy|$V_`2UmYhTzm04W7BIs0XJsc}Mvb>}cF^%Z}l&Ik+4
zoho(=9(;jm!!KF}V;Ga&+OGGsga!jUcr*=XW9|U^P%USVi}7()P)uYQUO_00fhu>D
z#$(m@K{!_fG-hkQbG}%Avz=%m=Y4Eh_XWR7)*fHv(#TSsmxL&R$3B9lR<;kIB4Oeie+
zbw!d}->C%AU@x%^Qdn>QH7sf@H>mw^digJQRqaz4NOUv8S8m
zXEWTQ_0n6GG#WFGe?%yU4y%q2$;Ap3tGPgJ{=|M2*xv|tR(QU9%`7}AtL1$+e2WtH
zPM}T=kQ0%9KCB2ih#2b*0iADfP($9A=Gnf9lvJ(dGGEAJGCJ3B20?@sncoQ^4WBb2
zUY9?E7Nt2tmlFSZX&&yLVG(P&atY?mOr05ZOn`L}bsIBD=Ohg0T
z++q)l91L#&e@V0UsEexUi6iW_w#q)&_+T!g`Fh?q0Vr=77=~%tq-KICvWpt_mo$=<
z1I|hIE3UO>BSUG}Qi>eG%?ltv4*PM)abZ$HI7;8_##yu*urm$c@Y%LdTPL`;RDnDC
zK=KZ?3d!itz`1`JIV!Ygs
zGGHkHUho9CNN=@Q%t9ER2I#U&kQVTLftg5kG0A9?c4tyN8R^voSfwY
z$?Pwh&v7-{p_X|oB+B@uVehNN9#Mxecn^a%|BW{doTMAzrYecRlk4QG4Nq*D#A}gA
zVx#Lwe+U7wWz*t8Zh93gUCm|;&4mL+m%P9YdW*;DvfO)RXG(MJ(MvxV0CV$%l}J=9DYgx9
zfB%2i@FN$|hiA3q9KJpsc_wu7ZQVR|=ry97U)x`?
z1q(R7IXDw~6MQTh9iSq*usuzS%}Yv+7cJ^Aekw8TG!XQ|
za1bs4-c%OZw8-p{S$YB0UVcYu@7Inre}r4V(Hr)ZuQ2*48BZe)XTo0%98a0?!{ogc
zhHi+MzbE|_I@#YW27b#CIp0B_QkPHW%vD%-1?LqR$z5mK%ENop=US;3lt@N#4SX|I
zWpmcilNjw4rmLg%`!@K(-f4|_mds%YG-tLUGOy=i1vy^k5Ko$;G2@m#>p>6%e?WTl
z+l4j;_H#v~2v{&GqG&%>fqz2r}`6yk$kYdbu+ImpI
ze7s!w^b=EZt!j+raiH5Ayi0GG6qO{g2o61cI)FjgD#F|NJx6G+-uRpN2XqT)SBzDG
z=5Lb?ezJ?1hE;$siz_4>YXlixM3fArHGTfxkWK6VvWA>q&g_zkWY=)RyJT7$d*2uL
zoTDL8yPai<%l^13N$18kTcs{CqX;Y|_kjF>K-V1q4+uoj3zwnh0u#5f)B-sk1v51;
zH8Yp*@&Xt`PTl1Rz2>`Z6op$`H<-~iZXp9?^df|blLRWi#&DOg}a
z3DlVI4pk-vE}BWLm@rH_!-QoTEoe8|4}@pdOC|#I=#V7~7$+etw8to1=^k@Pe<>Nw
zEUjSZR%OW)CQ~XfTFCifhjB`q-PrV
zBoxsEK+1szY=zZyAozh{h_nH)0i<+-8AVsLV<{6PGoT?j&kPh)PBY^$70J<1>jsvF
zkiH6{XtxGkxUr5|EXZtNRzq9re{vR+c;=+XAi;18kkHf-Noe<84*=Dd03$8)0M4Xg
zUIl>B%o|Lu6!Q)@nA(RDSIa`_APkbh8>qxJU=kLjb_30Vf{CzTP!6r=H6Y$A7A#co
z=y%j_a8+jTq@EN7L%8t($Qnw%89p3?BWeoW;-mT9)Mte=5dQOsQz8
z7*a8s7sGi+O+^z&Y^_~Ht}b#&MKzyhGM_89eO|1&epa+u|QwKDD_*eKZ{<9l^`
zLL;9%8SppXt}Dh5h8NX
zF36JsCYWF(nJkJu9giE#fAf)ohn7U}#EVat5HGTfmynT!yx*_KzYX|y
zGdZs&anbUGKj$y_&PNe%2<2JJJ~~m9a2mKkVc}##>%x;KD_htyK+ZqmLiyzqCTP-{`#wk(noe-kUq8c~FR4!R=F
zwUveQqcO8rc@h`kPvgq`h#w!mpx>j*w!NPIgY%2Jy}UUs&YCO!`uXnB3x04}
z0SdsNWlGw*bGxLiBG(mdAGsd46slu6elTgyjw+ZO
zS#Eca@i*1ib~)!Pr9WLRr$6PtFa4>M_q4hr(`|NEBUIsNe}klW_OyYQa9SK3yeho@
zGXiU;xojrwvua#ThHW$X{i^*yrE8bvz_Efl?5p^paf{uln8
z{N)+=Ke6r{Q~a9PH>R*Gl^(mk%B8^rnj{&dE2PyYyQfg#UIcq`ka5zu`lZ>ra0f)um&f*zOl7!cVi*k4#Ea-`hms0owMFhcPB+Zwa
z_yUyyXtyx=0&f9-q;n{ybLnn1J)6|mcpOOQ)K|kR^n7@=ckp)q@B1$go2%hil#jQY
z(K!T0!wVdhljL?hB|p~Qvd1#eKfOp@LMTQ5kWA0$v}{Abp?i4!ys9rQ^DQk%eUC-J
zL@(Oms6Kl-z8F=k#1l?iUA?7$g9rS59)!&fb6gH5bRvF#goma>e$0ow;x!-fF>iP?
zuK0vcdCS|&NmcRoOT#~JC5(GD<~6>1X5Xm#`=6h`dplQM-le)D)jj&=s+VD{>O0?~ye%K1{O-=~@zI-(-4Cmao6&HxMt?lB!1N{k5l{Ndj{ap=`*NXs
zxkho@)mw>wuHH|f`7ZyF@9}5xsre_q&tLJ^{DA)gK92Ys{sEkv^3%!i?6;~NRiD~f
zeM0l`Q#_1SEkEOD%?MA*cp$zS@^i5GiGQm31;6B%->xsKF{g=(S*>CSo#zwQps`Po=R-vPN
z*$c^dJJ($bw?=oOXpJLKR8k}!#28HarwF6SN<7SBX~x72zZsublj&JAsa8VdL3#T5
z;rrdA{Y=ZoOl1Uk5p+tSKlFuN@M3@Zdz9(zQBun9$yeLAWUQAtXQhmF%-`~N;A}WO
ztLwHNomYI=QVv7fN*RSRSk=vCt9flTp+!8r`u%1&iplLWEYaLdV2q1NHEgR%Ki7@;
zsG3friDC$kZ>~;ZociK^>F;;``%TkU=cl8T39HYTcUphFH79oLp3@`$V>S?W)pDuAH>>pn^k{cx0DU|68X5$jgq*ikcCnS`uJ!b@PH)&w{~kK{!f
zqgqkH#Bt;+(vMI|G$z_J(a3RR(OY~0hwY9#{L*y@oX+_N7DV6VJ(rjnALr5zr7XA{
zfajgy>uzS(u+}UD7yQqijNX5=cbxI$UM3LA=Dqb~HEKIA-l!1~vOSzu@vqRe$ID)@
z)0_18m+W3WnYI*OOe5&_hxtZOT7Flbx0h3TDIY~=KR^>iSdCc08dkB=+p8(PzPh1TPy_yReLkJPD$cLk(u=62MEv@u
z9bu!IW^^p4Ny0`S1jT=w*{rjHHMSl4mMguBrH{K}Ex!Qsv)f7ane}On1H){bT|X?N
zctx+Zgj}7&%-6nkjySHjG@S@R$fMon?D0`MoU~i?F&VM)s2)#od>akv9qAT*QWjgU
zK`4E=B30*JZqY|$i+i<2ABV;J3GKSo=iz9JK0}K<^Zoj&ZkKCT?FgPMgUjED{4K7V
z=k0t$qxvlXvm^sJBE!3xR$KI8+Y*rO3Q=Z`Avugs!@ayqgWfo}IRyMIThh)Dv^E!m
zQvtAnrrWf+D<7=ck3gK?OENm)Mad#7Zl-(J(Q`~4Ho0A&nUKNFt;5D!CP>)~ySd2VfN1l%(FRzie%gB2v@^RzC+pq`wZ~%vJr0{tc
c=YDSO58P=W@0YOw10M=9I5P?*B}Gq03Z=Qh^8f$<

delta 37557
zcmV)0K+eCVfehM%43H%PG&7fx(*h`e%~#!Xn??|S_g}%pFVcf9_W=iZJe|665<8Q)
zuI%O|$#l-*ESQ2&04Mc}|MuS9E=XX@wN*9K7wxg^_wH{GQE%>1@9iG_2l~t9-peznNCQvGh_KkO67SRKq#ScO`aYfr%12EJ^!HlB;XEC)kzSO4jTO3G
zjwgob_t{mYs#}nlqM#K}GyD6en(OhG%Xh{-_ZTB_5OC{0j)|bYHxWLGWDMTl8t>ug
zdy}fd*fGjS1n5+i)`ksVhM_m%A&KGulsM&L!svv?;3l9R^NH}Kb2H&o5*bNv;zuMh
z)akq`7h}OjjRsPqCi7wvOD?T{B1JE#!N!xA2cy$P-KacQO=c|Eh>RP;LvF-T%rYk}
zw;w2&nChm=^tZ9}M=F1=4FNW6M;_4RSZKPI$I6Z=UMvJio~O{p2-+B}w^4{uRs&tC
zs)18^ZK*#xIXZrQ@lc^ny+lM}F1mU#_CUe9i8T6rElkD<3#CgojBy-)K66F~I=$44
zPH1KtlfO*cs9UNQ5OanxT;+Crfj6Bj?R-WspHAG2T>~!*yD2#mM
zv4EJDmG-Xpe%m(2^^IbGJgnMbW=xn_69Gb|(nZls9(*L+mOyWxX@HYQ?0^wT
zZIm4R^f=(>#jhvF7pE@)RkzC)OfPyK!7lqZ^RbG(zvLLVna2iy>^@;!cKgObuv<7B
z7tVi)LBvU()q}+`E7P)FCW-z`g}=z`QfRSi5%+Bz1S6GMq@tb8NUSg`%Sph+0FBZA
z28}#0mz^2+AB;vWeG)|e`o>?)=C-ix17$l{&ULd2r<^~EOLM2N9xiu;p&_;RBR8-%
z7o`w{w)4OL(|8hp7!d6PIResTS7t;H;2|)(!X5qs62S#-E=2g;Ss5}|q6mc31cc$~
zOcmNa(>2CXliP{zOT8(pLN$%Pr~bZN%z>A?250v6vyWy2HaBQTC5cWx>Z-Q4F$kCQ
zY<8^cS(PoDj+?4Fy;Nu~t6yc+Ouwt~ljniNgbahxVRDs!W3>)vX=RRK6n5tz3?Js(
zr18w)`4Rk
zd{8~kR8^&aT47DQv{!sLuLH5wqigyOQc1Q*MPMochJ0Hu7cRtTy@4Iu^`tMjHRo_}M}D*IRTU!05C3XXd`#Gpn(|%@&0Su@Eut
zyt2YZHEC7azgNy7?F(efthCiY-~r#m=xj*d&h*&yD9sy3W*b
zop%SW9lyOfI6ez~Cq-%GMb6E{i9ILAE^__Yxhb5FgRkBk4nr>-d}Rh|hS)V@#W*pu
z+lOHRiN$+$3(uk#sybF}gGg6HSOV<^+CrhjIVvbqOzP6)pux0Kuw
z{>bMRvtnEV&Tlv0gDHj>qcjXRbjD#E4minKRgtS-e{5-@=bX&TEGN&_v1XF==t70n
zI42`EV_a@>%t`d*<6roA|;rz{_z_Cn$l=799DLYS$cKt#m_{fBzWSsZyG`iIYQ{L=>@M;ZSr;32EeLRN
zJ{r#&wj9GkFJ}Z2GbF+Hbj&lpv{VzUXedIiYpAv$SK1kaHGw@B%#s9+XT5&iV&)?3
z!%i<%;`xSP3!=pwOo_ZKN840gMZvnIf3P2-G;R2PazpF?PvdCpdS7I}dA8IYGej{6
z6E@Q14+$P3&+ic%tZV-gd!8+b5gT`oa&YvF-C9#`Zwh{w0w{siPp9HxfPIAFV1^zz
z287WgZoE(UbVpSOe2^C0v9H5?YX(Wj&`sKA5}VzCErJA?S6G?r=L8`Sl7T>#dK2TbF*nfH)geb`ReY8ZH~3&*CHBes~%
zY&U63&-HvE7nPa6`s)*h46Xj8`g@fZ)z8rUs%o6oQ=(x8)ml(P-h2}x@D)8j>QI0p
zS3!blivA{r4okCZ)guVGx#eTee-_zCXPx5TR>jfP>EBPTuhA~`bz8NAW2UM~h8Viy
zLnwN8W|5fzy73H6xN#|1-%&X;Gcku684pNK70JB0uc%KGU7%qiXT-3$ug?Iag+;?h
zYEXdM>7TywDk-pgHO%JNIIFue!q
z)6`Iddlpdw#ip@IjHYn_1k~3BH>-2q!2#|1!+VP$48W)a
z0Q)5vD5I$hAvbJ;!GyEQf8fZ5%=gz9KOzG=)2$pgi{{)cX{|AU3)ZI}l>eqTYYq|?
zrf&=G4-!CdkhyLB`cCnvX&B3;B{8$uMkgRfZEHB^+Usv=p_Nm;p7ujOSZ%WB>HGJ)
zN;0vMl4>qhbGcN`s(WMzU1-??C^dbxniyx$4npIkoLuR*4;M&TRVeTwo
zA;62^&ZM%2tGf(!o&Y;PHf`2BQWLnSGOh~u$C;)n=i+srqZ}VkRU!hE#TezRI@Z3?
zCG;EmUv%v_@KNA-f8DO#a|7gt>A%>v``~e5<8csDHPN@;6CyKOihY}Q?4lsT?Q8A{
zl#6jD$jC5*B(P%-pFphOXulTTJUxy2_1@OOyC@EKY~hEVn<5W)nx0}@ZRzM$kfKO;
zw4Nc^f~+k6Y7QxX$_cb>ueSBdPmr$@L+avB_`aeERuN=Kf9XKf?}0BU<`^EKhQ~=(;i)B4uOgd_G
zOlF(U|4K}eLpjK2s2H=S$a$lm_Fv{rqf?P~O@}ywMj*g@KWU6s3aV@3!?_T$S>h+_
zxp3u)UJPc7f77=4UP#$EK|vVptE(2mzT-dgZj+|SkK-MaK8|A8?R6cgTXcGog>{h)
z+}%^tW-fSuZ5MY3w$TIO{gA?&=zHkgb?L_#oABP3Vf*3eQDwW&Or2cb$@DMu2({%h
z;bRoz7ks48N?~8t`Jy&gr`CHs&89UpFf&Iq0QKi$EOn}Zq+hZ+q5w;Bxs|4b@2F$ynCWo~D5Xfhx&IW;*m
z3NK7$ZfA68GaxVuFHB`_XLM*FGchqaGncXS0Vq7Uby$_%x;;!vC<2m_i$=P;ySuv<
z&7wO6>29Q?ySux)yQD?BL*QG!`<$(NpWnaV#RZFT=a^&O^O+BqrCI_(M{p`Qf`Ne(
zkqjUX1OXkuP7{EUJ3tobWT@h92V?|L8vX+mY#p6wjSL;ZZXn3a0tEa7P7$`Xb9b;X
zGk5x3gPE50cctIimn~ZY837xYM_U3S0fm=pTLLP7{@;DTfxpvbMO6e3^>Q
zzzA>wIyhSVZu?){$id72f2e^|O&x4){%HW9G3u}AY)++1UUkKCyCkq%V`6a5}X9K
zJN=t~7+46W-!-lO6%KF&0{^3pxuN4fxiSh0G5{Mx3y>2KWC$__2Ra!#IXeOj{;`3-
zfhH9HA_xQsJ3Bc1?jifXE{A`&`CsZnw&0cNSbKUKy8ic$8G@W0J^s?>KbLK63v#q@
zbaMPxMIgY`!W#ISz2omavjF{LlNFSc6cbf{R-u&v4<3kC))uS|h|bB)>7VG|^#ny^
zz@x~{0bpWc0x*DwR1{<)Y-?i!X6=ahTRssBuue|44({~-XRfV4wyq%0|7$n30GXKn
zR^G(fj$RdHVebr-6#1WMunF;x%?#)SU;qH^0YEonbNb)y{+X8FX2#!UungXwcD8nZ
z08>M2N1(TbDG>aD=;>(a0t7fYI0L;s|91Q*LS$qIm{=G)fd?IYSP=iIE(tQV1#te$
z3}*7buKyVU%6|^(C-5mXu?1PX15ALXi1c!{PT+x{{Qu{i{Z}tBXKQOYLmMFFe@pt`
zafUV)*6#li`Ck$0z~5Xc2r{z<
zg7@Sflj`r&WDOo$@T14#_mc}i%gDz5Uq0|e8e4&Yj*b8}&VO7$unPah7cBj6wg7r{
zbrl6sIqLs2GXI2$f{blVEI?)eCRR3pp@V~=J0b&k4wzV30iKNDkv0Lk{WBWR#Y^(r!!QZBTAvOTL&>zGOpcnpwH~{n_e-I~tUi9CHodG~E
z_6IQn=*9maCIG#}AH)oxm;8fR0Q6FS5V*U{9|Z0$`v-x$%l$#%?(+Xe9N_K>e-OC4
z;vWR=uJi|iyDR@e;O;7a5LgL+)jtT#MePp)b5Z{{;shhZeKwFVF3|5{jBep_s8{#pbBSVNP)Ah_k9rGO`k9{3-B9oT;R?VSy+
z|4IQb$@EVOn477E%U?BqyKS8v{z?FcnEj~;_M82_>w$lVfQkN*hXuSt=I(apK+s1qu&oc
zv%feng2k}?!xCK6_OC2|Mn>?;?EbjHJ?sp@7u9)wpQH-EUnKsyBN_fYTL0$_>mRJ_00P~B#)!)cw#M9FER!38ihV?Lr%GVSIO&edF!?m3Vqun3
zr`m9_MY6Vuf&6)&oBYzq^K4}#xO9CIKZ6Q1$i84$zic!oluurpC<^Qt`pEj=z84i7
z{ia5z>YpaNgbU$XItlgLnPD0E9zwuu}(?LS~jd}
z{v2Z?x`XuxwrC+kkFuibQdTN;ChGgL
zqz?Bee(TH#vh?aIWn&S3%?rT!Rw;;$H{irR!>FAl96?JGJhA9kHIz)*sqkw~E;Hb<
zR$Q#9n9vZ%%OB5iH^a`b;d5;fybT*1xzSN8(uYld92U9vhTjZ-EM{unUC@ok5JAr)
zmhkB$5_UTL0AXFNE#p-xBi;xIERpI(g!
zA%yjQWZ#TZO1S?}@_w}ssE~Nhxq9%3zweRJiXFRv{d)9j_M#S0Mm#g(Ve3lz`Rse!
z5Mxn)_8@Pc+Mx!v{YRUpysB~yxtG8Kt4vuJA~-I{x~W|S=7<>A0>95{nEZKKHzr6X
z!a|#^_l#(c(P3FdYMH%)$l(|;_4y8~8mhyk*6Shh>3qdgE8h?J4!QFKgHJZZo>>O-
zwr(cSN`~iT@iZffb*o#h)%}skl?*tU=-|13O8SJhgkpBNCI|VmW=9%J(T2OVbwt{o_Lu`RR13pV(jg#xC_0V3?o4JUX
zDfpTlAk1Ud(2NVBHkMJ*?xKYdu-pBDQ-;J#DWLYya#LOWq{FkTm?Ai^%%+t_B`y$u
z^yT{%6jER@CJ;*}Q)(V=NITAj>u0f(YeX;h+rWoO(Zc^}SK->dCZgZBRCU}0*LrQkl)yzamz
zH{NY?E#+BTSccg$?qC=vQ$JbDQat{F+~Nu7=SX)96j1k?kJj|~S1Oz;TQ~o~g5g`%
zxPjFNz!Dnjnb7$cW2buL*FX!x4tzw8$Fq+>o=9CCyg5^JeOU+X;5gzhzJZ#52GVZ~
zci`erZ$6+ZGdQuuO)a~8{-Aqrc;T0kDxiaDZXUR8-w?H}BQwddrC&u-uq$=EpONT?
z0L{6>$*yZqm_o=y{_BSo>Bdr)%EY*Nu2}5Akpy0@$l95Pn9|A9Vm{HkCC#Mt7SYEO
zq06x=DYEVr#1xpKi%0)$5=MA`(JZpX>d<^gn@JLNOC?@r>p+r{u@HY1kAaVk7+e#w
z*XA8Uc>Rn=yS3w_j>GQLc&Hu4E`82J&7A&)Cpj?vX74`43r4kxkV%q#Mr6~fWy~dVk;-WuaHre@xT$tu&C9+4`S8#}=xeHfT&wil
zz#Pd%8;zwTJ&W>ORg%C}$KIvu*uo+C_Z73p}Htz?!
zlho1W;tLczA+IV1gkZhuzL&Z*V<+>KA`Ci~xVMR*Y^lHnuD;VSDM*c#a(L4fe5{bq
zEUW5UKcR?)SuUoI^GJqZFP+%sQ^=Rc7L9LO1a39~s*X1Oh>9h{EJk=AI)1*Nzh%aX
z_e5c#!6=_gVnLOEiZfQ#*NnoJ*=C(%oAqXFJ4vymz`EKK+6gzAbIi*Te7BFYGCo05
zxPCf=>j%&H{nPpCy600zQ}+*oHF>EvEf06cRU|HpPeXP#pN1a9zQHNsm{bVJ%OD!k9+f20yh4s68P-STs;Vl*7pu}TQwT5Z
zOsXym_V~DeMJX$Tm!H1vOo6wdMcP5~8Dw;o`g)Fgun9nTRKe
zdXvWJzxuhiy-xQmY|WD_NAkWrxU$3z7WE&gUC;5SfwH~JwMflqL3Yjh|yVw`%aA%l<-c}qc`E79^OtEn=Os_dZO?(GIG#A4y;ipS@)D>cEoyEGs
z()|#XECeQ^>{a@aPphDgON?3b`n(rBxg5Lb8=tSHh32a&k0GgiD$cAIH$$LI_QN
zmpKt~tHY&tuyrr1fUop0g-0%Jhs<&7r2!5j#Dzc%EuA@r0hW9;V9Q{
zIFrPWli;|1OV-1T^DNKyk-3+`0fvx=kjsIZ2I+DMcfa90h<+dKk-&|^8o8i<#c_3x
zPbh!T0dj7fmCDcEx9Y7O`RvGE+iY?R;aVQ=OW^W%gNLU*m39g@tKhd}4nB5YI*RH!
zHFCKu=RpWR?8gvYg2V+axpMrC2_i{)=<6M5K0uqj#>EZd*=RzZ!n3?UedLaE5Y$V5
zrs2FJ7z17~yz9}{W~dXtVGn12Ki5^(Gt=yjpOe`FcyLuSEJ-yRhRGCq4iY~a;24tR
zMK*il?pOKXX;+)%vS9)1Sgqw~qCnHTHNkX@E0I&1o2(E)=1XM0D@O?O>Tmnz6!o(t
zV7%UjVJ`|y?x)~2wGYnPQ-x^0XRC#QMqELn8mCq-UH%b^JE`ByqFN|_;{(anuQ2G(
z@UTG|{Q~S=bGsNtRoUmp4JG2<{H2da{v-4}yQ!7m5Xh`UM=M(3yTY=8vYh$KyCN$+
z)sL%EKN#Ogma_V3o8I9?cUZj=y{BSA<726!_33*&kE`{MK}!g4^o#;VoY
zOx!6npt_+_z5K4*a&vgU^_F#WX+*$7a5M+D?5)~p&+E2m-F!%YdNRX8*^^`A@eTBm
zG|eXpQ@LY#hHP>ih@?`WUp1{s)I32s`HIsni{2`ksfw{Mr!s=I*Sjtigt3jJm+nCQ
zk{!&g7XO){L|P$vpVELT1vt5-wXZMCcUdYHr(ZDTyo*jS)U#vhf(~2e8ziMqhMNZ)
zvKIEIG0{O`nJ?OZbSW=auDfX-Xu<`l$6omk*{nj_BOjoB`6bCO1b4}x@Ao|YxAfQb
z``$M1rZCfvUY>jyGl&j4EVq5*kV)9U9htbH=6qRpiXN$o5PtR4%;bG~YWlp8;2Cgg
zHAz-P>-!S#pKnLv*&AMhZ;u*i_RTB1gh1mfF=QEcHylNO@dEK8WrQ_14^Ewx>vMhl
z?7C6r5>Uqv636H{dGT)L=RE?w`uBDz>z4@T1WzE_6+Uk!(8LE_HG(oxRO%!j4HNnd
zXR$Rl8zfYeGdyO(wr9^}ST2_Ra4a|ibGR7SEtnmLYEf<3?jxaO#FXiJ;5Mo1j=&Cj
z>jSgDj8Jg3uNqpVWyqwSQd#lq32SzJOX?3^
zO-zYdCYoNZ%Kd9&tWu4jqW%v8bmn|ZX*_!mj>+_pQTy*-bEOzr
z7n90=Ggu|y#|ox-M0>)+_#5t95vXu)nxZ=%l7-NMhi;u=<`apJ0|NHcrr-F|by>{@
zN$$*}!tXGEpqMvC<`K+3Izh3{eSp*NFXI?iogLUD6xf%w0I61mn^B>r_f6Ml*GeZx
z#_GGNnrwZ%;K^_M@v4e9C5D{o$0ra2#P3Oe><-PNfswnI!DT-ALH{_i1OJV*Hz7NR
zp_)(4Rs=A+J4qjIM(rbobyNOtDrM+phh=C8e;FsynR#d
zJ)<`HH{Oq#5lCebHf+p}nQjKkB-+v@6$&^yCG=!%YjF<|uitnzJ|k!+J=MMsV00pX
z|72j|NPzUlbsTeQ`Drmo?fF)iPJQ(KFeJZEZtPGT-Au@e+|&@JsbfPfY05Vgo4}16
zP++_xa_%jLRjhnJg=5%PJr&rWDw5?9<1eNdJ8^cs1-D#YUivv%KgWE6wM;M*N?u!@
z6U8^{c{Y|*`YVJQLn51Bem1r$aujcWOAsw(Hs&4ny9WAF?3)po@|Y
zERmA!ckA(n6ROS_2h&tD)2_SIpCJvSv83a6I{qGdz;0Xkyy_>OO0Za0gs*(rdoQS(
zeez2V9=y_M-5B>Vw_=TUb`D1|TP#`G&X_bxjdBvUcjoUC4y$9Td-Kh;nl59jWdklY
z6V-vpM~yvhA~@kizZUqO<|2}kHhfV<|_+iIpY4fq7_XH_9YvIdblz80{CKu6TJ
z(??462=U#D9&A->%
zQC)&^9kQa{H@o3U4$3Hh+BF5C%UwG6$2m0t-(6XOR=R#U2umWQRDdm63@!o;5e5=-
z61pZWVEC_Ia_UvnV9iEeh8n+3n
zMR5F;xtHzT>AqLJ+hX6726ad|D2gm4;3PRQ`s%2boH5n=zo?uya|NDncK4XMhgs7U
zL-aCxMEBPVF1?q-C|d^6e_^lvvds(q%j^u~mCX7!l<$_xdF-0|z|nAG1-2|AA~h?p
zw!X*%hLQ$@9A#jC6N3i)7Ai;Sq_
zfTimBN(yMW&?6@1>HL!SY>XWt;M@giwi`qmb)y?Sj?_Q8Y>)6`ch_hy>=Vy)n;a62N%ozSeBs8;OM^rhp27jH|GR8r4!n+gx9a9Y!Y67D#v
zCPOPPW!)#y6{!SO6rNrdC(btp-4akYG8;I!OOR)!3O(kDiF}eg^E--}eXN6A(j#bJ
zhsR0za|4ZJ=E%tm&6#N&y|jPcTF^J;5^8mSux6)}SE=gATOlEMOYu7WT-~LN@5ZK&
z_dXb3tgJA4L;n?{R2K7XpvNoWh<`!}^BzY^CEbharD?CEMCE4eME24#mwP1Zsxz(0@wuK)QWy{X~91J2J_28(MK8vh>
zcA8lA{E^J7yj~R@Bvg2H4SNBf>S$8`V%+vRQnQXuAT*~7--%pGd4@m5eEO~t%?|8X
zL=QXiwpjpjJuUxx3A2NIMT^>z?qb7LlHQiQ59k1A2-Y+pzJ$iRy8xL~WX$F}=~JZ_
z6nx5Lh|IZz)GgqlPg&Cq))OQ29$8|43j`gM|DH^1ZTte&ka4`GO0?w7y0P1vetbdY
zq1obhQj0)*kr$WMD+@bg?5$pZj0q-5W(;LrO6|Q(%sdo1zUtYGn!v?V99a}l;13>e
zxOj!GmZhH^gvA+gQV2E3xR~xV_?5HzD=1yxWk2XRBCfTJ(KI=($(O>69hVV*6my1j
zkjVvUq!`OIT6r2#L8ep5O+}IQeF=(2X6>(@A6tP@Kb6vuPawUjG$}YQp77{eZOMQU>&Y4lsZAK6A3?
z&67bY{U89Lr{;j%dh>3BlF*CG|9v(E({gz~wg3X(W8=*l@%Kw)D$zeg?$?U>Nun4nkw(MdfD8AI#8`_rm>#yIyb
z1*aLAsC!hFacFOURb$c3MZ@-+{K1?gf{64ssSzy+HGxt5qBHJ)ieQy`>AGhBO_taD
z#_Wp<8<%h_gX}$7Qa*}|@)RT==i##>I$bU#v3;H|>uow%0fym_gh9iSa4?YXcidyb
z2SfJ~KDJE4yuNa5rJ}JvT^a7^8}|A`;26WKLyrT#P&4cLW|=!Gqdu4-#OKEd&G=5x
z3~AS|eE+4cXcB{e&}0h_!MU;a_+4~UVg*MD$5mgsF7QX5SkZ3xr>OX%D;9ca@up)a
zzmn^?&<%MB;8k0M&-GNsh|YKx#F0-~dlOsH-9b;K&+2aHehElntMF-i{i(A3J8I@pY~&M!TLNeMV06YN)(IxqR(wufCVzQ`{&s!DK3cl>6yAAO0GN}xA$(cm0!Uo}4$Uuh`MJY&lx`$=8Xp4e$fa8LzO(z}2Ee0Cwu
zywjwfe>ki)efk;qWdc25UcWS)-z2YMU*6ZI;NAT~)jX6llz1x{gsqs7f{8DCuGQNc
z{ON`0%8N>WqrC9AERtj7m2k(tD8)L_YFW}!&3^xe2B_l+>Y!^KNk9w54g>I-X_@hh
z1jlJAqQ&zfHo)x)w|X7Z2JU2ERLHIaQs9<($eNU8Y@{yom#?bN!_2hF^(>;Xb
zVYT)zuhIxX->$%LJre&0nvi!jlfuxT?1-o7`5UEe^0%
z)-$Ysrdo2Y0{6_>bW;z(PtsS1%(LIL6G(q!6|hW&63IdH7Tefm#4K`D(2%ygvyHI
z_6axpm8;`)#$R28K!ifA!_84p9*OD`^mYV+rZ
zdgiF2G029`5sw+_8=r5NY`Z@xubEV!T*?
z5TNi0a)cq%sDv>BmIEOVto(MGQX%DY63GWRf3QK`wP8V?MX&Hx!(WA3m}OrP(QnFp
z4ig*x;yDxA9~Q*L#Z@*_^mi1X`uX
zB4lw&+GKu7GqFWEl4UN7C(?KL{xV}T=0eEfv1<$Uc5w}wK!_5%tFLRw4&66M#ML7%
z^z5ZdebEs0aoHCBthg{ej~FR2
z;gvw}**!91u;Qq#O7(N!jvnk_g<_rg;Zyq9o0!XRH%+3rnK1Yw9Pe(~;_fXa5r=Wz
z7aP-X8B9!xB?hgUqWmK8DtuXmaJ~FQ(cbf2AD_m`#z#W9H5HE<7zuBGkgzV%rdzjx
zSNulUoDzOi;=UnUIx^9$s;IYbsFWsxdVMrZKb|Bl_CWAZPt>WC^;>K-bq4>Y&OQThw(XQ%4U2sawjIe36zGCcOD8@ixpT`X1>t
zDzD=-hLTSk=$qo4SP%(+(UJ@c*;YQKJv^Gi2-+8iR52%U8X>yZQo~xOc>{W4T)j#7
zv>$aa40aF|Q(5m!AOzJXhfI8nQaE4)(QJ90ZILZl2xSquTUYDpH8Gi3()&_?_ZA*&
z0kIC@x=0m0ukF`N_qjbUVOwP^*gED}+@;}Y`ES|bhe_@UQ+sWH`CiO`#6NV@9mr_P
z6Ng;m=kI(Sdm&~|5pK{&|pC}$)Oez&8$
zCKl9Lt;0K=I@Wl3pc6{wu3#VJI9t+LRZ+DX7<@H8o>?mrH+AXGBo-Mt_h!n(Q)ZH@X7mq5;Pcl8;?z$5nFP|-N%
zozLuvWrIK7(jAcW3_}f_W7i@uLwii;ZNQq^ehur-D;Lk>i+&o@1DL|&op`%SL^SqK
zh-y^V)(7r|4v+H@6A;pqL}ZwsZ1i5<(-mw#I~*a!{6GGGi5eI+SIV`NEZ~%OKd#2;
z-d>u;5+T-k@SOMmxStSnwTh+)0T<*CVhQ;a?zO=UbY>pSGGc{hA?v}W+84s-EP>w%
zUkJ^fY%t52tbSI4QfVwMlq*PBLTcu4KU1NuD>!z}!TH_l-a)HCk03kjj`me#{@u^1!i|-99Dc5ve5&=^LqKqA3yQOW
zBkK{vF!Rpo%A94nyOMM0KnpyYf{B}MjXK;lfNZGBoiRHu&1H!R7SgzoACybED@ew`
zLTSPmHG{KWtBVYtZ$2h$jNZXAdl}xL47WHH$ms)r1s+B2>Ufr7NYZQx48Cz62W7u;
z>~-Vso$%tJ{`qInm!m&S)DRV-f+sE__{5SfhwPPaOMRtvs?!37-f;c!uTdXQt`=0W
zy`icw@lZ;ge-XKzKH_9
z*^gqb&n03~*saUJyt_h0TkMoo;Puyar!eIp5;0>mLfLliD;bPO`*hx#K~l`m*tS6a
zZB*{~3JaG3jiwRdC+|#e3BTA5BHg}m&zQ-7_6i$gsbA{ewimy9Jsl~fbaYh$?j8PK
zQI}K?Lao_5jJ6tV7_PNagL0SsvHbl#Vb{o9-?dE*KjxT`NZaO-L@r~tl+cy?+*=`Q
zqS8QIy5Pz_8kkoNCx%E_~f#EUQ*O4c_8WTd^QJZCAtrV!?xTnwCBV8~L-fPsoD
z32((zM`rl~FALiqw};wnQj^|0VHULGKYcpdK~&i9+~NcRB%K3OE6f@^*(-zAq{;o>
z`jgQ@g|MG2!L+}1!Ht?ez?KND_>g~p3d!d;w-vWk9k;DZ@}@Y(`+nz<0;sZvK}|Ca
z5G;0}Epz$OypaH88uFv0GU7DINKE6R49mUQpDy(kGled6NW6HthrtU_@9Z~^$EJZ6
zR)Nx2JBbi;(|PBg1Al#gCB<8iQjk^z(_HzX1x2FZuxKx>ycFqnV2WgJ_CC$4RfsHG|eAAI5qF6LxQXUCecZ*Id&gKUbglK=R4{l6=iQl_NF3z3_qr%
zYIK=aDyxiRGl~?)PN~oshov&bcn*|;sKpH*zcB1_<DH&19^ATZTk@tmz!jTDjO)PLcAmVyox;kzX{n9e_ZB5iMy(Bm9S
z8Fg@3dX1rdbZ!%t8@CgGT|Wl8EQ)nk^h<4!CPU#+qlIz9>G;(ds{!7YEe&&MVFT#g
zmJdoxIg|)KLYg|j#AK5eTKa_uzI>jI*IXaTH9vlTTBgk$)GQ34==d0
z6h-GV`*2DF$R7;4vev>e=5Ymd6!Y~1@po+N>_(qm8LyBHYN-99Afe7L7-7myLsU%d
zTt?)ik#7`BTTp+0B?qpi&y0n{Eq(JhZk4Rh+GBfs!)p_vtPtkjz2U;Fft*1@Ta~qQ
z`t?rWO;1hbD*XkwvU2Jb%74+PWZ9RF}u?Ewl<0Zy@)b}N@!$&nX7c%~YEdK%&0@~??4$?Qb~pk;Z$`Bo5rw>4b~&
z)3m7cJ*@^irFKs@y4lU_Z0E7x8ggYtb4R;Oti3>f@M!*xJs~f@kdCDq9)2+1ma%`s
zhca9lhML!Z6AHbQbE4{i<#_V&@9^HZne2r{WA@fG%~e%jxsZ~tFcjcW{j3}9{`n=>
zaiHQMfA3t(3G$SS-13FCw>TJS^GM!N8u6Cjt3rh^Ly>@X!oP1oP;87X6*m0LJj$+&
z#RHQvhVed}m?P=*rd}^bDXeap^IW$8OY1(@i%Lp=W(8!Ba>4fb^{kLAIDKTfUiA_P
z*n0bTP$fLEPH(-+>fC_!$$H&VQJ%JANgq?mZsdiZVsbRPS<@~hkqMIE!%OzbWLEDy
z{WTy*nvDOWht~NZggy`&^X;<2B+(&V5{!vtzD7}`kd-wIC>1`sP)C?3?(~3`W_}mr
zNC%I9^17aVTF0~sjr@*eg6y*#L$Hb6g|%LE@SV(4=r~D;lZYmOEl0>r;palP&xMNK
zsi;rxI$cmJgJBPb5VCXeROn#aMn9}(6a6^(9kI-F*~N4W3fD)aGR&Q^oN?$Sj|f0K
zv0s}i-8js4FSkq9Efyf9#E!0bYa_Os?49I)mceppUFdX+E_3yBs}`(OzMhhgN%LcH
z!)SAP(j?NcK`pX_p=#P(ow^rTsCAbBP9hM`170CLJ@O+
z=#xB0lVL!)eZ{%O-d@mznUQ0d;p7b3h+kZ=?ICv*RBc=xGz!~DXLIH=9eNv4ojwvN
zyZJH~C=vNljb9+xdzyU66&kwDqW;6C#S51I5eV`3Zg
zhRyeaX4yppYAXdv4vTmWKMoBKDR`IaUS}6oOfTvY*pJnc;&-;k#}z_cwjr*6st10-
zyY-sr#Wtr*MI@q;1PtDPP+=S26R6#t0o{s5$+b0G?>m{FV8U>i5ZEs`+Iz0?XmfkF
z=dt3|;`qH0{p7wIR&G;RZ4Z|R&*5jCq(o`2#kw>Y;^o3FgC``z6fB7Ob3-A|*)rR>
z3zrompG>W54E=SK+0-^|@FN6&%;KwQp37N=j{0@A^e_noDFv0O>*agrqPr(+g26pR
zF_k0na_WFHO43hr3=^y+7)Ta0e0i|0>1*x#4f%xBlo(rwkvCMTa!}6;4$j>)HS?v*
z49q2quwL(6+yW6BL|>ohV2aBrMz9n#YixSPFr_&3+j3o)X(?J??4WOdgb@X(I7rK5LC^=i&KjEnsn9BKeyK&jy(Pf4m)i-uz`U>rg
zBkLNOcB7(q<(C*)CE0nkMdk$+Hyf~@*~hl43*2^ZOZ_C1JKLaB#;L(?QvhKLx60`W+gyN9kc+QrCvNYtN
z-qoY%&L09G^~XgFk>S;pe_CL%+#K?3a#1e42pn0(6jtJFNhiC@>>U(kF0RKC=%rKT
zsb{^CODg1FlpbPSm#;-NX2-0N^9G+c+ABVT2
zKt>ig>*lt3>YWM9OMQ&r@=;u?=>h7HzxsM(lPf25Y=mHA;$y)<=5
zrw=>*V8Fg4J=$AHNY!~x{j5$6dEwdG@*bsC-U3jBsVmBLDn$2+qTHO=3??1@l!PJ7>3T8;>%O}S%*E4WWaM8
zabLD=LCuEaT;pEx+2ry+5V=qGe
z3G?TKz6ASKt;j%}$=ENtZ=!JoMite(@rNR$7_ETvH%`(O&f(%wFFLKIiX02Or4_{I
z_SnlK!@`6PRB`QH(9CY4f;=^@r7Av-ne`@xh2$L;fD&#aE7RblM
zXT--0-l^=nV}>C&iwa&d-R=8izp1fgW!eBXw-lRQEXqs04}P#2uu
zijdo>P2VMd;Zz!oMe-%56tYgLWmtXep}wc35D#e5X$$?4%z;?{lZyio5hT
z+R9X|ObO*D}OQxw>&Cv}wG;
z>6Cvk;_IabL;Wxhy8N_H>BmtxYc@_B8Rs{H_CFbwe^Q~uQ7bQAs?z{vseHKEa~YNc
z7z}Dkhl|IoeBPh6EvEVx-r~3wg2ta&zJh`)(v-WJAkruIX|T2+hfSH^*0=jvCUk(F
zC>?or(ywBcN;jmcm9=&h>8+HfD#i32G55@OV2`?u5s=x-svwg>!dD?)T3^l;{eBkm
zkg|!7e^(o&!m)pwh@FmVU$_{ns*)dkSSO_QB-`6Qu<;D!4^Mtuc_mdM#X=w+;;);o
zBVeS8^V33=qhVzy3#VMTG)dTa7i$Unl;NQM;Jxj=`kmJU*$5e{^Grc}jG;NP7_?wm
z=%fqLz2JqtZo0ci%N@eGnDGXKpP-<#IMD)te~apa6oc`^qKWoU6qHCcr>p+m%TMnW
z4KCH*A&}B8Om)<4yZ?Am<|S`>?hBW2;LjI#$tEGX_+QklA3pqQu#))!^9Eki?f&Sr
znEPU{D>i%X*J`+$@>&Nimcr2(FaAS)$D-W24r?oY6u-+VbM#SAvveS)
ze>$7cxRqDYs#)jPH=1pm_#BwoJKND4uk=I?hh~r0j|N&s!&GvD>1IpFDqPJJO5&00
zz5p!l+8W~BcgZ$NYdI_05MKpYgzJ>3=i?UC#Fz3uo?i>sxw{+;pu*PVqLH##;X&f?8*8vlgV6zi2|bki%sy+<<>=kE}%
zlA*ksZne@n@+nH6=Avm7GJ5%~urw>Ni@9$*J=gUU5=CmxX8XqHvOc-u)ZNkGcdbm{
z%AZlzD&s2ykzH&-J_nuRA^<0O(^(NH*RobI70iWa(OOzHO5+gaN@60=lz~LXe|Kha
z)a3MUN2*^5EbWI6pTyh*Pi}9xu=z>yk?wbbFm*rw%$UuDo_YAv{FFCzRJpUUU?-P*
zVpt=?okB=ad2WD>zJ&O^ejxpAN3~H*@Ecl-+_S)QYiDh+oXw=dt?$A&UEHPRZU5I}
zj$q$?0rrQ!)#i{Mzub^E-ETfhf60iC930SzE+m}Sjy@^kXSc+kCNOfMTE8cRzH45>
z##QYSlmDXP%VX+1BIL_u1}LyTUNnf#u+t0+;v|D-2!V?veUL%Vn7
zM%c&~*;y&N?wkHWhZj;4heGi@&F@(ND?1~n$(lU~sXQ8U7URcX{?pAuf4mYcBZmk(
zBRc1sN>%N)8mtKYNIQ#zzD)*pavc$*)43j+WrJODM;JJ^>_+OCpInv13(9~SPou+5
z+P&%8V@FE9{iOz>xb0+Nn^kq-zbRTVZ()KSdc)2gt_!j}CqyjbgEw*0f^h_}wVYzK
zIuaQuJ3J!rF%uTZ#E{^1e@V)c22(6{A^2aCllb_rsZY7$aJ4+3`6JPr5vXf3K!L*g
zHA!fOe!^#liL7;dx_fvbag3&&l{THD(6lQES__GXvhdXVW7~TcMZ+XPS{h+{{fBrx
zffud>guKU=Q+%dCbb&ESs@vhE)8UM5HH(PH^zt5c@`mfq?-hZXe~uqMu1q~{GtGd;
zxJ)2(W*H*NJB}#SDbL;zbU>PYd@YAJa)sYi+CeC6)8jrsYv~Q;mmcrAO<UE#elz#a%8G$Br*Dqj;3_&MEH(MrGtnqQpSj*=Tq0v4&YdR4x
zIc78$r8%>Vf12-!C5Qo@Zcoj}@BC{vXe7w~0lx@Cv6;zv238hZz56m)I(MQ!=~sIE
zx2Tn9rtN*M_&#<^?qFiJsH!>`Ve*iPjRr|xL8Cm)SAxgyS>+em1%Y^P?nCj~tquHh
zw?D3fh_Ccb@EFs^E|aWXN)-u&4+9oWcRQ>E5|IqXf5f=2Eq@INOl%{p9S+z_(h^(U
z>s|!1R6I=Xs%_Zd#m&>MUx9Gq9HGT8+O9xG$sw-p}2V&HT#^(1x
zMj;`te=H;@lBViiwUCt4disQk618c9jR3cyhHH<>sU=rg(o1Uv9KHhT`1{Hdb8FP
z^FJFwc+mrbaqk+&i1w}H*Ke1<>~5TAG}7rpe^&Mheq((oA}^ar_-yIv2vF2|y=2qZ
zw<5|2&(^H)vm){uYSEfZYl0=xY*?mMDAl$mMPR&?pna}sTJE9}RzoP(i;HeXNo}jA
z@e}KLT>_FZaZN}C^oZ^J+-ne`SwePql%EU9Z7ujwJz1F7_}V1!ZN)U*&Q0i@{o1d4
ze`#mx;S-7^pk(Fy>V|8$s~BGN?_;c{k%
zMba+%wS3G~zYo4w<^Mjeu%Wj$nj*sMU&^f~w9p_RX
zOWC7HUy6&5Ue^02@~Qd7jdN~g2hm>B4G}kA{JN&XTMrGzD-M}c@mc$%x=DZ6e{mAa
zc4(YHZ7yn-{!8}g`=OrP#m+cP27-@WWP87eT&vitp0bElwUNiriLx3D8ac3$CfO3+
zVJ?Q52Tz=;+X%)E^GWPupX~Oh$5P+TdW!Cijlcs(@06fOnF`(%M+VEu+?~Kj#-b)o
z1$}yZ<1-Vd5QBc6Eat3e`UYWAe|$^GPrx9BY2Sf*$X~E4Ac@J^zzSGxpz2`8QTmII
zXpV}u!wWM{>n=rSYq=w*S;raWi1BNgI^x!fH54w}V&x_u9SMp(6PgF3EZf(6Q<@HC
zi6WEFiu*(*xL3CgW&X#b#kHP!WH-DmzT+XWD;ITpIjTs+{7o-_1Qc_WKx1I2nGTV_f39>rWN^w1dRB|D~pfUPEzQJmX$L5r5-
zE`PMh3i?i%@nSvj<8xt?f05T?QYTzF1eUBcK!q%HAA;Z)cX`2L;ww-?5PGKJEgYbe
zM2F_Ns87&h7EW%6Vl&m#ole>EPATeYqBpf`a)pAZ@9nYPBJ33*@SC(=7ZHtxckH9_
z!d{|IiTn%ln{|zt*(0V9;$|;#ox_3Ss^XsB-a<)t*&XBq_SEJ3f7J=4P#5%F}%sNZ4Hhlc9
zu<#5LJhwB)@qVV#e>Wp<^2uzf`&52ys!l!VqgH60p6Lka+&*al<@}9c<7`O3o0i}%
zBFUq_b7e9jkKDCjw%Q^N={
zzM0i_dzTaA19c_O!`d~VNk^HT@?p=TmUw!KD?~K`1zP3ie}~s1LKe3n$WYyI<7vz)
zwBxNvA1}i@0=_h(pGV_~*43EgO0ObMXnAu6m{i7%J|qh${scKi@1wR#s
zVgOAX7jULNXs&^*vgSZ#Eq!Ya1e}?dF4n+iermkK5iLTg)#7tLY
zfXcxVqV2Am+)s9nGb8Nt3jIo-FwX@9
zsEmgFT()1*y~O*_1yw?%Bq8))O}h7JxU@mXAkYaJ;{M1yckZs~OQEu)Nr^nzWUL_&
z&t>|3f5yW1#fM-07HgeREST*?4R&7>$y*Yh)KeJXUUPvI(DqHonVFfAj4kA;saZ7H
zrO|);6w0Lp0-U));dk!~k;(N6PU%ry?g7B6I2=Uso1e@Ase*{vK*fe(sBJR2bHE&T
zZzBr>_=+R?BZ+CdF|5!DFV0n5Mr+}r6x>EJf0qUwo0d%$Fz81dbg*r<)1Y!8y(~jZ
zD>}3S<>>_D8n*4NX$r0BfHL9@#+;6eOq*?;#%EJ9)KrsG@zS$@G+n$rjK`^#92c-%
z6QPNBkR6qdWvgw$mvwdM8?<&PWYqr-2@x!zKjOM3%(gLKpaK~K&RR9(3-4gupa#&Q
zf3_|P9j#}Oki5X~_zMGaDUI>aAneW1VOSTZb9cHS>4!f&8X+*m*bqsR7aNN8VxLWH
zYxSQ1nX<-m1>My!sx}C+sF*HZY8GN*<6YJ5)yocJpWQR1e}S?i
zA-87{kJ@$)CsgoC>Y>1_k2q4+ZQ1+`u1+55>m3tG6%r*BvPz>ltdl&{U~Ss*Oh_(}26G8HD{4=8pWr9kmYm97CW
zk2a=AZ`R<&<7_a{S6nco0FbXgy}8=E-)5CJ18vvV$yxS+!Etr-*$T8?l|rhQ44UDF
zYoxhVw`dvsl5L$yFT+(^AVTo1^K4c$P%BUq)XTaA-s`tSiVQ5hxM$hH=vR9N~63$lg~
z^}1vbb?^+oICFXlQzZ%bJ6^SWyaD{N@;+d?h5>hGbs8BG-lWe^e8I<(HF4WCA@1h1^`6UOx%n
z^3fq9A#~^*d``%eYen78kU+t~f2jw|h+jhMU!va(KzJOc>;4A0+nvVx1zPI|v@(;}IVY^|ke`@sS3U@nliib{+stdC
z=@+1v?$h7=3!2Zbf9sHv6X2H89-FU~Ze(Oz;mFp2L8lHc24?*okd8_&v_dn|=U7vO
zvynT{GKPaAe27!BP3ePab434VGe|J?>2b~>MP6qWyMLFb9mMH9pr5(#6}uBT&2}r49xUIZI517dPsFv2uy||1DoD*XH0$T85w&jt)Y!t7Y*cH
zYKCa`92pstC(iIrU34U^6Fx(LwQE_Z#!UvP!4hM>j<+k8SxYq#->20;0!5fK?OE*h
z(@0LYnp)6UfBzXGFc~X9FQScG#7Z=914dnTJ@Y+e&DwoQEHRuAQaO%_ra?VNdi_3l
zupx{h@+R*i16Lxwso~XEyp1^w)Z8#nope~%M1vng`beARtrv5s&(kY9O6!zM$Qy|Y
z#Ll7C8TgdPYyj2>T0jc0?jxy(?1mJfAW4m3(No;1UeQ~(2;c1SrSCf
zkAD~M*Kjw{H@50b*pKs=05G0w7HkfI(>KSRU^8*6rH0jBC__`41EZ$#j!5G1(2}=r
z+QTw_L6Llfte%5F*oJXqqVQELD$8$FP=5j&p^Sj7n7Lforfk^voa)iUqgOEdpkws!
zs;Odce@WixcjuA|JunM-r!aCzNWBGCQSvZW>Z0h0d%$#O!AT=*(cYVDoyQ!XcGyq95|&mR>>#}ssLx@t`xX&Td&
z^GE28jbti)t4iCNNLqZ`q_~MKh2kyA!KfW@yLr64c^eE{zxrwwVB_L?VFzP6V_x~j
zf56a?Gr5+wD>*9&bM2`L^m^U;d|QoZU6N=ulB&9Q^6pF2H_4O=Xs@
z4yzYO_zPNwJTp#VITv`r4QlA>cU1Ijf6q^wy4FD2;;IW02AWb(OsHUPeH*6DvBV(y
zt~}hav`>&#=()P0U1~tW)*4K#zVAXfKd1~NeD^Q$!vv67V8D5=zpbVG*3ZS2YGxTj2G^Ii-^Cq{
z913|QC3(W^PG->cHGCbFxhfV}8h=P2>|n|qI(`xOFExs@nZec-*C$)SS)Sq;AKt($
z-}w^?x$K(14^+Eu;W&MNQHx7Ce*;S&HCj4&dXd}u4dGNqAD*!aJrWiJe44^LGhlS^
zMQ!3etR`JiZsr2|RK}f!8bAmzGOyipBX`u)#U3f|YIydUZz2d=#SBvTz!;*ePcSHk
z`#%~0XjaqgaL}gZy{};w^ASks9ZG+|#|zVz2qoY&;!<^~
zHt`Fgpj-pv=HB?Ik$VDK@j*CrSIP*<_C`#u(9iGj#(P2nw1o-CQ0_>5+-|pQMmEW*
zfE3n$-eb272l+vC>)*U4e+yUd@JmDb8Y~k#sBo0B1@!qe_>Lt?y}YCbM#GK9HkHIm
zF}mwfLYLy!!AIfoF3enz<72MBy7$ViiC3id@y>^}7>D~8i?j@L4Q;g_@aeN*;f9a_
zGiF!cd3b~;)4RiCtiq^9b4f1SHo&mZyDFI=4@Aqmu-rLDx>L!{nXde_(#`0#p#lzaexd8JhN2
z<)F{dpQvTs|=Zd_5YU6t}t)G$MICBOdbbL`qyUp?~Dv!U6VjwADB8C_F
z$(f|owD5GyKn%!z=mJq;`;AT{XVQ8YkV$S%1Z>P6H?4JE<^$$GC|)W@K+C
zgett_u7v%be+|idH_5JKf!2Nii_(w7Dhf8Tr>6(QTN$g*snt(-!AF`R{nqFz)-@Tm
ztW-9{hwRCL)plidaLOcOt@dP7pj7+}8d
z(eW*AJ(#$NZ;UJvt%~!1I3uyidU_sLZ#$pG!*gpPe+%UZ53@2|I*B%)#3IJ@_X*PC
zKPIVXC-8H%^nX*Ol^h-?6?oP`oMj)WA2+ET8{Y)vWz)>H$C|_cR(C!}0eziV@g$Dn
z?Y3-#mY$ufPD)(qv-e0qs8d_R$$q|qDuh?R5GOt%vu=
zyfH4-2p9P4PUxXLwg3FbB{CPye9?xbe~8uj^gL?C#bZim1aq3k#+G%;(%QPR9%_J#
z1i-Q4iS?fgW@K1#ZH*{U4Lt`=P8W*_$XeGB#ZHla82i549{pl3?J7{lvsM3=omxSq
zt10+dMQZvd+AS-^kyLB|&eh0C0W$?&l6`Y_t`+X<#^<;K7vb}@$&=JB0NLxle>;3n
zYasuD7P?WheF3e|puVW0dFi!tSX5Zrt~)z12m^HT-1Jvs?;`q%)Zsy{T4jpwq=4(f8URC28Yps}Cg&?Z%Z!~XPdrdP<*-4y9Fx&uM
z*67eJ=^G_D@!oFzx1nk4bz&dNU*@}z)i+M^BXpwR?`3#uhfY>WkbpzrfxQLAp1PW}
zQV$!1vfy*)Il>Gc6Px8BPiw#{*->AD93YJ(AYh`h+^Qx(omYGirXh6GNrv_4^nvz1k$NUCf~i4(h6_
z%_vRf?V31wFZZR}N*Z^x5xiajA6i7vdBtJ|3-PBXNX;9D;cG&O$g)ozMApJMwB{y?uEoe6mUV}e<8U##FrsIt4y9BkYm~^Vhf6-;(?RW)wED&a?SKnX2ZM_47M4}j+(ZIFFur#uM?o=?w0_?OvJL#qP3<_)`A`(x;`2!54a*Oj13$*tkR
zoZsl+p>>t>e?UT3u0mfJ5HxPQ`68EhPjh|;qVnV(tcxfEYpO?XjdE^C@|B4n1w7)b
zj>6oFMrBqAaS3_8S>p>E*19FhdJ6{@4Nk+4IFC94v<$HH@_P0ka0iQjA;QOke~ycl=q|C(vBy*;BcR4MydTzJ
zg#STmD!#rLXqjzNrChk;rGRv0Uoa8c7Z6(RcUYMv&(O5}%hXM6{9WQo6*WV&*8vEl
zQi;9H4F>7H44t-}q|b!eb}>TrvrU;{DY-bFBuSF=G1YVk)%Bc_eJ~dMiNv9p6mE4W
zFOJdFe*<^$E%$*>=aij!q0?>ky4S%+6_XV{DkCoeZnse?&np|LlqB0il&=fKT&bgt
z4*YU6e+LeBK>iuie-W^b@~vEQ6aFvlRWO^+l=vpeiR}IR
zB~#HPzu{eiU5FH*#S%)rofH`q@9oTZIt%4%#!4*cyL1|EcIqOhFHrEhT~uaoK`T{B
zyfa*)7AT!*6;7Ne1pPN{X7tj-Utq^B09fq)OTP6wyT{M`eDiTiFcda*V5(LIj|MSV
zf3@y+&2|{W;&Dgw#KSPm<4sal)rge7VorNhjJ_ZEMwbKg`OLr7xjgvZe6|_9h;?>r;o3*Y@Qon-)1KQ-;*_!mh*o`9gm(0_&dlZFKO%
z-aq>5490SFI{b!3G5gqg&4no_UW;+Uf2cM{G;<^)B`#f<&-Jr|mh9Ub
z_3R}HV!gB@$bC;nxc6fx>)%hv{-CcUC06O`o5HN0Rrx}L%rM~||A#;1^BqOS7|Pwh
z;d79U5fM)8$Ue$S|6`IYE61cAQG-mYQd$Yo`czEMkp?f|z2z6Sk&WC@rH?E4WyERg
zx@z~uePPB@iL#E4UGJowK`w*)f2be0ztj#_2M)A`TR9H^3P2;r-?agMdnCF9w1j*W
z78@VWEAWBd{6;nF@BNgsyZs9^ZH}fHNp9F_opHCWt{~?ync=B!86Ed8zuVt>}@X^?p`xcp`Vn09j3wB<6H=oS@SDA5KxiZLA_
zAa9!CEGm0G=+6-cJ3Pt+7u{XE|5-#o7!+LDwu;n!yI0*Ljx$~hlw7g2i7Y}ut|G`9
z^lvOSnEfg!^}VbZ^VUOBe?#_eWki`rAvv@L%>NESSUc8mzqe153QcRe&jUM*vDml&
z6>iLGU3ONk2WO;gZ@c@W=zKeNGv(
zUisVu(N;Ryc&{-ru`g<>pIZN<@lX2g_WC?iJ!5L@RSp=H0$8>8f3n*qC^MHBiyoTK
z30Q97_l_GY9eM9k0AAmfoX`liF#uslUcloH8RQ-&LJ>T0yIrEPJ2Z2snf@Q>Q9A|%WfciN(Xt!8Yr1cj&A(!!TINfy1n=Z5
zc-y`UR>{rcv^n-zdc>B|r|vj4^=QzE7PTDVEA{6T!+zz9f5yBYh8H=#k-&}1`|!4+
zASal|ZS&jZwb@@HLQZ>H)Ymn5Vy#TLX{Po$W5AR&I>DnQ_cQ>JKhj`KLb@)N5pC_B
zPt!S)-?a|;+B*eDF?j~{?*O`40_oatS^0Ji9EYGQG)IWOxA$Y&gy?U4A-|kd2sofjLH=
zaFq_-HJ>a$#OTV=1i16Yi@C^B9q9X3hEW?s6a<~0ywrAP`RvX~ncTpdr7e5N-tjWf
z=-PGoz>TDqr5x5_nPStW=FBT!hcvcT1HEY1Uyx-RE2-6_-92w8bFD2tzCm?`{7WJa)qULs%OqR1eiE9TU+UQ)R4EzFd
z0tY1N$JD%DEg2n}OzFHM#caryY_5pH@3U;oz3GKq;+$3^$0+e47C6E>8rn#v(la?a
zK_6?A4Qb5xq4h!GqwpBAtNUE6kLX9478ye5e-}Z)aiYZQMvnAQ*>p>C1W8>l2I4fg
zgr<+6nW$<$*KaJu#sBqpg~Uk#(W_&L28M#f?`@$~8TFHg1*H_amn|%yMn60)Cj9N6p|xTr
ze^ZmP)*YtwZ^`%i3i!6vUi7jatrTbKgP+d+OBfjs-pye3EQYGsb}$UZS0LX8f=EA#
zT`t`aih?{0fud*_(xM5A0CVG-!Dzy|$(#r0XjNba__r(Zn)2XIgZM-Iy!Qlhk=pTQ
z^WdUWEnqQygy9Xt(y-4~5v1*IUv-a0e_tfm=#%-D_hjAg!gLaD-#iv-kT~}M05wQr
zFto%@l(^C<*`7|4NS9c2CJqwpfs*1Ec5f^G^j>|nNfSUvN~0c@)ziYCNd}Qbx}+R*
z;04U`wH^Q|mz`*UG&j{RNn^|FYey&m+qfQXS#($c;^E7sNziW0Iz6X*630oQe?8l_
z5H3+s{B;pYFdz-QS{Q~aQ8hkLa{W%b6d=?75L(#;+eVzIsn9av>-6LeT%U#v;G>|Q
z0B$8bL6g|&_xgk;mYqfhR4@6CH$Me&enw^yinHt%aUa4h)Rs9)><@f<)UzvD+w?Dv
zk=D^2lblyqF#{#`s}R@Ufwy0?e<+EfAYh4#N^pdoYJHnqKV;pBjZ=$fKsLhu0vb-l
zE3v7m40FTd$_)y&k)28z@>VZ6P`S1FA*rgqtBg*Knh
zAU|I&<$KM}2T!drN^yvC84?+SCNNN2OgEV3NxIRjwOiTXdX0?tg%WP3K;vG6<|@`U
z7MERuloL>>uXt_U27&%>I|4Yg!s@Gg_tc&zS!R1i{Ds)mivJate|E?i`O8-pbmOw}
z^-o|P@jdQ0&>OtURa%L^$0e*nb0wkI8v9q0)L2P7^PyrD^NHF*d^oY#
z@*{m0=bx9TeG#!Le>39h4!Z6UdDqB2qE;KCrTSL-?w8Sg*1$aa_lGk4H@nYXPoQ;P
zyqlB2QYc-_4qw~*5(-7n^4nnlDzM#Js(xhBCxZG*DTl9;C5TX27J{AKp1Z2@=B`%0
zP7`O7u3)>U4_kj0gcx9-`4**JAh`jgv9&)3FG`ID97FCWf8|nMy+}eSIL$kOU#%J{
zCA1$uNWsplM!g1nGtp^sKPYk4Be&&K^d&em;i9Gji^f<1UP~z*YEEAe9{;M16>cXX
z51~+9*cge~2*RmmI=Mxojq2kNTA`7v564WObV#Sr&*=si2RaPq0yqN48hYD|ZRs?t
zr#O02rofz*e;RYD?3z|q?V*;s?1|2-k_Ij@8QM+h_LeOv+{)&6SiYDiZpuR{c%s@b
zQdd5^^ns#LAtjmj4Q|UQRT8jEwcr0thOhbW=7{D$mC>|`q~?Q)o{1#*lfUvymC0SL
zq<%2^S1D{iMo)TBwvf!mwD41a*sFCj;_ox40)ZTf*z#QGZxgli%~
zjK-tt+w2y97uPknDi&T7Uji>08MC%VhXhkAY5dlf2Qi4K!%cMU<}L>Yei{I~DrT(&
zJFpo3Mx-bIBRLOjW*Uzs>6P7;fm(I!JnKB6#mz#4&&i)?3Hk
zS#F8zf4*mR^T6-+73S7pi)A@o*EL&&lBBM2d38Ch_j!M|P@o2O&KzCZ_OY@|tYge&
zE@97-%?t^i3lI|I@9KMQ?lW2!X7~}gdVp?^XAguK%i5N%j@w*&-1EI>lnD%o-IL7L
zF7Jb4zvi`kX^S~8RWWoZbw~h_gUUJ#<~Kpsf8tM#!4J}DBJ2qV)V&a!{8A9R$XN;>
zG`s{&D>B!?Pm?*9icldtAmA*Dy
zz|dMB0OiHl3QfJ_DoP~>W=IpVMKSZ!I(t@s{k@zp{WwV6?wKhT5kWL`3e>R0Z
zN)M8C0!Ym%NrXPA-}#7!u5dUQ8vc*{N;V!kmfH~_T%@LWGI_w
zOHiP`snxT0Zubbhbz3Xh`lYhIz!CejCtb`CrMh>|D4DG2M_ZT|%n%`M5-6hvm`s07
zGMN}&`4iZ1p3q*w(g?ujs^~}hC~9sGD_~G=Tnnd^qA`L}+|u{&qp~j2e*htJ*D$aO
z@Eq|cLc=`_qE%YS>K>gI&O{Ue`2+Vp4vt)6Y`c2-jGH$43>m^^)=2p-Q~EB{uc^JM
z8i@(BXP{p5Tks2gd@fq6HqT+{pA8B8cWe0AeVMra{5#0VXq_>fye6x9iQ3qR)D1^T
z-E1-PKyEY@v|j7!CNOEBe>&C9g$l>}eg+F|h%{Ds7m=a=vFD$6WIc3ldI8l&6SEey
z!^(r2A7%g&c744dESZ(45-5qeKXNT!cNRL@FQImeb&sn~l6yc&Ol80gguYE~rlkd4
znzgg&28PqN(G~bueSFa{6a)yO{>L(oLE}N4b*=%eO2EmZS$*HoeN$L@y2WTo4!-&hx6JOfDb%eQHXbrguP9u>%9;Si{y`$<4Ye(0K*@tQXfqqkAhG_8khs_+>V40O<8*6&GZ{g{g@C
z*3xZTN3S!>e|IE4P;dazfBO^xO7f)Lde|0C%V7)g9)P11B(@$2g7}i1T?{8lP;M6g
z-dUO8c<84$iXNSK6_RkqSvGKZwbn$-5L#Q6X3c8IH4dSqFyAXNh7&u3Ng~U}K_~s3
z`;9WHk2gyJBrc5da(Y!MT8-`F0&2{!B!JK@~@nyQLS5RZGE4qC|Fu&r4Q=BmIxxW
zAeh2w%Se^kc203ay>O4qfSbDoSj2Od7wqGg7yfmY>!qB!5u2X`GMdj`c|3&tFtq)d
zLEMt0e|Vg+)?*--JG=h@zjXrF3C!>NZQKOBH;D&~7AOcsE7!L>-%R91kx3)RTGW5o
z$t_%s@LVzHho(L6yA-^Pb!UrK1)_cbc)ZtyJ@Ptl$jHBngJNcXe#e{{v>tKK6((+6@|a6)G|o80{4CBH2*
ztUc7jCL35XX5Sde=|*`!i~J7@aNtvWdY8FNWn%?5(QXkkN<>|j41>;`u>
ze+5cGOv5KAjzd-1Kt3n%gzau~CFkcbl!9*kH1gS(z3%0g2pVTh)o9!{LP4x#gVH?P
zV}>;7bxF3BV8ctEL$*Zup=ZA#Q7{dJd^|Wn3e=lKh*M
zI~tha`RX1#&D+@aPg*v~V`{hlGjm+be|na6@Yr&c6AJ>OJ
zE{_Tnxh)q5hZNRt?={&UY~Rn58cU^J-tW;MM|p1;Of{6+jVm|CS9e!jXG5Zuijz$3
z^V*vKO6Pi}{jhfq$L)}%3J~30>LIo=qtk5
zAQhEIJVH+1UVUIu-7`x(Pb3CXvq;21P^^t#QxOL~2-;2_R1lA<8?|D``bpeH{4_1s
zQWj5mMg7>EDv#e=h%Axkq>>JT|6RwlUxAUk;=VzvAN_#wce>qd1^Bcn7zy
zhdzX;Cl;!CmJKV%2Ur`U4A%`Ep%cWH0D-(4ei0wx|JD+WKxwvTXn4H5g)r3?pJefW
z!G6LfFxZQ0#UoY~pXtzrBT5A-8zH_GmNX9*xtVHXi?E+WF%>ZAteWMWVaJA&7fMjE9Avmi6d@6O2qP`8MIb8{et)P7EK4p$Q$Cx6n@~m1Vo@`v_}_P1w>&#|l8oVVqzqgXE;^-dMj2vT
zXU24+n3i!f&M;?$
zT!%Gxs_jwI7>dkutL;_73tV=668~jrFu9QvY@HbClgQ?g&YYCrHg@|v!WE$m`g*sQ
zuRB5$LVKoeb~_^A4OAP7=WFxw{U{F#jUeJ)LZ%lV|CWolC0z-t|@}(c5*OyM_l4kT2!oo=#7@EX9rAz?e>=fwVq}eMlgp3{Z8Sy
z?qua*^e~t>16G2bn{1i4kzBF;_7QD-weXbokeu;
zCvco6e`Ra$F}PSBQc<&X1d~jfFsC|;q;ln0h*Bq8XjB;}jvzf#N1
zF|3l`XblK#QP&F8e-)~l(P{F^po-Iptf*mSs(Hz=LH3ukJLHVPhmg&@SVxW9ltNa;_eJQ0Ycb
zi2);8_E}(Lwek8^9etdVQLRugFqh;GI+&rqc#%mQ24=U4EWVSedm9-nGnc+IZ!*oM6!B*dIWyPPe+Uj}
zzkx97%AoMif_?Rub_fpxPcVe;Ik(BY#uW|;vUF?+%(g2j8`jLkG)y6K7DU8jKSEq_
zUkI0%C3`9zk{}Fs8j{E*`#l*|eV~V9)MG&>#4f&>dj*wdrobHEBl)y>fLul}Mc4)$
zTcXfYS*BmyAepg=QrC}%x4PE=f5DXf!WDk*%Rxr8l;U*(J`%z01S{V>A5&
zDOB-mX;olL5soQ2*lnjdREnSOWiYnGXY5JSS+w7738ZwyX?xi)w+Xz-TexXx0e@$4
zT}5eS-k2xL3x4ats=|I#dox&YN*~6M+``hPuo9dgdwS?p__MSzh@e%a_tPC>R(elj
z(N$QT&R>nYPL)_1f~NBOV7YMu&z-3l`cniDxBsTSBPQ>HFLsoJv9*GUn4j?s@GX}P
zPOK1?2>HC$c-_@Ytwr^fwpJ!k6Mtts-x}30BDKa>i~5n>qFz2Wn1J6
z3WIEx?RC5Y{WWpj{N79_im4)O5~zQLBk8z{Q@CpV*+%x3ezianR`!$mRFNix=lIkiZ9+r5%(torN>z6?p
zD_x&-ebn_BEcHxK%U0ARg@Lz*nI#{0?{ItpCLZWaB|n*TW5|^`3ZQ%0^n-C
zkF9^x)sxy>IrK&6*=T#YJa7#B-IpXg@rV_(LeLit*%*Ig(R)mWt<4fY6KCyCp48c0
zI^^*LDo*a`wPMsNm%GV}LbpB(W+W2H9fAzaXai*{iU8lJnt!dWGNZ{4uS?p2H-qQD`-|BIk6P!Fr?ZWa|c&ot%7m2(a
za$#R7Egin50Ct4vz#d6cf;kDpS2so~Pmdp*>xN=i)M-C>{PGfni0`b*(bw^U{Y@7B
zkZ2O+gvPs_wtpnFykGZH`ze65rX_Qh&z`|W`)dh@CC$F2?EfMI^`#7(=bV|3DOQ04
z?8VE|OU-%UQDVz_qsq0|g&flc&l!ageM&`7ixN;k8uO`t
zY{EHZ-!snlEPIj+ITEFz$&E^b3kmEyYKis8k|txu0)I7BVY@kjZw4qq0ww9cHE1&3+MKx0rQ1dC9R7Pcf?>5tHAzXZW4
zVLwwF=>e%CI<1coe8UTzi&c*p_95%bA)q2szT*gJlG23e)=C~?2fv;REtUX**?tXs
zN$+WiQ-6$bNxv@MJ@vWqRVDA+*6F%FQWz>SNpkhCt!5<91_oXK
zMQpMKC-nd_z5c#JSKep0`Wtk)NP%a9MiEVU&VeQ#Bz
z;H=8~RRp--3N0Ib6vyW+lH65P=g%V>DErTvp?{?*e&*4{&u8QQgEK*HXCMs<3NK_p
z@fE26tsp5a$D)^k|Grq!di_zds<4pK#k~s@{IoOz2ikL7$!U^n>P;BzSq|#(WC%Cp
zE|L>iZdTupZhRwoW45cTeP#;*fV#@S=f=pu2%@uDQ1<_e!3FTSN&MHFro8efM=elD
zoPTxWqh=4_E%B6}gCdshz}N&*e-g{cc$UKkRQjviY)n%o?U{{Y91;#gUr7y?jf-6e
zT}8<)iyDcz5>wE~2Hza4YdWY0$Nnx@S;TcftKRhwHG~C7$Q(F_ph_~EP}>~i>Kl5=
zTlScd>k?t!pnRyM)&-hM<4@3BPCpXxx;xG9tcht=}(ez&p~1)=zW
zt*ar8=~$PsFp~8_Yk_~b(==igHkd-a2?Ll0iwIHku~dmnS7xXeHq8A#&(Z@jYr_tP
z_WR(FA+bTdQX6-BQCCNNQFA?{hoX7fuIy)>h21MvG-Gm6d4AIKZGv!MFtC2&-5%Al
zTD3PypkC4>G$S2-93I-=ta!L2ZvFoOJT){zm(k$@6SsQP0y!Q9Ff}qWIG4Eb0v-i0
zH8L|em)r3I$pJN&k<$Vwf8|=+cH6iWeb-muF>Y4~;tq6W&04WNPSUXx*N&4(Gk%b5
z#%4zrJrbSEe0}!;Ac>SL%TA~5!#oHCfdgQleJ%h+3RW`1RLLw8rC@;xB~W9+J5-qz
zxM(J|V!|-#3=@`Vw4mK+KMo|3rF+aFf2CwJv$TStTa_hK
zm`tg_Xd&kZ61^IephXy?nL@jDlF`y0g%+4!2&N^j1_ifx}4Yp$PFtNQ@9lg4){?uZEh#$6QW<
zFp^9b#h#DHe+}mONWnu(!VdA`(+!DxzTHeNs!3e5
zJmoL>E57ql#2Z3+-m;HQ6lDn~maeeyc%gOS$&-~WY#AW-oZasNexhg2M
zP3a3K^t~wLACCf8Zz;Rk!XP(kUlv~Ydr_#hDDGMoe@Tgnm1T`6LO=&yks7s?h4Z9*
zRwU}dpFevR7vRt1%KVt09KE97ldHD9nf{IQ%euX~JuA+eYyRft?(r*rcvS%k#_ZQ;
zli}ps)^|e{!4?wPVun@1P$jP4jkUSDnASx`TsQpX@S>XX4!}#?@rlHk0pUUIvFoc`8a$v$l0mvcTJ5x^S{y%<@V*GSB#B;MlumW(d+1Mg=5Q;e
zMkbZB79uzG
z_xA#C0e`e}D5i7iZZ$oh)Hiq>Naxho!)x?>c)fS{ZvU_Q2S?5Ia4gEF+s)_#0;Az2
zj><`LJD!rCYH!(78R(y0q%I+pqJK!H=X6@OA>hzGym?vGmsk0g7NowXB4DCd?Qm3|
zKObL?DpukNr>(Bv(Z9h1{&OCL%?@*14JULWet&|8rXzmBhrHr7AMr77cr&i}gim?P
z+p9@c@%Br@KW`c9A}VD@^>?G3-72fsLHtfd)m
zs!82kMCPZX;q{;KSjUB>Ms&e+gea%u#s;
z538a()$k(npqm_lohVx42o#kRiH9);lm02fD6$d{vsjujam#PV7u95X-b|{M5P4Lde*gaM;g7E~
zEgLhH5#UA8DTV&f7k0smf9da0rng5)DZeLQZQqfx4wiD(34h1mgSFxGysq1NbW!nP
zOIZwwE9Df*VO2Mqt!B2>lok>3>bKkBD5kg1utjq_fjKTG)v&E5{cJblqiQ;hMv6f^
zzP&z!dFsoDCBWbKZ?{cbU7U?lF04Ld-f8{y&aBw6d`^)3_m$M(f9}|?ejJ}S7xnlO
zhN(Y&ssMuivHK`J^uu9(fnk9jhpan+V^7UwWfHO?2`_<(S`**|J(3q`jA}&%6UULS
zNI!xp(U@q@L?g?QMepzi9Jkjw1kUID0}G;W@}5h~jE|FPhf)??4#A5~_;t6l8(3==
zgbV)XPDbzAJI;9ee;^YGW%KTOx*E5gS8vpa7}*|9tN3T=+5=`U-059<{8M(Xo=jT`
zFs2c9`@?)AC^5gUFWRdqy_S!nGobW7JvO{;PR2FbD*7M#&iryO&NZjOK29qhj?-+$
zsUDB>o`c&GRJ9CM`Yu!{7Esk@sQU3x?>XBnK{YF^njWiRe*x8QhH4%U^`4W*5>&Sg
z)yZ|Ny3J7SK+et{l48t>Q-V(=^j$MptRhK)c;Ro3VE@M
zRduk+C9FoQU=6ES>HXD|USQqQOQ-?=slJ%bUl!+=ZRu6iQX+nH+m5hNO*1-{(ho~4MIWL?p80-#UAIfCb_7qCX2IpJME(-j&GUA?qEY=8fLW3O
z9FgJOPOB~Yv~3AUcZDc3$B-Pxr{P}Sr$KKV+#CY_jxA|t2wI!VLGsP{+xwZrEsPbl
z_j+c@%jy7L&QGS*!Z+XCRO9p>n?4`ROZ^-FB}I^zsr~|NQ9(C0H8nOxIWa;vLqtP4
zH%3M|GB+_pH!wCgLq$VHFg_qWK{qxvH8w>#F+w*(L_;|@Mn*X@H!(vuFg7=dLd|OV`-r;
zVQFn|X=Ne!2KIIqf`x@35)cK&HqN=t$AP&s1J}%~8q9(z{M;Cog(3(7w81viKrQ58
z3ldNVNk~CGG(aOXLA%T{{zn>`VFi{U1B)=7%_=WN%`Xi~|n}H90W~B_%~qMhfj+XmJ1l

diff --git a/inst/sql/sql_server/794.sql b/inst/sql/sql_server/794.sql
index 0f417a10..b8bb2cbc 100644
--- a/inst/sql/sql_server/794.sql
+++ b/inst/sql/sql_server/794.sql
@@ -85,71 +85,12 @@ FROM (
 
 ;
 
--- custom era strategy
+-- date offset strategy
 
-with ctePersons(person_id) as (
-	select distinct person_id from #included_events
-)
-
-select person_id, drug_exposure_start_date, drug_exposure_end_date
-INTO #drugTarget
-FROM (
-	select de.PERSON_ID, DRUG_EXPOSURE_START_DATE, COALESCE(DRUG_EXPOSURE_END_DATE, DATEADD(day,DAYS_SUPPLY,DRUG_EXPOSURE_START_DATE), DATEADD(day,1,DRUG_EXPOSURE_START_DATE)) as DRUG_EXPOSURE_END_DATE 
-	FROM @cdm_database_schema.DRUG_EXPOSURE de
-	JOIN ctePersons p on de.person_id = p.person_id
-	JOIN #Codesets cs on cs.codeset_id = 0 AND de.drug_concept_id = cs.concept_id
-
-	UNION ALL
-
-	select de.PERSON_ID, DRUG_EXPOSURE_START_DATE, COALESCE(DRUG_EXPOSURE_END_DATE, DATEADD(day,DAYS_SUPPLY,DRUG_EXPOSURE_START_DATE), DATEADD(day,1,DRUG_EXPOSURE_START_DATE)) as DRUG_EXPOSURE_END_DATE 
-	FROM @cdm_database_schema.DRUG_EXPOSURE de
-	JOIN ctePersons p on de.person_id = p.person_id
-	JOIN #Codesets cs on cs.codeset_id = 0 AND de.drug_source_concept_id = cs.concept_id
-) E
-;
-
-select et.event_id, et.person_id, ERAS.era_end_date as end_date
+select event_id, person_id, 
+  case when DATEADD(day,14,end_date) > op_end_date then op_end_date else DATEADD(day,14,end_date) end as end_date
 INTO #strategy_ends
-from #included_events et
-JOIN 
-(
-  select ENDS.person_id, min(drug_exposure_start_date) as era_start_date, DATEADD(day,7, ENDS.era_end_date) as era_end_date
-  from
-  (
-    select de.person_id, de.drug_exposure_start_date, MIN(e.END_DATE) as era_end_date
-    FROM #drugTarget DE
-    JOIN 
-    (
-      --cteEndDates
-      select PERSON_ID, DATEADD(day,-1 * 1,EVENT_DATE) as END_DATE -- unpad the end date by 1
-      FROM
-      (
-				select PERSON_ID, EVENT_DATE, EVENT_TYPE, 
-				MAX(START_ORDINAL) OVER (PARTITION BY PERSON_ID ORDER BY event_date, event_type, START_ORDINAL ROWS UNBOUNDED PRECEDING) AS start_ordinal,
-				ROW_NUMBER() OVER (PARTITION BY PERSON_ID ORDER BY EVENT_DATE, EVENT_TYPE, START_ORDINAL) AS OVERALL_ORD -- this re-numbers the inner UNION so all rows are numbered ordered by the event date
-				from
-				(
-					-- select the start dates, assigning a row number to each
-					Select PERSON_ID, DRUG_EXPOSURE_START_DATE AS EVENT_DATE, 0 as EVENT_TYPE, ROW_NUMBER() OVER (PARTITION BY PERSON_ID ORDER BY DRUG_EXPOSURE_START_DATE) as START_ORDINAL
-					from #drugTarget D
-
-					UNION ALL
-
-					-- add the end dates with NULL as the row number, padding the end dates by 1 to allow a grace period for overlapping ranges.
-					select PERSON_ID, DATEADD(day,1,DRUG_EXPOSURE_END_DATE), 1 as EVENT_TYPE, NULL
-					FROM #drugTarget D
-				) RAWDATA
-      ) E
-      WHERE 2 * E.START_ORDINAL - E.OVERALL_ORD = 0
-    ) E on DE.PERSON_ID = E.PERSON_ID and E.END_DATE >= DE.DRUG_EXPOSURE_START_DATE
-    GROUP BY de.person_id, de.drug_exposure_start_date
-  ) ENDS
-  GROUP BY ENDS.person_id, ENDS.era_end_date
-) ERAS on ERAS.person_id = et.person_id 
-WHERE et.start_date between ERAS.era_start_date and ERAS.era_end_date;
-
-TRUNCATE TABLE #drugTarget;
-DROP TABLE #drugTarget;
+from #included_events;
 
 
 -- generate cohort periods into #final_cohort
@@ -162,9 +103,6 @@ from ( -- first_ends
 	  from #included_events I
 	  join ( -- cohort_ends
 -- cohort exit dates
--- By default, cohort exit at the event's op end date
-select event_id, person_id, op_end_date as end_date from #included_events
-UNION ALL
 -- End Date Strategy
 SELECT event_id, person_id, end_date from #strategy_ends
 
@@ -184,7 +122,7 @@ from ( --cteEnds
 	JOIN ( -- cteEndDates
     SELECT
       person_id
-      , DATEADD(day,-1 * 1, event_date)  as end_date
+      , DATEADD(day,-1 * 0, event_date)  as end_date
     FROM
     (
       SELECT
@@ -205,7 +143,7 @@ from ( --cteEnds
 
         SELECT
           person_id
-          , DATEADD(day,1,end_date) as end_date
+          , DATEADD(day,0,end_date) as end_date
           , 1 AS event_type
         FROM #cohort_rows
       ) RAWDATA